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ABSTRACT 
Jessica E. Laine: Investigation of Nutritional Biomarkers Associated with Metabolism of 
Inorganic Arsenic and Infant Birthweight 
(Under the direction of David B. Richardson) 
Exposure to inorganic arsenic (As) in utero represents a critical window of susceptibility 
for iAs associated adverse birth outcomes. Ingested iAs undergoes hepatic methylation 
generating mono- and di-methyl arsenicals (MMA and DMA, respectively), a process that 
facilitates urinary As elimination. Differences in pregnant women’s metabolism of As (e.g. 
increases in %MMAs and decreases in %DMAs) are a risk factor for adverse birth outcomes. 
One carbon metabolism (OCM), the nutritionally-regulated pathway essential for supplying 
methyl groups, plays a role in As metabolism and is understudied during the prenatal period. In 
this cross-sectional study from the Biomarkers of Exposure to ARsenic (BEAR) pregnancy 
cohort in Gómez Palacio, Mexico, we assessed the relationships among OCM indicators (e.g. 
maternal biomarkers of serum B12, folate, and homocysteine (Hcys)), and levels of iAs and its 
metabolites in maternal urine and in neonatal serum. We also estimated the relationship between 
OCM indicators, iAs metabolism, and infant birthweight using a causal mediation approach, 
where we measured the total effect (TE) and the natural direct effects (NDE) of OCM indicators 
on infant birthweight, and controlled direct effects (CDE) of both OCM indicators and maternal 
metabolism of iAs on infant birthweight. 
Interestingly, the prevalence of folate sufficiency (serum folate levels > 9 nmol/L) in the 
cohort was high 99%, and hyperhomocysteinemia (Hcys levels >10.4 μmol/L) was low (8%). 
However, 74% of the women displayed a deficiency in B12 (serum levels < 148 pmol/L). 
iv 
Differences in lower B12 levels and higher Hcys were associated with increases in total arsenic 
levels in urine (U-tAs). In unadjusted comparisons, infants born to mothers in the lowest tertile 
of serum folate had significantly higher mean levels of C-%MMA relative to folate replete 
women. Furthermore, beta regression results demonstrated that maternal Hcys was positively 
associated with both C-tAs and %C-MMAs. Interestingly, levels of folate modify the effects of 
B12 deficiency on infant birthweight. The causal mediation results demonstrated that there is 
evidence of interaction between OCM indicators and iAs metabolism.  The results from this 
study indicate that maternal OCM status may influence neonatal As metabolites, and interactions 
of OCM with iAs metabolism may influence infant birthweight.
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To all the women in science that came before me, and to those that will come after me: Let us 
continue to defy stereotypes, let us continue to overcome marginalization, let us embody respect 
and equality in our work, research, and life- but, most of all, as Vonnegut said, “Science is magic 
that works…” I challenge us all to continue to make magic real.
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CHAPTER I: SPECIFIC AIMS 
Arsenic (iAs) is a toxic metal of particular concern for human health risks is, as it is 
currently ranked the highest priority toxic agent by the Agency for Toxic Substances and 
Disease Registry (ATSDR).1 Contamination of drinking water supplies from iAs is a critical 
global public health problem. Regulation of iAs for drinking water is based only on these 
levels of iAs in drinking water, where the EPA and WHO standard is set to not exceed 
10ppb; however, differences in human metabolism of iAs may play a more significant role in 
disease etiology than just exposure to iAs alone. Additionally, certain populations may be 
more significantly impacted by exposure to iAs than others. Poor efficiency in metabolism of 
iAs has been associated with the development of several adverse health outcomes in humans, 
including urinary bladder cancer, non-melanoma skin cancers, carotid atherosclerosis, and 
chromosomal aberrations (as reviewed in 2).  
The prenatal period is a critical development window of susceptibility to iAs 
exposure is during the prenatal period. Prenatal exposure to iAs is associated with adverse 
birth outcomes and susceptibility to later in life diseases.3 Specifically, prenatal iAs exposure 
has been associated with lower birth weight, preterm birth, reduced height and head 
circumference, increased susceptibility to infection, including inflammation and infectious 
disease, and cancers (later in life).4 Additionally, inefficient maternal metabolism of iAs 
during pregnancy has been recently associated with decreases in birthweight and other birth 
outcomes.5  
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The inclusion of metabolism efficiency, and in particular in susceptible populations, 
would be a more informative approach to the assessments of risks and regulation for iAs- and 
thus prevention of iAs-associated diseases. In addition, metabolism of iAs and toxicity of iAs 
is influenced by many nutritional factors- where many vitamins are known to be important 
cofactors in both S-adenosyl methionine (SAM) synthesis and one-carbon metabolism, which 
play a key role in iAs methylation/biotransformation. Specifically, there is a relationship 
between folate, vitamins B12 and B6, cysteine and homocysteine choline, betaine, and 
methionine in the human methylation pathway.6 This has been demonstrated in animal 
models where suboptimal intake of many vitamins and nutrients that are required for SAM 
synthesis, including methionine, choline, folate, and vitamin B12, or the knockout of the 
folate receptor impaired iAs methylation and increased susceptibility to both carcinogenic 
and non- carcinogenic effects from iAs exposure.7-9 For example, Vitamin B12 plays an 
integral role in folate-dependent homocysteine metabolism as a rate-limiting co-factor in the 
conversion of homocysteine to methionine.10 Studies have also suggested that metabolism of 
iAs can be altered via folate supplementation,11 though this effect is less clear during 
pregnancy.12 Additionally, removal of homocysteine is a prerequisite for adequate one-
carbon metabolism and iAs methylation because the precursor to homocysteine, S-
adenosylhomocysteine, is a strong feed-back inhibitor of the SAM-dependent methylation 
reactions, including the methylation of iAs.6 This betaine-mediated remethylation of 
homocysteine is may be important in individuals with low folate/B12 intake. 
The central hypothesis of this research is that nutrients involved in one-carbon 
metabolism (B12, folate, cysteine, and homocysteine) influences arsenic metabolism and 
birthweight. This hypothesis is based first upon our previous research that showed that the 
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metabolism of iAs, as measured by the levels and proportions of monomethylated arsenicals 
(MMAs) in maternal urine, was associated with significant decreases in birthweight.5 
Second, our preliminary data suggest that there are relationships between maternal nutritional 
biomarkers and iAs metabolism and birthweight.  
In this proposed work I aim to investigate factors that may underlie the relationship 
between prenatal exposure to iAs and metabolism of iAs, maternal nutritional biomarkers, 
and birthweight in a cross-sectional study with the following three aims: 
Aim 1: Examine whether levels of maternal nutritional biomarkers involved in 
one carbon metabolism (B12, folate, cysteine, homocysteine) as measured in maternal 
serum at delivery are associated with metabolism of arsenic.  
Metabolism of arsenic is measured by the percentages of iAs, MMAs, and DMAs, as 
well as the two methylation steps  (i.e., primary methylation, defined as the ratio between 
MMA and iAs, and secondary methylation step, defined as the ratio between DMA and 
MMA), in both maternal urine and fetal cord serum measured at delivery. This aim addresses 
the following hypothesis (Hyp1): Maternal nutritional biomarkers are associated with a 
woman’s metabolism of arsenic and the biomarkers of potential fetal exposure to arsenic and 
it’s metabolites. Specifically, decreased levels of B12 or folate or Cys and increased levels of 
homocysteine are associated with a decrease in metabolism of arsenic; specifically, there will 
be an decrease in %MMAs and DMAs/MMAs (second methylation step), and an increase in 
the %DMAs. Nutritional biomarkers will be modeled primarily as continuous variables, 
however nutritional deficiencies will be explored through categorical analyses. Other factors 
to consider in this aim are the correlations between the nutritional biomarkers as well as 
potential confounders.  
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Aim 2a: Estimate the total effect of maternal nutritional biomarkers involved in 
one carbon metabolism (B12, folate, cysteine, homocysteine) as measured in maternal 
serum at delivery on infant birthweight.  
The total effect is any effect that is operating through the path of maternal nutritional 
biomarkers involved in one carbon metabolism (B12, folate, cysteine, homocysteine), iAs 
metabolism, and birthweight.  
This aim addresses the hypothesis (Hyp 2a): Maternal nutritional biomarkers are 
associated with infant birthweight. Specifically, deficiencies in folate, B12, and cysteine are 
predicted to be associated with decreases in infant birthweight and elevated levels of 
homocysteine are predicted to be associated with decreases in infant birthweight.  
Aim 2b. Estimate the indirect effect of maternal nutritional biomarkers involved 
in one carbon metabolism (B12, folate, cysteine, homocysteine) as measured in maternal 
serum at delivery on infant birthweight that operates through iAs metabolism. 
The indirect effect is the effect of maternal iAs metabolism arsenic as measured by 
the percentages of iAs, MMAs, and DMAs, as well as two methylation steps  (i.e., primary 
methylation, defined as the ratio between MMA and iAs, and secondary methylation step, 
defined as the ratio between DMA and MMA), in maternal urine on infant birthweight. 
Mediation analysis will be carried out using the Baron-Kenny approach and the mediator will 
be allowed to vary naturally. This aim addresses the hypothesis (Hyp 2b): The effects of 
maternal nutritional biomarkers involved in one carbon metabolism (B12, folate, cysteine, 
homocysteine) on birthweight operate via the pathway of iAs metabolism that then effects 
infant birthweight. 
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Aim 3: Investigate the total and indirect effects of maternal levels of nutritional 
biomarkers involved in one carbon metabolism (B12, folate, cysteine, homocysteine) on 
infant birthweight by different levels of drinking water iAs.  
Exposure levels, characterized by the levels of iAs in drinking water, will be 
categorized as either above and below the WHO guideline level of 10 μg/L. This aim 
addresses the hypothesis (Hyp 3): The levels of iAs in drinking water influence the effect of 
maternal nutritional biomarkers and the health of her newborn.  
 
6 
CHAPTER II: OVERALL SIGNIFICANCE 
Prenatal exposure to environmental contaminants, a global public health problem 
Disease burdens associated with impaired fetal development, including disabilities, 
loss of human capital, and deaths (among others) are vastly impactful to many across the 
globe 13. Underlying several of these burdens are preventable exposures to environmental 
contaminants. Exposures during the prenatal period are important, as it is a critical and 
sensitive time period for development. This period of exposure puts infants and children at 
risk for several adverse health outcomes. In fact, while an estimated 23% of all deaths 
globally are attributable to environmental factors in adults, this proportion significantly 
increases among children of 0–14 years of age, where the proportion of deaths attributable to 
environmental exposures is 36% 14. Additionally, across the globe the per capita number of 
healthy life years lost to environmental risk factors is about 5-fold greater in children under 5 
years of age than in the total population. Furthermore, estimated perinatal conditions, 
including low birth weight, prematurity, birth asphyxia and birth trauma that environmental 
causes account for is an average of 6% (range of: 2—10%) in developed countries, and an 
average of 11% (range of 3— 25%) in developing countries 14. Importantly, many of these 
and other health impacts associated with prenatal exposures persist into childhood and later 
into adult life. 
A particularly important modifiable exposure during the prenatal period is 
environmental toxicants. This is particularly true because the developing fetus is highly 
sensitive to the negative effects of exposures to toxicants, as this is a critical time of rapid 
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cell division, differentiation, and tissue growth. Prenatal exposure to environmental toxicants 
is associated with several adverse reproductive, pregnancy, and birth outcomes as well as 
later in life diseases. Susceptibility to later in life diseases from prenatal exposures is a theory 
that was put forth by Barker termed, “fetal origins of adult disease” (FOAD) 15. The basis 
behind this theory is that there are specific developmental periods whereby an organism is 
“plastic” or “sensitive” to its environment and exposures can alter fetal programming- 
meaning when a stimuli or exposure occurs during early development, this may lead to 
permanent changes that persist throughout life 15. One toxicant of particular concern for 
adverse birth, early life outcomes, and FOAD is iAs. The impacts of iAs on infant birth 
weight and FOAD are just beginning to be unraveled. Interestingly, as it relates to the 
research questions here, FOAD as a theory was originally founded based on the perinatal 
outcome of infant birthweight- a measurement that is still highly relevant and of great public 
health concern today. 
The proposed work here is significant in that it addresses the highly toxic and 
widespread compound of iAs exposure in susceptible populations (in utero); in addition, this 
work is founded to better understanding mechanisms underlying iAs-associated alterations in 
infant birthweight-a risk factor for FOAD. Equally important is results from this study may 
be used to inform public health policies and potential interventions on exposure to iAs, in 
efforts to reduce disease burdens from iAs exposure. It is imperative these risks for iAs 
associated diseases from prenatal exposure are continually evaluated and that we work 
towards effective ways to eliminate this modifiable environmental exposure to prevent 
adverse birth outcomes and later in life diseases. 
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CHAPTER III: BACKGROUND  
Birthweight, an important perinatal outcome 
Birthweight, an easily measurable health outcome, is simply the weight of an infant at 
birth. Specifically, infants’ weights are measured within the first hour of birth, to avoid any 
amount of postnatal loss of weight. On a population scale, the distribution of birthweights 
follow an almost normal frequency distribution with an extended lower tail 16.  
Several terms are used to classify different categories and health descriptors of an 
infant’s birthweight. An infant is classified as being born “low birthweight” (LBW) if it 
weighs 2500 grams or less, regardless of gestational age. LBW is further categorized based 
on gestational ages, where both “premature” or “preterm LBW” are terms to describe infants 
who weigh less than 2500 grams and are born before the completion of 37 weeks of 
gestation; “term LBW” is used to describe those that weigh less than 2500 grams and are 
born between 37 and 42 complete weeks of gestation; “postterm LBW”, are those infants that 
weigh less than 2500 grams and are born after the completion of 42 weeks of gestation 17. 
Two other descriptors used for infants’ weight for both clinical and non-clinical purposes are, 
“small-for-gestational-age” (SGA) and “large-for-gestational-age” (LGA). These are 
statistical calculations based on a standard curve for the weight of infants by weeks of 
gestation, where those infants with weight less than the lower limit of the confidence interval 
of the normal curve are described as being SGA, and those infants that are greater than the 
upper limit of the confidence interval of the normal curve for weight are described as being 
LGA 17. Additionally, the term “intra-uterine growth restriction” (IUGR) is used to explain 
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the condition of high mortality of LBW babies who are born at term and is based on any 
etiology that limits the potential for intra-uterine growth of the fetus that results in low 
birthweight 16.  
The rate for LBW in the US is 8% of all live births 18. Being born at a sub-optimal 
birthweight has many health consequences, starting at birth, through childhood, and later into 
adulthood 19. It has been suggested that LBW in itself may not be a cause of poorer health 
outcomes, instead abnormal birthweight may actually be an indication of abnormal fetal 
growth due to an underlying problem 16. Additionally, the relationship between birthweight 
an infant mortality is non-linear, in that there is an increase in risk for mortality at both lower 
and higher birthweights; this shape varies little among populations 17. The lowest mortality of 
birthweight occurs at a weight just above the mean birthweight, a finding consistent across 
all known populations 20. The relationship between birthweight and infant mortality should 
be interpreted with caution, for even though birthweight is highly predictive of infant 
mortality, it isn’t necessarily deterministic of neonatal survival- as there are many paradoxes 
with this association 21. 
Importantly, shifts in birthweight are also linked to fetal origins of adult disease 
(FOAD). For example, both epidemiological and animal studies have demonstrated that 
when LBW is followed by exponential childhood growth - a term referred to as “catch-up” 
growth- there are increases for risks for metabolic syndrome, obesity, insulin resistance, 
dyslipidemia, and hypertension 15, 22-25.  Additionally, infants born SGA are at increased risk 
for developing obesity, type two diabetes, coronary artery disease, hypertension, kidney 
disease, premature pubarche, Polycystic Syndrome, dyslipidemia, short stature, and 
osteoporosis (as reviewed in 19). 
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Majority of perinatal studies focus on the association between LBW, SGA, and 
smaller babies, however, those with normal birthweights, and LGA may still be at risk for 
adverse health outcomes in early life and for FOAD 26-29. For example, infants who are born 
bigger or LGA have an increase risk for diseases, including obesity and insulin resistance. 
This is likely based on changes in maternal behavior where LGA children are less likely to 
receive breast milk and may exhibit more weight gain in the first 6 months of life compared 
to those who were not LGA 30, 31. Additionally, there may be exposure-specific biological 
mechanisms, for example disruption of molecular pathways that may regulate factors related 
to weight. Therefore, it is important to recognize this U-shaped relationship with both high 
birthweight and low birthweight for risks for later in life diseases.  
Not only is birthweight an important outcome for public health purposes, it is also a 
widely available variable in reproductive/perinatal epidemiological studies as it is 
consistently recorded and measured well. The most direct measurement of this variable on a 
population level is to examine the entire distribution of birthweight, rather than classifying it 
into LBW, SGA, or LGA 16.  
Up to 40% of fetal growth is influenced by genetic factors, and the remaining is 
thought to be due to environmental exposures 17. Specifically, genetic and hereditary factors 
underlying neonatal growth include maternal and paternal birthweight, the sex of the infant, 
chromosomal anomalies, and alterations in the regulators of gene expression (i.e. 
epigenetics). Environmental factors (meaning anything outside of genetic influences) include 
socio-demographic risk factors, including maternal age, race and ethnicity, marital status, 
education, socio-economic level; maternal medical risks before and after pregnancy, 
including chronic hypertension, renal diseases, glucose metabolism disorders, chronic 
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cardiorespiratory disease and other disorders that involve hypoxemia, genitourinary 
anomalies, autoimmune diseases and inherited or acquired thrombophilia, obstetrical history, 
gestational hypertension and diabetes, pregnancy weight gain, parity and time in between 
births, placental abnormalities, vaginal bleeding, increased α-fetoprotein, anemia, infections, 
fetal congenital anomalies, prenatal care, maternal stress, including work and psychosocial 
stress, maternal nutrition and the placenta’s ability to supply nutrients, (amino acids, glucose, 
fat, oxygen, and growth-stimulating hormones) maternal and second hand smoking, alcohol 
consumption, caffeine consumption, maternal and paternal drug consumption, and 
environmental toxicants (as reviewed in 17). 
Clearly there are several known associations between environmental exposures and 
an infant’s weight at birth, yet many of these remain generalities and there is much still 
unknown about specific mechanisms, ways to prevent extremes in infant birthweights, as 
well as FOAD associated with alterations in infant growth. Additionally, the role of 
environmental toxicants in the etiology of these health outcomes is still an area of research 
that is in need of further investigation. One toxicant of particular concern for adverse birth 
outcomes, and in particular neonatal growth is exposure to iAs, as in utero exposure has been 
associated with reduced growth, and several other adverse health outcomes, discussed in 
detail below.  
Sources of exposure to inorganic arsenic  
Inorganic arsenic is a naturally occurring metalloid found in soil and rocks that can 
become mobilized via natural processes, including from mineral weathering, biologically 
aided mineralization, and volcanic emissions. These natural conditions can contribute to high 
concentrations of iAs in ground water due to the strong effects of water–rock interactions and 
the tendency for aquifers to have both the physical and geochemical conditions that support 
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iAs mobilization 32. In addition to natural sources of iAs, human activity can introduce iAs 
into the environment from both commercial and industrial uses, with contamination from 
mining and smelting for the production and use of transistors, lasers and semiconductors, 
processing of glass, pigments, textiles, paper, metal adhesives, wood preservatives, coal, 
pesticides, feed additives, and pharmaceuticals 33. 
People are exposed to iAs through a multitude of ways, including via ingestion from 
contaminated drinking water, using iAs-contaminated water in food preparation and bathing, 
and through the consumption of food sources irrigated with iAs-contaminated water or grown 
in contaminated soils, and through inhalation from smoking and occupational exposures. 
However, drinking iAs-contaminated water is the primary source of exposure to iAs for most 
individuals, where it is estimated that more than 200 million people are exposed to elevated 
levels of iAs from drinking water worldwide. In particular, iAs contaminated drinking water 
has been observed globally in China, including Taiwan, Bangladesh, Japan, Korea, Iran, 
India, Chile, Argentina, Mexico, Europe, and in the US 4.  
The levels of iAs allowed in drinking water that are acceptable and enforced by 
regulatory agencies vary by region. The WHO and Australia, have a set guideline level of 10 
μg/L for iAs in drinking water and the U.S. Environmental Protection Agency’s (EPA) 
maximum contaminant level (MCL) is 10 μg/L. However, in many countries (e.g. 
Bangladesh) 50 μg/L is still the commonly adopted guideline, and in Mexico the MCL is set 
at 25 μg/L. It has been suggested that these differences in regulation may primarily be due to 
the difficulties in remediating iAs below the designated MCLs 33.  
There is a wide range in severity of exposure to iAs from contaminated drinking 
sources by region. The most widely studied and large-scale area of exposure to iAs from 
13 
contaminated drinking water is in Bangladesh. When exposure in this region was first studied 
up to 94% of tube wells in certain regions and 35% of all wells in the country contained > 50 
µg/L iAs 34. A recent review has highlighted the levels of iAs in drinking water samples 
across populations globally, where the levels in Argentina range from less than 10 µg/L up to 
7,550 50 µg/L, in Chile 600 to 800 µg/L, in China less than 50µg/L to 4,400 µg/L, in Ghana 
< 2 µg/L to 175 µg/L, in India < 10 µg/L to >800 µg/L, and in Taiwan < 1 µg/L to 3,000 
µg/L 4.  
While the U.S. has adopted the WHO’s standard for municipally supplied water, there 
are still several areas in the U.S. that have exposure to iAs in drinking water through 
unregulated private wells supplied with groundwater. In the U.S. contaminated groundwater 
with elevated iAs is prevalent in the West, Midwest, parts of Texas and the Northeast and the 
South 35-37. The exact number of households affected by contaminated drinking water is 
largely unknown; however, an EPA study in 2001 found that approximately 13 million U.S. 
residents are drinking water from private wells that exceed the federal drinking water 
standard for iAs 38. Another nationwide survey by the U.S. Geological Survey (USGS), in 
2009, found that 6.8% of the 1,774 wells tested exceeded the MCL 39. State specific results 
also indicate several additional contaminated wells. For example, a USGS survey in Maine 
estimated that 24,000–44,000 households may be affected by levels greater than the U.S. 
EPA MCL 40. Additionally, another study that used predictive modeling, estimates that 
42.7% of the area of aquifers in the southwestern United States have iAs concentrations 
greater than10 µg/L 41. Furthermore, our lab has demonstrated that there is a local concern 
for iAs contaminated wells, where out of 63,000 private drinking water wells tested in North 
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Carolina 1,436 had iAs concentrations greater than the MCL, and a maximum level of 806 
µg/L was found 42.  
While drinking water is the primary source of exposure for iAs there can be exposure 
to both organic and inorganic forms of arsenic from food sources. These sources include fish, 
shellfish, meat, poultry, dairy products, and cereals- notably, arsenic in seafood is mainly in 
the form of the organic arsenic, a less toxic organic form 33. While majority of food exposure 
form iAs is thought to be low, a recent report on iAs in foods from the European Food Safety 
Agency (EFSA) identified rice, seafood, algae, wheat bread and rolls, and bottled water as 
the top food sources that contributed most to the intake of iAs by the European population 
(outside of drinking contaminated iAs water) 43. The daily dietary exposures were within the 
range of reference values, however the authors concluded that the possibility of increased 
exposure to iAs from food can not be excluded 43.  
Sources of iAs exposure via drinking water and diet may differ during various life 
stages. For example, infants have different dietary demands- where newborns’ diet consists 
of primarily breast milk and/or formula. In general, studies have reported that arsenic in 
breast milk is low, regardless of exposure 44; however, the species of arsenic most prevalent 
in breast milk is currently unclear 44 and may depend on the source or magnitude of maternal 
iAs exposure 45, 46. Infant formula can be a source of iAs 47 as can the water that mixed with it 
48. Additionally, children’s intake is relative to their body mass, which is higher than that of 
an adult, 49 therefore dietary exposure to iAs can be up to three times higher for infants and 
young children than iAs exposure for adults 43. Also, because children consume a greater 
volume of rice products, it has been suggested that children less than 3 years of age may have 
the greatest exposures to iAs via their diet 43. 
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Properties of inorganic arsenic  
The chemical properties and forms of arsenic are important in terms of biological fate 
of arsenic, and are essential for assessing associated risks in human populations. Arsenic has 
four oxidation states: +5, +3, 0, and −3, represented by arsenate, arsenite, elemental arsenic, 
and arsine, respectively. In living organisms arsenic is found mostly in the pentavalent (+5) 
and trivalent oxidation (+3/-3) states.  
In considering arsenic exposure from water sources (e.g. natural ground water) 
arsenic is typically present in inorganic forms (iAs3 + and/or iAs5 +). Organic forms of arsenic 
are rare in water because they are a result of biological activity; however, organic arsenic is 
found in seafood, with arsenobetaine and different arsenosugars being the most common 
forms. 
iAs can exist in either the trivalent form (iAs3 +) or pentavalent states (iAs5 +). iAs3 + is  
generally considered to be more toxic than iAs5 +  based on its biological availability, as well 
as physiological and due to its increased toxicological effects 50, 51. IAs5 + is rapidly reduced 
to iAs3 + when ingested and will exert toxicity to similar endpoints, however it has different 
toxicokinetics 51.  iAs3 + is considered about 60 times more toxic than the iAs5 +, because 
arsenite’s ability to react with sulfydryl groups, whereas arsenate does not have this reaction 
in humans 52. 
Once iAs is ingested by humans, it is metabolized in the body to produce 
monomethylated and dimethylated arsenicals (MMAs and DMAs, respectively), this process 
is often referred to as methylation of or metabolism of iAs. Six major arsenicals associated 
with iAs exposure and metabolism have been detected in human urine, namely arsenite 
(iAsIII), arsenate (iAsV), monomethylarsonous acid (MMAIII), monomethylarsonic acid 
(MMAV), dimethylarsinous acid (DMAIII), and dimethylarsinic acid (DMAV)53. Most of this 
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metabolism of iAs is thought to take place in the liver, however, there is increasing evidence 
that the microbiome in the gut may play an important role in metabolism and impact 
absorption/excretion of iAs (60,86).  
In humans the average half-life iAs in the body is about 10 days (79,80). Several 
different biomarkers are used to assess exposure to iAs. Specifically, in some studies, iAs 
concentrations are measured in urine, 54 blood, 55 and toenail samples 56. Urinary iAs is used 
most often as a biomarker of exposure and is considered to be a reliable short-term measure 
of iAs exposure that remains consistent in adults, even during periods of pregnancy. In terms 
of metabolism of iAs, studies that have examined multiple biomarkers suggest strong a 
correlation between metabolites excreted and retained in the same individuals, with positive 
correlations between blood and urine metabolites as well as iAs measurements in hair and 
nail samples 57. 
iAs has many toxicological properties. It is genotoxic and has multiple effects on 
cellular signaling, cellular proliferation, DNA structure, epigenetic regulation, and apoptosis 
58-60. These properties can be set even before birth from prenatal iAs exposure. 
Prenatal exposure to iAs 
In utero exposure to iAs increases the risk for both childhood diseases and for FOAD 
3. iAs is a transplacental toxicant, 61 and maternal exposure to iAs has adverse impacts during 
sensitive embryonic development and on fetal programming 62. From epidemiological studies 
we know that prenatal exposure to iAs can increase oxidative stress 63 lipid peroxidation, 
interfere with hormonal activities, and perturb DNA methylation and gene expression-
including those involved in deregulation of immune and inflammatory pathways 63, 64. These 
mechanism influence fetal programming and may contribute to a wide range of adverse 
pregnancy and birth outcomes 65. Specifically, prenatal exposure to iAs has been associated 
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with adverse neurological outcomes 66, 67, increased cardiovascular disease, pulmonary 
diseases, susceptibility to infection, including inflammation and infectious disease, and later 
in life cancers (as reviewed in4).  
Neurological impairments observed in children from prenatal and early life iAs 
exposure include a decrease in motor function 66, impairments in verbal and full-scale IQ in 
girls, 68 and cognitive impairments in children at 6 and 10 years of age 67; these impairments 
may persist into adulthood and lead to a vast array of neurological  based FOAD. 
Cardiovascular impacts from prenatal iAs exposure have also been identified. A 
retrospective study of Chilean adults who were exposed to high levels of iAs prenatally and 
as very young children had a high standardized mortality ratio (SMR) from acute myocardial 
infarction compared to those who were not exposed to iAs 69. Another study found an 
increase in blood pressure (both systolic and diastolic) at 4.5 years of age, with increases in 
iAs exposure, measured by maternal urinary markers 70. The authors suggest that these 
changes, if sustained, may be damaging and long-term, particularly in genetically susceptible 
populations 70. 
Pulmonary disease endpoints, both cancer and non-cancer, have been observed in 
prenatal cohorts who were exposed to iAs. A SMR of 50.1 from bronchiectasis was observed 
for those exposed to iAs contaminated drinking water prenatally and during early life 71. 
Additionally, there is an increase in pulmonary tuberculosis from prenatal iAs exposure 72 A 
shocking reduction similar to that of smoking throughout adulthood in forced expiratory 
volume and forced vital capacity has been observed in adults who were exposed to iAs in 
utero 73. Furthermore, a decrease in forced vital capacity and a restrictive spirometric pattern 
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in the lungs of children has been observed from exposure to iAs in utero and from early life 
exposure 74.  
Exposure to iAs during pregnancy and childhood is also associated with increased 
incidence and mortality from various cancers both during childhood and later in life 69, 72, 73, 
75. One study found that childhood liver cancers were 9–14 times higher for those exposed to 
iAs as young children as compared with those who were not exposed 75. The same trend was 
observed for childhood liver cancer, where SMRs were 14.1 times higher for individuals 
exposed to iAs in utero and during childhood as compared with individuals exposed to iAs 
during other periods of their lives 71- indicating that the prenatal period is a sensitive time for 
the development of liver cancer. 
There is also evidence that exposure to iAs in utero is associated with an increase in 
inflammation, risk for infection, immune dysfunction and diseases associated with these. 
Altered immune-related health outcomes, including an increased risk for lower respiratory 
infections and diarrhea has been observed in infants and children from prenatal iAs 
exposure76. Changes in immune-related gene expression and cytokine production in 
lymphocytes have also been observed in infants exposed to iAs 77, 78. Additionally, studies 
have indicated that prenatal iAs exposure induces an inflammatory response where reduced 
numbers of T cells as well as altered cytokine profiles from cord blood were identified 63 as 
have changes to the number of specific CD4 + T cell populations present in cord blood, 
increased cord blood T cell proliferation, and greater IL1β expression in the placenta- 
indicating that this could potentially lead to immune dysregulation in the infant 79. 
Furthermore, maternal urinary iAs during pregnancy is significantly associated with reduced 
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thymic function in infants, which is linked to reduced immune function in children and adults 
80.  
In addition to the detrimental health consequences observed in children and adults 
from exposure to iAs during the prenatal period, several adverse perinatal, pregnancy 
outcomes, and birth outcomes have been observed 3. Perinatal and birth outcomes of 
increased infant mortality, increased spontaneous abortion and stillbirth, gestational age, 
preterm birth 81-83, as well as changes in fetal growth factors, including birthweight 5, 84-87 and 
height and head circumference have been associated with in utero iAs exposure 86. A recent 
meta-analysis examined iAs exposure and the risk of spontaneous abortion, stillbirth, preterm 
delivery, birthweight, and neonatal/infant mortality 88. The authors of this study concluded 
that there was an excess risk of 102% for spontaneous abortion, 84% for stillbirth, 51% for 
neonatal mortality, 35% for infant mortality, and a 53-g reduction in birthweight from 
prenatal iAs exposure 88. 
Alterations in fetal growth factors from iAs has immediate and later in life impacts. In 
a large prospective analysis maternal urinary iAs was associated with a 0.05 mm lower 
newborn head circumference 85. There is also evidence of changes in head circumference 
before the 3rd trimester from studies of ultrasound measurements- notably this was in a sex-
specific manner 89. These negative associations between iAs and head circumference may 
also be independent of birth size 86. The impacts of iAs on fetal growth may persist 
throughout life and lead to an increase in susceptibility to other diseases. For example, 
decreases in head circumference closely correlate to brain volume 90 and head circumference 
at birth is associated with later intellectual function 91. However, a few studies have not 
found any associations with fetal growth, including a cohort in Taiwan 92 and a small study 
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of maternal-child pairs from Tokyo who had low iAs exposure 93. Other fetal growth 
implications have been suggested from iAs exposure where there was a negative association 
between iAs exposure and Ponderal Index in children that were overweight/obese and this 
thought to be driven by longer birth length in boys, but by lower birthweight in girls- to 
which the authors suggest this potential mechanistic differences in adiposity at birth could 
influence later growth trajectories 86. Their findings are also supported by a study of mother-
infant pairs where prenatal exposure to iAs was associated with an inverse relationship 
between children’s weight, height, and growth velocity at age 5 94.  
The exact mechanism by which iAs might lead to fetal growth is largely unknown, 
however a few studies have suggested some potential mechanisms. iAs increases oxidative 
stress 95 and inflammatory processes 63, 64, and given that these factors are associated with 
growth restriction 86, this could be a potential underlying mechanism. iAs-associated 
alterations in fetal growth could also have molecular underpinnings, either through epigenetic 
modification, 96 and/or altered transcription 97. One study found increased expression of the 
iAs transporter AQP9 in placental tissue, and the authors suggests that this could cause a 
decrease expression of the adipose tissue-derived ENPP2, 98 a gene that regulates adipose 
tissue growth 99. In addition, iAs could influence fetal growth through other mechanisms 
such as endocrine disruption 100. Furthermore, iAs exposure may worsen factors during 
pregnancy that can contribute to low birthweight, including gestational age and maternal 
health 101. For instance, prenatal iAs exposure is linked to increases in both nausea and 
vomiting, 84 which this may influence maternal weight gain during pregnancy 101 and 
contribute to poor maternal nutritional status 102. Two studies have indicated that iAs may be 
mediated by gestational age 5, 87. In fact, a recent study demonstrated through structural 
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equation modeling that prenatal iAs exposure was associated with decreased birthweight in a 
dose-dependent manner, and the effect was mediated by both gestational and maternal weight 
gain during pregnancy- with greatest effect being gestational age 87. Additionally, differences 
in metabolism may contribute to the underlying mechanism of iAs associated fetal growth 
patterns, as previous work from our lab found that maternal metabolism of iAs was 
associated with alterations in fetal growth and pregnancy outcomes. Specifically, maternal 
urinary MMAs were negatively associated with birthweight and gestational age, and iAs was 
negatively associated with birth length and gestational age 5. 
In addition to these many early life adverse health outcomes, prenatal iAs exposure, 
as well as exposure throughout life, is also associated with diseases later into adulthood. 
Exposure to iAs and later in life diseases 
Diseases from iAs exposure are vast, and the disease burdens from exposure may be 
mostly observed later in life. The International Agency for Research on Cancer (IARC) 
classifies arsenic as a Group I known human carcinogen. Additionally, several non-cancer 
effects have been observed from iAs exposure 1, 33, 103. Furthermore, iAs exposure from 
drinking water has also been associated with an overall high mortality rate 104. In fact, no 
bodily system is free from potential damage as iAs affects the integumentary, cardiovascular, 
renal, nervous, hepatic, endocrine, respiratory, immune, endocrine, and hematological 
systems 105.  
Interestingly, the relationship between iAs and cancer was first identified via 
epidemiological studies, as animal models were inconclusive for inducing cancer from iAs 
exposure. Ecological studies in Taiwan have demonstrated that there is an increase in 
mortality from iAs exposure and internal cancers, including cancer of the lung, liver, bladder, 
and kidney 106. An increase in mortality from iAs associated bladder, lung, and 
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kidney cancers has also been observed in Argentina and Chile 71, 72, 75. Case-control and 
cross-sectional studies have also identified an association with exposure to iAs <500 ug/L 
and cancers, including total and cancer mortality, 107 bladder 108 skin cancer 56, 109, and skin 
lesions 54, 110. From these and other studies, we now know that the excess cancer risk from 
lifetime iAs exposure at iAs drinking water concentrations greater than the WHO/U.S. EPA 
limit of 10 µg/L is approximately 1 in 300. For comparison, this risk is much higher than 
cancer risks estimates for exposures to other known carcinogens in drinking water at 
concentrations equal to current U.S. drinking-water standards 34. The estimated dose response 
relationship between iAs exposure to cause a 1 % increased risk of lung, skin and bladder 
cancer is 0.3 and 8 μg/kg bw/day 111. 
One of the first clinical manifestations of chronic iAs exposure is cutaneous lesions 
and alterations of cutaneous texture, thickness, or color of the skin around them and can 
occur within months or after several years of exposure- even after exposure has ceased. 
Specific skin diseases from exposure to iAs include, hyperpigmentation (melanosis), 
hyperkeratosis (keratosis), squamous cell carcinoma in situ (Bowen’s disease), invasive 
squamous cell carcinoma, and basal cell cancer 4. Epidemiological studies of skin lesions 
indicate that lesions can occur at levels less than 50 ug/L, however most reports of lesions are 
from exposure greater than 100 µg/L 112, 113. Even though lesions are one of the main clinical 
manifestations of exposure, the vast majority of iAs exposed individuals will not develop 
lesions, but are still at risk of iAs-related skin and internal cancers and other non-cancer 
diseases 4, 104, 109  
The association between exposure to iAs and non-cancer endpoints in adults has been 
thoroughly reviewed elsewhere4. Here I will broadly discuss a few of these non-cancer 
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endpoints, including neurological disorders, respiratory diseases, immune dysfunction, 
cardiovascular disorders, and endocrine related disorders.  
There are a few studies that have found associations between exposure to iAs and 
cognitive dysfunction. This includes learning and memory deficits and mood disorders, 
where exposures to iAs may result in memory loss and emotional instability neurological and 
cognitive dysfunction114. Specifically, peripheral neuropathy has been observed from those 
exposed to iAs contaminated ground water in West Bengal, India115. Additionally, long-term 
exposure, even at low levels has been associated with the development of Alzheimer disease 
and its associated disorders 116. Also, there have been links to scoring lower on tests of 
cognitive ability and lower education levels in adults from iAs exposure 117.  
Studies have suggested that exposure to iAs has impacts on lung function, acute 
respiratory tract infections, respiratory symptoms, and non-malignant lung disease mortality- 
particularly at high levels of exposure, as identified by a recent review and meta analysis that 
examined associations between iAs and respiratory health118. Specifically, iAs exposure is 
associated with poorer lung function (particularly forced vital capacity) and increased reports 
of coughing and breathing problems. For example, in Bangladesh impaired lung function and 
tuberculosis was observed with both low and moderate exposure to iAs 119 and iAs exposure 
was associated with chronic cough, blood in the sputum, and other breathing problems120. 
Many epidemiological studies have suggested that there is an increase in risk of both 
cardiovascular disease and cardiovascular associated mortality from drinking water that has 
elevated iAs levels. Specific cardiovascular effects include carotid atherosclerosis, 121 and 
ischemic heart disease122-124 and hypertension122, 125 coronary heart disease, and peripheral 
arterial heart disease126. Cardiovascular effects may also be increased in women during 
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pregnancy as a recent study found an increase in blood pressure over the course of pregnancy 
from concurrent iAs exposure127. Mechanisms that may underlie these iAs-associated 
cardiovascular health endpoints are increased inflammation, disruption of lipid metabolism, 
endothelial dysfunction123, 128.  
Additionally, there are several endocrine effects from iAs exposure, this is evident 
from both animal and epidemiological studies. These include, but are not limited to, effects 
on the endocrine system via disruptions in hormone regulation via the retinoic acid, thyroid 
hormone, and estrogen receptors100, 112, 129, 130. 
Interestingly, differences in disease susceptibility is attributed to many factors 
included dosimetry of iAs- where low vs high exposures may have a difference in disease 
etiology, genetics of the person exposed to iAs, nutrition, as mentioned previously- timing of 
exposure to iAs-where there is increased susceptibility during critical time periods of growth 
and development, and differences in metabolism of iAs. 
Metabolism of iAs and disease  
There has been recent evidence that an individual’s ability to metabolize iAs 
efficiently may play a role in the development of many of the diseases discussed previously- 
in fact this may play a larger role in disease etiology than any other factor. Again, efficient 
metabolism is one’s ability to convert iAs into MMAs and DMAs and inefficient metabolism 
is characterized by the proportions of these in various biomarkers and tissues.  
For example, differences in methylation of iAs has been associated with the 
development of several adverse outcomes in humans including urinary bladder cancer, non-
melanoma skin cancers, carotid atherosclerosis, and chromosomal aberrations (reviewed in2).  
The differences in metabolism may also differ between the two-methylation steps for 
iAs reduction in the body. A recent study found specifically that %MMAs (and thus efficient 
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metabolism), may be more important at lower exposure levels where at higher levels of 
exposure the risk of developing skin lesions did not depend heavily on the efficiency of the 
first methylation step131. 
Furthermore, pregnancy can be a period where metabolism efficiency of iAs is 
particularly important53. Inefficient metabolism of iAs has recently been associated decreases 
in birth and placental weight5. 
Factors that influence metabolism of inorganic arsenic  
There are many factors that may influence methylation/metabolism of iAs including, 
but not limited to, the level of exposure to iAs in drinking water or food, age, gender, 
pregnancy, nutritional status of folate, homocystein, and protein, creatine, and genotype for 
arsenic 3 methyltransferase (AS3MT). While many of these associations have been 
established, the exact mechanisms remain unclear, and there have been very few replications 
of these associations across multiple populations. Additionally, even fewer investigations 
have been focused on the mediation of exposure disease relationships by factors that regulate 
metabolism of iAs. 
Methylation of iAs is conducted by the enzyme arsenic (+3 oxidation state) 
methyltransferase (AS3MT). The importance of this enzyme has been indicated by a 
reduction in iAs methylation from gene silencing in cultured cells and in knockout mice. 
Additionally, genome wide association studies (GWAS) have indicated that single nucleotide 
polymorphisms (SNPs) in the AS3MT gene influence arsenic methylation capabilities132-135. 
Previous research in our lab also supports this mechanism during pregnancy where maternal 
alleles for five SNPs of AS3MT were associated with maternal urinary concentrations of iAs 
metabolites, and alleles for one SNP were associated with birth outcomes/measures 136. 
Moreover, these associations may be dependent upon the male sex of the fetus but 
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independent of fetal genotype for AS3MT136. Perhaps the most strong and intriguing evidence 
for AS3MT’s role in metabolism of iAs comes from indigenous populations in northern 
Chile137 and northern Argentina138 where individuals are exposed to high levels of iAs 
drinking water, yet even at levels known to impair iAs metabolism have efficient arsenic 
metabolism139- this is because they have a very functional genotype for AS3MT. Furthermore, 
a recent study has suggested that there may be differences in AS3MT SNPs for different steps 
in metabolism, where certain SNPs are more important in the second step of metabolism of 
iAs as AS3MT binding affinity differs between methylation steps131. While genotype for 
AS3MT is important for metabolism of iAs, comparisons across studies indicate that majority 
of populations do not carry the very functional genotype and therefore most efficiencies in 
metabolism of iAs would not be observed based on an individual’s genotype136. 
Other influences to iAs metabolism have been observed in epidemiological studies. 
For example, there are differences in metabolism by gender, where women had decreased 
levels of %iAs compared to men140. The influence of age with metabolism of iAs is not clear, 
levels of %iAs decreases with increasing age141-143 but associations have also been observed 
with %iAs increasing with age 144. Increases in BMI have also been associated with %iAs142, 
145, 146. For percentages of MMAs, lower levels have been observed among females compared 
to males141, 143, 145, 147 among those who never smoked147, and with an increase in age141 and 
with an increase in BMI143, 144, 148, 149 however, lower levels have also been observed with 
decreasing age144. Higher levels of %DMA have been observed among females compared to 
males143, 147, with an increase in age141, 144, 145, with an increase in BMI143, 145, 146, and among 
those who never smoked145. 
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The levels of iAs in drinking water also influence the levels of metabolites in urine. It 
has been suggested, that the ability to methylate MMA to DMA is reduced with increasing 
exposures- though this is not very clear. These levels of iAs in drinking water may influence 
the second methylation step. Previous studies have found that this step is inhibited at 
increased exposure levels (particularly elevated levels of iAsIII and MMAIII) both in the 
experimental setting and in human observational studies131. A recent study suggests that 
metabolism of iAs and the development of disease may depend on drinking water exposure 
levels where efficiency of the methylation steps of iAs was effected by lower vs higher levels 
of iAs 131. 
It has been suggested that the efficiency of metabolism during pregnancy, may be 
increased61, 83, 139, however this is unclear and may depend on the levels of exposure to iAs. A 
recent study found that in the second trimester at high iAs exposures (≥ 50 μg/L), 
methylation was inhibited, to which the authors suggested that this could lead to 
unmethylated iAs and MMAs in fetus blood plasma, and this could threaten fetal survival 
and growth131.  
Nutrient status has the ability to modify iAs diseases and metabolism of iAs 
Diet and nutrition may have a large influence on iAs metabolism and/or iAs-
associated diseases. This is intriguing from a public health perspective in that it may provide 
a way to mitigate the health effects from iAs exposure. 
Previous epidemiological research has indicated that intake of fruit and canned goods 
has been associated with a reduced risk of iAs-related skin lesions 150. However, intake of 
bean and betel nut was associated with an increased risk of skin lesions 150. The mechanisms 
behind these dietary associations is not established, however the authors of the study suggest 
that the positive effect of fruit might be due to the carotenoids and other nutrients from fruits, 
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and betel nut could alter lipid and protein metabolisms, which would increase the toxic 
impacts from iAs150. 
Animal studies of vitamin supplementation have demonstrated that there are 
alterations in iAs-associated mechanisms of disease. For example, when rats were exposed to 
iAs with folic acid (vitamin B9) or vitamin B12, or both folic acid and vitamin B12 there was 
reduction in oxidative damage, apoptosis, and downstream changes in hepatic 
mitochondria151. Additionally, treatment of iAs exposed rats with Ascorbic acid (vitamin C) 
has shown to improve mitochondrial functions 152. The benefits of vitamin supplementation 
may also occur during the prenatal period, where supplementation with zinc and vitamins C 
and E had an impact on the reduction of some of the deleterious effects (cholesterol levels, 
TBARS levels and catalase activity) from iAs exposure in rats and pups during gestation and 
lactation153, 154. In addition, increased intakes of pyridoxine (Vitamin B6), thiamin (Vitamin 
B1), and Vitamins A, C and E could lower the number of skin lesions in individuals from iAs 
exposure 155. A reduction in risk of iAs-related urothelial carcinoma has been observed with 
supplementation of Alpha-tocopherol (Vitamin E)156. 
There are a few potential ways that vitamins may affect iAs metabolism and toxicity. 
One is that vitamins as antioxidant can act as free radical to reduce oxidative damage induced 
by iAs. Also, many vitamins are known to be important cofactors in both S-adenosyl 
methionine (SAM) synthesis and one-carbon metabolism, where both play a key role in iAs 
methylation. This has been demonstrated in animal models where suboptimal intake of many 
vitamins and nutrients that are required for SAM synthesis, including methionine, choline, 
folate, and vitamin B12, or the knockout of the folate receptor, impaired iAs methylation and 
increased susceptibility to both carcinogenic and non- carcinogenic effects from iAs 
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exposure7-9. For example, Vitamin B12 plays an integral role in folate-dependent 
homocysteine metabolism as a rate-limiting co-factor in the conversion of homocysteine to 
methionine10. More specifics of folate and those co-factors are discussed below. 
Folate is a source for the generation of endogenous methionine to add methyl groups 
in the methylation process- this process of adding a methyl group to many chemical 
compounds is involved in hundreds of essential chemical/biological reactions in the body. As 
is pertinent to iAs exposure and metabolism of iAs this is important for the reduction of iAs 
to MMAs and DMAs. This methylation process is driven by an enzymatic response by 
methyltransferases that use S-adenosyl methionine (SAM) as a methyl group donor. 
Methionine, as a source of methyl group in the methylation cycle, transfers a methyl group 
but only when it is activated by ATP to form SAM. Folic acid can increase methionine to 
promote iAs methylation. Notably, iAs may cause a reduction in SAM157. SAM, the methyl 
donor for As methylation, relies on folate-dependent one-carbon metabolism158. By 
increasing methylation of iAs to DMAs, folate aides in the elimination of As in urine, thus 
this may be an indication of a lower amount of iAs in the body 158. While this process is well 
understood, there are still many factors that regulate and can alter these biochemical reactions 
in the body and more in vivo and in vitro experiments, as well as epidemiological studies are 
needed to further demonstrate the influence of folate and other folate-dependent vitamins on 
iAs metabolism and toxicity. 
Interests in folate’s role in the metabolism of iAs have been a focus of a few 
intervention studies- not only because of its inherit biological properties, but it is also an easy 
and affordable supplement to acquire and distribute. The importance for the role of folate in 
iAs metabolism has been supported by a recent RCT that examined folate supplementation in 
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adults exposed to iAs11. Interestingly, the researchers found that after 24 weeks, people 
taking a 800 µg dose of folic acid, including the ones who switched to placebo halfway 
through, had an average decline in arsenic levels of 12%, compared with 2% for those taking 
placebo11. Furthermore, these findings were also strong in people who already had adequate 
blood levels of folate, where a higher dose of folate lowered the levels of iAs 11. These 
findings could significantly influence the amelioration of the numerous disease burdens from 
iAs exposure.  
The impact of folate to reduce the toxic impacts of iAs during pregnancy is less clear. 
There has been an association found between the levels of folate and homocysteine and 
metabolism of iAs 159. However, in an RCT targeting the use of nutrition supplementation to 
increase metabolism in in pregnant women the results indicate that there was only a marginal 
effect from nutritional and folic acid supplementation 160. In this study participants were 
randomized by a 2x3 factorial design where all pregnant women received 400 ug of folic acid 
and others received either food supplements during their 8th gestational week or received 
food supplementation by their own choice- these two groups were further supplemented with 
the either 30 mg of iron (Fe), 60 mg Fe or 30 mg Fe + 13 micronutrients. The researchers 
measured change in metabolism of iAs by gestational week and identified there was no 
change in metabolism with supplementation6. However, they noted that other measurements 
of micronutrients as well as participation in food supplementation may have impacted their 
findings6. Furthermore, the participants in this study were highly nutrient deficient, including 
foliate deficient and may not have had adequate folic acid supplementation to impact iAs 
metabolism- additionally there was no control group in this study. 
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Additionally, many of the other micronutrients essential for one-carbon metabolism 
and potentially iAs metabolism were not fully measured in these studies. Of course, these 
measurements and classification of these interactions in human studies remains quite 
difficult, costly, and require higher volumes of biological samples. In particular, there is a 
strong interaction between folate, vitamins B12 and B6, choline, betaine, and methionine in 
the human methylation pathways161, 162 and it has been suggested that the betaine-mediated 
remethylation of homocysteine may be particularly important in individuals with low folate 
intake 6. Therefore further classifications of diet and nutrition as it relates to iAs exposure in 
these and other populations are needed. Homocysteine must be removed because it can act as 
an inhibitor for this SAM dependent process (via hydrolyzation of SAH). This removal of 
homocysteine can occur via three ways, the folate-dependent pathway, betaine-dependent 
pathway, or via transsulfuration. Thus, lower folate and B12 are associated with higher 
homocysteine and this can cause a decrease in iAs methylation. However, homocysteine can 
also effect arsenic methylation independently. Previous studies suggest the potential positive 
association between homocysteine and %MMAs and negative association with %DMAs is 
likely to reflect inhibition of the second methylation step11. 
Notably, both of the previous mentioned RCTs were in highly exposed iAs 
populations and there was no inclusion of health endpoints that may be altered from changes 
in iAs metabolism and mediated by nutritional status. It has been suggested that nutritional 
factors such as folate158, 159 and protein intake 163 may modify the associations between 
arsenic and fetal growth- therefore further investigation is of this relationship warranted 86. 
As nutrient status relates to the aims of this study, the role of folate during pregnancy serves 
multiple purposes for birth outcomes, and in particular birthweight. 
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The role of one carbon metabolism indicators in pregnancy and birthweight 
Not only is folate an important factor for the metabolism of iAs, it also plays an 
important role in pregnancy and birth outcomes. Clearly, the maternal diet during the peri-
conceptional period and later in pregnancy is an important factor for the development and 
subsequent health outcomes of the developing fetus164. Interests in the role of folate during 
pregnancy and supplementation with folic acid has been a massive public health effort in the 
U.S. and elsewhere, as women with insufficient folate are at increased risk of giving birth to 
infants with neural tube defects 165. Additionally, lower maternal folate status has also been 
associated with low infant birthweight, preterm delivery, and fetal growth retardation166. 
For clarity, folic acid refers to the oxidized form of the vitamin found in fortified 
foods and in supplements, whereas folate is the reduced form of the vitamin naturally in 
foods and in biological tissues. The bioavailability of folate can depend on the form, where 
there is a higher availability in supplementation of folic acid and lower bioavailability in 
foods167. The CDC recommends that women take 400 μg of folic acid a day, including for 
women that are of reproductive age and/or planning to get pregnant167. Additionally, it is 
recommended that supplementation with higher levels of folic acid, 600 μg of a day during 
pregnancy and 500 μg a day during breast feeding167.  
Folate deficiency status is measured by concentrations in the plasma, serum, or red 
blood cells, Serum and plasma reflect recent dietary intake, with serum folate levels less than 
6.8 nmol/L (3 μg/L) suggest that there is a deficiency167. For long-term concentrations red 
blood cells are most representative of tissue levels, however these concentrations are affected 
by vitamin B12 deficiencies. Another measurement used to determine folate 
status/metabolism is elevated plasma or serum total homocysteine as it is considered a 
functional and sensitive marker of both folate and vitamin B12 deficiencies168. For 
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homocysteine, an “elevated value” is most often set at 16 micromoles/L, although slightly 
lower values of 12 to 14 micromoles/L have been used165. 
This measurement of homocysteine may be important as folate and vitamin B12 have 
a synergistic relationship and their role in the conversion of homocysteine to methionine 
along with the role of B6 in the conversion of cystathionine, and during early fetal 
development may be influenced directly by elevated total homocysteine or through other 
downstream effects of folate impairments167. 
This interplay between prenatal folate, vitamin B12 and homocysteine has been 
established as important factor for birthweight. Folate is important for cellular functioning, in 
particular in the synthesis and repair of DNA and in gene expression, through the process of 
DNA methylation 169. Elevated total serum homocysteine have been associated with, 
placental vasculopathy170, 171 which influences fetal growth 172. Additionally, limited supply 
of vitamin B12 during pregnancy may have an impact on fetal growth. Specifically, vitamin 
B12 is known to be a significant predictor of tHcy levels in neonates, with relatively greater 
importance in the first few months of life, before folate assumes primacy as the predictor of 
tHcy173.  
Previous researchers have established the association between maternal folate status 
and infant birthweight. One study found a twofold greater risk for low birthweight for infants 
whose mother’s had a lower mean daily folate intake (<240 μg/d) at 28 weeks gestation166.  
A positive association between maternal folate intake infant birthweight was found from 
maternal folate levels at weeks 18 and 30 gestation174 Additionally, low serum folate levels at 
30 weeks gestation and a an increase in fetal growth restriction has been observed175. 
Furthermore, maternal deficiencies in folate is also associated with intrauterine growth 
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restriction166. Such studies suggest a role for maternal folate in the determination of infant 
birth weight. Moreover, several studies have explored the relationship between tHcy and 
birth weight, with mixed findings 176-178. It remains unclear whether tHcy is merely a 
biomarker of folate status or is deleterious in itself. Three intervention studies have shown a 
significant increase in birth weight associated with the use of prenatal multivitamin 
supplements, which included folate, whilst three other studies have failed to show an 
effect179. Clearly, the exact mechanism behind the relationship between maternal folate status 
and birthweight remains to be determined. 
Current efforts in preventing exposure to iAs and altering metabolism of iAs  
Reducing exposure to iAs from contaminated drinking water and preventing the 
associated health effects from iAs exposures is a multifactorial problem. Exposure levels, 
metabolism of, and susceptibility to iAs can be highly individualized. For example, there are 
many differences in exposure levels of iAs in drinking water across the globe, where the 
levels in drinking water may be based on proximity to naturally occurring iAs in bedrocks 
and sediments and/or proximity to hazardous waste sites. Therefore, drinking-water sources 
with both low and high iAs concentrations can exist in very close proximity to one another. 
Additionally, an individual’s differences in susceptibilities to the toxic effects from 
differences in metabolism of iAs is highly individualized- as previously discussed. 
Furthermore, as stated previously, susceptible populations such as pregnant women and 
children may be more significantly impacted by exposure to iAs than others and have a 
higher risk for adverse health outcomes. Current regulation of iAs in drinking water is based 
only on the levels of iAs in drinking water, where the EPA and WHO standard is set to not 
exceed 10ppb. While top down regulatory action to reduce exposure to iAs can be effective 
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there are many obstacles that need to be assessed in risk assessment and future regulatory 
actions to prevent iAs-associated diseases. 
Mitigation efforts in areas where there has been high exposure to iAs have included 
pond sand filters, home-based “3-pitcher” filters, rainwater harvesting, digging deeper wells, 
and switching drinking water sources180-183. In an area that has experienced and is still 
experiencing perhaps the most widespread exposure to iAs contaminated drinking in 
Bangladesh there have been many mitigation efforts to prevent exposure to iAs and iAs-
associated diseases. For example, wells that contained more than 50 μg/L of iAs were painted 
red, and residents were encouraged to collect their drinking water from nearby green painted 
wells that had lower concentrations of iAs. Other strategies that have been put into place 
across the globe are suggesting that individuals switch to bottled water for drinking and 
cooking, installing treatment systems that focus on a single area of water use, such as a 
kitchen sink (commonly referred to as point-of-use or POU), and treatment systems that treat 
all the water entering the home (commonly referred to as point-of-entry or POE) 184. Bottled 
water and POU treatments have been most commonly used in many areas, exemplified from 
a survey of central Maine residents with well water iAs levels above 10 μg/L, where more 
than 65% of respondents indicated they were using either bottled water or a POU treatment 
system to reduce exposure185. Interestingly, these two intervention strategies remained the 
most common methods even for households with higher iAs levels in drinking water (above 
100 μg/L)185. 
However studies have revealed that many of the current strategies in prevention are 
not that effective in reducing exposure to or the levels of iAs found in human biomarkers184. 
This is due to the many limitations to completely removing exposure to iAs including, the 
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high cost of water filters and their monitoring and maintenance, the limited effectiveness of 
water filters in real-world settings (e.g adherence), and the limited availability of low iAs 
wells in some regions 11. Additionally, long-term chronic exposure to iAs may lead to an 
increased body burden of As that persists long after exposure is removed.11 For example, 
after a bottled water intervention in Arizona there was only a modest reduction (21%) in 
urinary iAs levels observed 186. For bottled water and POU treatment strategies, effective iAs 
exposure reduction is also highly dependent on behavioral factors such as willingness to use 
only treated water or bottled water for beverage and food preparation, as well as for drinking. 
Of importance, even the occasional use of untreated water for beverage or food preparation 
after switching to bottled water or installing a POU treatment system could still lead to 
dangerous exposures to iAs, especially if water iAs levels are high- this exposure may also 
result from bathing-related contact with untreated water187. 
A recent cross-sectional study in the U.S. examined the effectiveness of various 
mitigation strategies for iAs exposure from private wells184. Shockingly, they found evidence 
of water-related exposure among families that relied on POU treatment systems or that 
supplemented water with bottled water, where even occasional consumption of untreated 
water was significantly associated with higher urinary iAs levels among private well owners 
who have elevated iAs in well water. This relationship was particularly true for young 
children, and to which the authors note that children’s ability or willingness to refrain from 
ingestion of untreated water may be less consistent and enforceable. These findings support 
that compliance with using POU systems or with bottled water interventions is not effective 
for reducing iAs exposure184. 
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Taken together, these studies indicate that the primary focus of removing the source 
of exposure to iAs (via drinking water) may present several issues and limit the ability to 
eradicate iAs-associated diseases. There is a need to investigate the potential for providing 
nutritional supplementation, as it may be a low-risk and affordable treatment option for those 
who are at risk for iAs-associated diseases including those currently and/or those who have 
had past exposure. The ability to investigate this relationship outside of expensive clinical 
trials has been a limitation, however the research suggested here could fill this limitation and 
research gap. 
Application of mediation analysis  
Knowing if an exposure or treatment causes an adverse health outcome within the 
same individual would be the ultimate study design for an epidemiologist, which is why the 
randomized trial is considered the gold standard for many epidemiological studies. However, 
with many exposures and specifically environmental exposures or treatments it is not 
possible to randomize or expose individuals based on feasibility, moral, costs, or other 
reasons. Additionally, knowing if an intervention could prevent the number of cases/diseases 
before the initiation of an intervention or trial would allow for the assessment of many more 
potential public health intervention scenarios before the initiation of costly RCTs or potential 
ineffective interventions. To this end, with the development of and continual updates in 
causal inference methods, causality can be better established (as long as certain conditions 
are met) and these potential interventions can be modeled. The idea behind an experiment is 
that when one is looking at an exposure disease relationship you can essentially ask the 
question, what if you could go back in time and change the exposure…would this alter the 
outcome? 
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Currently, many epidemiological studies measure associations of exposures/disease 
relationships and associations instead of assessing causality. To clarify, an “association” of 
an exposure/disease relationship is determined by a difference in an effect measure from two 
individuals in a population, where the individual’s actual exposure/treatment is either that of 
exposed or unexposed, whereas causation is the difference in an effect measure in the entire 
population under two different treatment/exposure values188. While this is a good and 
appropriate approach for many disease/exposure relationships and epidemiological questions, 
there may be reasons to delve further into causality, and in particular to the topic here 
provide information that may allow for direct public health change across populations. 
Recently, there has been much development in causal inference methods to address 
the potential of modeling interventions and applying these to environmental health studies. 
As this relates to mediation analysis, causal inference methods can greatly improve many of 
the current limitations by traditional mediation analyses. The question addressed for 
mediation is what if the effect of an exposure (A) on outcome (Y) is carried out through an 
intermediate variable (M) A M Y. The application of mediation analyses can serve to: 
(1) Understand the causal mechanism between an exposure, disease and an intermediate 
variable; (2) Confirm or refute a theory; (3) Refine interventions; (4) Intervene on the 
mediator when we cannot intervene on an exposure (perhaps due to costs) or target 
subgroups most at risk (in resource limited intervention); (5) Jointly test an effect can 
possible identify exposure/disease responses whereas testing an effect alone may fail to 
identify such a relationship. Specific approaches to determine mediation go beyond classic 
regression approaches, which are limited for application to nonlinear relationships and 
models of interactions; however, standard approaches are appropriate in certain 
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applications.189 Instead, I suggest the use of causal/counterfactual framework. New advances 
in causal mediation analysis include using g-computation (the g-formula) and have been 
recently applied to mediation analyses.189 These methods allow for the identification and 
decomposition both the total effect (i.e. the external exposure, mediator, and outcome 
relationship) direct (i.e. external exposure to outcome) and the indirect effects (i.e. the 
relationship between an exposure, a causal intermediate). Using a causal framework allows 
for nonlinear models and interactive effects, while addressing the potential bias arising from 
overly restrictive statistical analyses and suboptimal study design190. Furthermore, by 
examining the controlled direct effects, mediators can be set or fixed to levels of interest 
across the entire sample. However, the application of these methods for both environmental 
and reproductive epidemiological research is lacking. 
Causal mediation analysis in detail has been described fully by Vanderweele and 
others189. Specific to this thesis work, methods include those described by Valeri and 
Vanderweele 191. Where the following is denoted: a reference (baseline) level of exposure, a0 
and a new level, a1; let m denote the mediator, for both a natural and a fixed level. Under this 
framework investigators can measure: the Natural direct effect (NDE), which can be 
interpreted as how much the outcome of would change if the exposure was set to a new level 
of exposure (a1) but the mediator (m) is kept at a level it would have taken in absence of the 
exposure; the Natural indirect effect (NIE) which can be interpreted as how much the 
outcome would change on average if the exposure were controlled at level a=1 but the 
mediator were changed from the level they would’ve taken if a=0 to the level it would’ve 
taken if a=1; the total effect (TE) which estimates how much the outcome would change 
overall for a change in the exposure from level a=0 to a=1; the controlled direct effect (CDE) 
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which estimates how much the outcome would change on average if the mediator were 
controlled at fixed level (assigned), and the percent proportion mediated (PM) can be 
calculated by the following formula: NIE/TE x 100189. 
Importantly, in the application of these methods there are strong assumptions for 
interpreting these findings within the causal framework. Specifically, the estimation of direct 
and indirect effects, and subsequent causal interpretations require that there be no 
unmeasured exposure-outcome, mediator-outcome, or exposure-mediator confounders192. 
Additionally, when modeling controlled direct effects if unmeasured or uncontrolled for 
confounders of the mediator- outcome relationship occur this can lead to biased estimates193. 
Overall study design and methods  
Source of iAs in the study area 
In Mexico, it is estimated that more than 450,000 people may be exposed to levels of 
iAs in drinking water that exceed the MCL of 25 μg/L194. Levels of iAs from central-eastern 
regions of Mexico have been found up to 1,504 μg As/L195 and up to 215 μg/L196 in Hidalgo 
and Zimapán, respectively. Reports of iAs-contaminated ground water and wells in the 
Lagunera region in the states of Durango and Coahuila, Mexico in the central part of North 
Mexico began as early as the 1970s. In the early 90’s, Del Razo et al., found that in the 
Lagunera Region more than 50% of samples had iAs concentrations greater than 50 μg/L, 
which at the time was the MCL of the World Health Organization197, 198. Additionally, 
studies from the region of Lagunera found that individuals who were drinking well-water had 
an average exposure of 400 μg/L of iAs and had an average of 560 μg/L of U-tAs in their 
urine (range 320–1560) of iAs198. 
Previous researchers have concluded that drinking water is the main source of iAs 
exposure in this area196, 198-200. Additionally, a study in the region that investigated potential 
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iAs-exposure from food sources in this area found that the primary increase in iAs from 
foods was dependent on the amount of water used and cooking time, as most foods were 
boiled or cooked with water before consumption. Additionally, the authors suggested that iAs 
contamination from seafood is not a large problem in this area, as marine foods are not 
usually consumed in this area201. 
The geological and climatic properties of these areas make it prime for iAs 
contamination as they are mostly that of sedimentary basins and are inactive volcanic 
regions. For a long time the cause of iAs-contaminated drinking water was controversial, 
however, recent research has suggested that iAs present in groundwater in the Lagunera 
Region is ultimately a by product of water scarcity in the area and aquifer depletion. The 
depletion of aquifers is due to the damming and diversion of the area’s rivers and a 
simultaneous overdraft of groundwater202. Additionally the area is plagued by a lack of 
rainfall, as Lagunera Region is also one of the driest in Mexico, with an average annual 
rainfall of 260mm,202 and that most of the extracted ground water is used to grow crops for 
grazing cattle202. All of this combined can lead to a higher demand from other sources of 
water- and in this instance ones that may be contaminated by iAs.  
Study population 
This study uses data and samples from the Biomarkers of Exposure to ARsenic 
(BEAR), a prospective pregnancy cohort that was establish in Gómez Palacio, Mexico, to 
better understand the effects of iAs exposure on pregnant women and their children. BEAR 
participants, adult women, were recruited during the time frame of August 2011 to March 
2012 at the General Hospital of Gómez Palacio. Recruitment took place prior to the time of 
delivery, which for most women was within 24 hours of birth. All procedures associated with 
this study were approved by the Institutional Review Boards of Universidad Juarez del 
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Estado de Durango (UJED), Gómez Palacio, Durango, Mexico, and the University of North 
Carolina at Chapel Hill (UNC), Chapel Hill, North Carolina, U.S.A. For each woman 
participation requirements at the time of recruitment included: (i) one year minimum 
residence in the Gómez Palacio region, which included urban locations of Gómez Palacio 
and surrounding rural locations, (ii) confirmation of a pregnancy without complications such 
as eclampsia or preeclampsia, and (iii) good overall health status (i.e. no signs of chronic or 
acute disease).  A total of 221 women were approached for the study. Of those, 93% (n=206) 
consented to participate in the study. Six women were not included in the study as a result of 
confirmation of a twin pregnancy (n=1; 0.5%) or sample collection failure (n=5; 2.4%). The 
final cohort consists of 200 mom/baby pairs. 
A social worker administered questionnaires to the study participants to collect the 
following information: age, education, occupation, time living at residence, smoking status 
and alcoholic beverage consumption during pregnancy (both defined as yes or no and 
frequency), daily prenatal supplement intake (yes or no), residence location (urban or rural), 
seafood consumption (yes or no), source and daily consumption of drinking and cooking 
water, and source of bathing water. In addition, information on previous pregnancy outcomes 
including number of pregnancies and number of previous pregnancy losses was gathered 
from questionnaires. Information on birth outcomes/measures including newborn birth 
weight, newborn length, gestational age, head circumference, placental weight, and 5-min 
Appearance, Pulse, Grimace, Activity, Respiration (APGAR) score was gathered at time of 
delivery by the physician203. Data on adverse outcomes were collected, including preterm 
birth (gestational age < 37 weeks), low birth weight (LBW; < 2,500 g), small for gestational 
age (SGA; birth weight < 10th percentile), and large for gestational age (LGA; birth weight > 
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90th percentile). SGA and LGA categories were based on newborn data collected from 
northern regions of Mexico204, 205. 
Biospecimens collected around the time of delivery included: maternal spot urine 
samples, maternal serum, and cord serum, as well as blood samples from both where DNA 
and RNA was later extracted. All samples were immediately stored at -80°C. The 
concentrations of iAs in drinking water (micrograms As/L; DW-iAs) were measured at 
UJED, Mexico, using hydride generation–atomic absorption spectrometry (HG-AAS) 
supported by a FIAS-100. The Trace Elements in Water standard reference material (SRM 
1643e) (National Institute of Standards and Technology, Gaithersburg, MD) was used for 
quality control. The limit of detection (LOD) for iAs in drinking water by HG-AAS was 0.46 
μg As/L. All urine analyses were conducted at UNC-Chapel Hill. Concentrations of urinary 
biomarkers of exposure: U-iAs, U-MMAs, and U-DMAs were determined by HG-AAS with 
cryotrapping206. Five-point calibration curves were prepared using pentavalent iAs, MMAs, 
DMAs standards (> 98% pure) as described previously,206 and the SRM 2669 Arsenic 
Species in Frozen Human Urine (National Institute of Standards and Technology) was used 
for quality control 207. The LODs for U-iAs, U-MMAs, and U-DMAs were 0.2, 0.1, and 0.1 
μg As/L, respectively. The specific gravity (SG) of each urine sample was measured using a 
handheld refractometer (Reichert TX 400 #13740000; Reichert Inc., Depew, NY). To 
account for differences in water intake/differential hydration, concentrations of U-iAs, U-
MMAs, and U-DMAs in each urine sample were adjusted by the specific gravity. Maternal 
folate and homocysteine levels was measured in maternal serum. 
Concentrations of iAs in drinking water (DW-iAs) ranged from below the LOD (0.46 
μg As/L) to 236.0 μg As/L (mean, 24.6 μg As/L). More than half of the women (53%) had 
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DW-iAs that exceeded the World Health Organization’s recommended guideline of 10 μg 
As/L. Maternal urinary concentrations of specific gravity adjusted total urinary arsenic (U-
tAs) ranged from 4.3 to 319.7 μg As/L (mean, 37.5 μg As/L). These levels of U-tAs in the 
BEAR cohort are generally lower than levels observed in pregnant women in Bangladesh 
(SG-adjusted medians, 23.3 μg As/L vs. 80 μg As/L)160 However, the levels of U-tAs in this 
cohort are higher than levels observed in U.S. women (SG-adjusted mean, 37.5 μg As/L vs. 
creatinine adjusted geometric mean, 7.3 μg As/L)208. 
Given that an individual’s efficiency of iAs biotransformation/metabolism known to 
influence the susceptibility to iAs-associated diseases this was investigated. The mean 
urinary concentrations of individual SG-adjusted arsenicals were 2.1, 2.3, and 33.1 μg As/L 
for iAs, monomethylated arsenicals (MMAs), and dimethylated arsenicals (DMAs) 
respectively. This corresponds to the proportions of U-tAs comprising 6.1%, 6.4%, and 
87.6% for U-iAs, U-MMAs, and U-DMAs respectively. DW-iAs was significantly associated 
with the sum of the urinary arsenicals (U-tAs) (r=0.51, p<0.0001). Maternal urinary 
concentrations of MMAs were negatively associated with newborn birth weight and 
gestational age. Maternal urinary concentrations of iAs were associated with lower mean 
gestational age and newborn length. The data support a relationship between iAs metabolism 
in pregnant women and adverse birth outcomes.  
Previous findings in the BEAR cohort 
A sub set of samples from the cohort were prioritized for molecular/mechanistic 
investigations, including assessment of iAs-associated microRNA expression209, DNA 
methylation,210 gene expression,209, 210 and protein expression211 in association with prenatal 
iAs exposure 
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MicroRNA (miRNA) expression changes associated with in utero arsenic exposure 
were assessed from cord blood samples (n = 40)209. Genome-wide miRNA expression 
analysis of cord blood revealed 12 miRNAs with increasing expression associated with U-
tAs. Transcriptional targets of the miRNAs were computationally predicted and subsequently 
assessed using transcriptional profiling. Pathway analysis demonstrated that the U-tAs-
associated miRNAs are involved in signaling pathways related to known health outcomes of 
iAs exposure including cancer and diabetes mellitus. Immune response-related mRNAs were 
also identified with decreased expression levels associated with U-tAs, and predicted to be 
mediated in part by the arsenic-responsive miRNAs. These results highlight miRNAs as 
novel responders to prenatal arsenic exposure that may contribute to associated immune 
response perturbations. 
Epigenetic alterations via DNA methylation and alterations in gene expression were 
assessed from cord blood leukocyte samples (n=38)210. Changes in iAs-associated DNA 5-
methyl cytosine methylation were assessed across 424,935 CpG sites representing 18,761 
genes and were compared to corresponding expression levels and birth outcomes. In the 
context of arsenic exposure, a total of 2,705 genes were identified with iAs-associated 
differences in DNA methylation. Site-specific analyses identified DNA methylation changes 
that were most predictive of gene expression levels. Specifically, CpG methylation within 
CpG islands positioned within the first exon and 200bp upstream of the transcription start site 
yielded the most significant association with gene expression levels. A set of 16 genes was 
identified with correlated iAs-associated changes in DNA methylation and mRNA expression 
and all were highly enriched for binding sites of the early growth response (EGR) and 
CCCTC-binding factor (CTCF) transcription factors. Furthermore, DNA methylation levels 
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of seven of these genes were associated with differences in birth outcomes including 
gestational age, placental weight and head circumference. These data highlight the complex 
interplay between DNA methylation and functional changes in gene expression and health 
outcomes and underscore the need for functional analyses coupled to epigenetic assessments. 
Additionally, protein expression was assessed from the cord blood from 50 of the 
newborns via a high throughput, antibody-based method211. A total of 111 proteins were 
identified that had a significant association between protein level in newborn cord blood and 
maternal U-tAs. Many of these proteins are regulated by tumor necrosis factor and are 
enriched in functionality related to immune/inflammatory response and cellular 
development/proliferation. Interindividual differences in proteomic response were observed 
in which 30 newborns were "activators," displaying a positive relationship between protein 
expression and maternal U-tAs. For 20 "repressor" newborns, a negative relationship 
between protein expression level and maternal U-tAs was observed. The activator/repressor 
status was significantly associated with maternal U-tAs and head circumference in newborn 
males. These results may provide a critical groundwork for understanding the diverse health 
effects associated with prenatal arsenic exposure and highlight interindividual responses to 
arsenic that likely influence differential susceptibility to adverse health outcomes. 
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CHAPTER IV: MATERNAL ONE CARBON METABOLISM AND ARSENIC 
METHYLATION IN A PREGNANCY COHORT IN MEXICO1 
Overview 
The prenatal period represents a critical window of susceptibility to arsenic (As) 
exposure. Ingested inorganic arsenic (iAs) undergoes hepatic methylation generating mono- 
and di-methyl arsenicals (MMA and DMA, respectively) a process that facilitates urinary As 
elimination. Differences in pregnant women’s metabolism of As (e.g. increases in %MMAs 
and decreases in %DMAs) are a risk factor for adverse birth outcomes. One carbon 
metabolism (OCM), the nutritionally-regulated pathway essential for supplying methyl 
groups in the body, plays a role in As metabolism and is understudied during the prenatal 
period. In this cross-sectional study from the Biomarkers of Exposure to ARsenic (BEAR) 
pregnancy cohort in Gómez Palacio, Mexico, we assessed the relationships among OCM 
indicators (e.g. maternal biomarkers of serum B12, folate, and homocysteine (Hcys)), and 
levels of iAs and its metabolites in maternal urine and in neonatal serum. Interestingly, the 
prevalence of folate sufficiency (serum folate levels > 9 nmol/L) in the cohort was high 99%, 
and hyperhomocysteinemia (Hcys levels >10.4 μmol/L) was low (8%). However, 74% of the 
women displayed a deficiency in B12 (serum levels < 148 pmol/L). B12 deficiency was not 
associated with As methylation in pregnant women. Differences in lower B12 levels and 
higher Hcys were associated with increases in total arsenic levels in urine (U-tAs). In 
                                                 
1 This chapter was taken from: Jessica E. Laine, Vesna Ilievski, David Richardson, Amy H. Herring, Miroslav 
Stýblo, Marisela Rubio-Andrade, Gonzalo Garcia-Vargas, Mary V. Gamble, and Rebecca C. Fry. Maternal one 
carbon metabolism and arsenic methylation in a pregnancy cohort in Mexico. Submitted to the Journal of 
Exposure Science and Environmental Epidemiology (2017). 
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unadjusted comparisons, infants born to mothers in the lowest tertile of serum folate had 
significantly higher mean levels of C-%MMA relative to folate replete women. Furthermore, 
beta regression results demonstrated that maternal Hcys was positively associated with both 
C-tAs and %C-MMAs. The results from this study indicate that maternal OCM status may 
influence neonatal As metabolites.  
Introduction  
Inorganic arsenic (iAs) continues to contaminate the drinking water of millions of 
individuals world-wide, representing a critical global public health issue1. The main form of 
arsenic (As) present in drinking water is iAs, and it undergoes methylation to generate 
monomethyl- arsenic (MMAs) and dimethyl arsenicals (DMAs). The toxicity of iAs in 
humans is influenced by an individual’s methylation capacity. Increases in the proportions of 
MMAs in urine have been associated with adverse health outcomes, including urinary 
bladder cancer, non-melanoma skin cancers, carotid atherosclerosis, and chromosomal 
aberrations (reviewed in 2). The role of metabolism of As in disease etiology may be 
particularly important during the prenatal period, as it is a critical window of susceptibility to 
iAs exposure. Prenatal iAs exposure has been associated with lower birth weight, preterm 
birth, reduced height and head circumference, increased susceptibility to infection, and later 
in life cancers3. Additionally, inefficient maternal metabolism of As during pregnancy has 
been recently associated with decreases in birthweight and other birth outcomes4-6.  
There are many factors that may influence methylation/metabolism of As including, 
but not limited to, the level of exposure to iAs via drinking water and/or food7, age8, gender9, 
pregnancy10, genotype for arsenic (+3 oxidation state) methyltransferase (AS3MT)7, 11, and 
nutritional status of an individual12, 13. The methyl group for methylation of As is derived 
from S-adenosylmethionine (SAM). The synthesis of SAM is influenced by micronutrients 
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involved in OCM, such as such as folate, cobalamin (vitamin B12), vitamin B6, betaine and 
choline14. When OCM is compromised, Hcys levels become elevated. This can be reversed 
through a folate-dependent mechanism where 5-methyltetrahydrofolate donates its methyl 
group, using B12 as a cofactor, for the remethylation of homocysteine (Hcys) to generate 
methionine15. Various biomarkers are used to measure OCM including, but not limited to 
folate, B12, and Hcys in human samples14.  
There is support for the supplementation of OCM nutrients and/or vitamins in iAs 
exposed populations to increase methylation of As. For example, folic acid supplementation 
to improve As methylation in adults exposed to iAs in contaminated drinking water is 
supported by a recent randomized control trial (RCT)13. However, the role of OCM nutrients 
in improving As metabolism during pregnancy is less clear. In a cross-sectional study, levels 
of folate and Hcys assessed in pregnancy did influence metabolism of As16; however, in 
another study focused on general nutritional supplementation to increase As metabolism 
there was a significant, but marginal, effect on the changes in metabolism of iAs over the 
course of pregnancy in relation to folate levels17. Furthermore, as these previous studies were 
conducted in nutrient poor populations, the role of indicators for OCM in other populations 
sufficient in both OCM and other nutrients is warranted. This may be particularly important 
for pregnant women with higher folic acid intake from prenatal vitamins and fortification of 
foods. Additionally, the interactions between OCM nutrients with each other during 
pregnancy may be important risk factors for adverse birth and later in life health outcomes. 
Specifically, imbalances in maternal vitamin B-12 status as it relates to sufficient and/or 
higher folate status during pregnancy may have detrimental health impacts for both the 
mother and her infant (as reviewed in 18). Additionally, in folate sufficient populations, low 
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B12 becomes a stronger predictor of higher Hcys, a known independent risk factor for 
numerous adverse pregnancy and health outcomes19. Taken together, there is a need to 
further characterize the relationship between nutrients involved in OCM and As metabolism 
during pregnancy. 
The primary aim of this cross-sectional study within the Biomarkers of Exposure to 
ARsenic (BEAR) cohort in Gómez Palacio, Mexico was to examine the levels of maternal 
serum indicators of OCM (B12, folate, Hcys) in association with biomarkers of iAs exposure 
and metabolism of iAs during the prenatal period. We hypothesized that OCM indicators of 
higher B12 and folate, and lower Hcys would be associated with decreases in %iAs and 
%MMAs, and increases in %DMAs in both maternal and neonatal samples.  
Materials and methods  
Cohort selection  
The BEAR cohort was established to investigate the underlying etiologies of prenatal 
iAs exposure. This cohort has been previously described.4 Briefly, women were recruited 
prior to the time of delivery from the time frame of August 2011 to March 2012 at the 
General Hospital of Gómez Palacio. All procedures associated with this study were approved 
by the Institutional Review Boards of Universidad Juárez del Estado de Durango (UJED), 
Gómez Palacio, Durango, Mexico, and the University of North Carolina at Chapel Hill 
(UNC), Chapel Hill, North Carolina, U.S.A.  
A total of 221 women were originally approached for the study. Of those, 93% (n = 
206) provided informed consent for participation in the study. Of these, two women were not 
included based on a confirmation of a twin pregnancy (n = 1; 0.5%), or sample collection 
failure (n = 1; 0.5%). Additionally, for this cross-sectional analysis there were six women 
who were excluded because there was insufficient serum to measure the OCM indicators. 
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Therefore in the present study to investigate the nutritional biomarkers involved in one 
carbon metabolism as it relates to maternal metabolism of iAs there are a total of 197 
women. For the assessment of neonatal exposure to iAs there are 188 mom/baby pairs, for 
there was not enough cord serum to measure the levels of As in samples from nine subjects.  
Determination of exposure to iAs  
Maternal spot urine samples were collected at the hospital before birth, immediately 
transferred to cryovials, and placed in liquid nitrogen. Aliquots of urine samples were 
shipped on dry ice to UNC-Chapel Hill and immediately stored at –80°C. Cord blood was 
collected immediately after newborn delivery using an anticoagulant-free vacutainer tube. 
Following clot formation, the tube was centrifuged at 177.1 g-force and the serum was 
collected and stored at -80°C until aliquots were shipped on dry ice to UNC-Chapel Hill, NC, 
and stored at -80oC.  
Arsenical levels in maternal urine have been used as indicators of prenatal iAs 
exposure. Here, concentrations of urinary iAs (U-iAs), urinary monomethyl arsenic (U-
MMAs) and dimethyl arsenical (U-DMAs) were determined by HG-AAS with cryotrapping 
(CT) as described previously20-22. The LODs for U-iAs, U-MMAs, and U-DMAs were 0.2, 
0.1, and 0.1 μg As/L, respectively. U-tAs was determined by summing U-iAs, U-MMAs and 
U-DMAs. To account for differences in water intake/differential hydration, concentrations of 
U-iAs, U-MMAs, and U-DMAs in each urine sample were adjusted as previously 
described23. The efficiency of iAs biotransformation was determined by calculating the 
proportions of the individual arsenicals iAs, MMAs, and DMAs relative to total urinary As 
for each study subject. Metabolism efficiency for iAs in maternal urine was determined by 
calculating the percentage of the individual metabolites out of the total (%U-iAs, (%U-
MMAs, and (%U-DMAs). 
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Levels of arsenic in whole cord blood have been used before as a measurement of 
potential neonatal exposure24; however, here we use cord serum values to measure potential 
neonatal exposure to iAs and As metabolites. Concentrations of neonatal cord serum arsenic 
included the measurement of cord serum-analyzed iAs (C-iAs), MMAs (C-MMAs), and 
DMAs (C-DMAs) and were determined using HG-CT-ICP-MS as described previously21, 25. 
The LODs for C-iAs, C-MMAs, and C-DMAs were 1.45, 0.06, and 0.12 pg As/mL, 
respectively. A certified standard reference material, Arsenic Species in Frozen Human Urine 
(SRM 2669; National Institute of Standards and Technology) was used to assure accuracy of 
arsenic (As) speciation analysis.  Here, aliquots of SRM were diluted in urine or serum from 
an unexposed subject and analyzed by HG-CT-AAS and HG-CT-ICP-MS, respectively. The 
concentrations of As species in SRM in urine (after deduction of background As) ranged 
from 88% to 105% of the certified values (105% for iAs, 88% for MMAs, 99% for DMAs); 
the concentrations of As species in SRM in plasma ranged from 85% to 90% of the certified 
value (85% for iAs, 90% for MAs, and 87% for DMAs. The sum of C-iAs, C-MMAs and C-
DMAs was calculated to determine C-tAs. Neonatal cord exposure was also calculated based 
on the percentage of the individual metabolites in neonatal cord serum out of the total As in 
neonatal cord serum (%C-iAs, %C-MMAs, and %C-DMAs). 
Determination of one-carbon metabolism indicators 
Measurements of the indicators for OCM were carried out on banked maternal serum 
stored at -80°, and shipped on dry ice to Columbia University, New York, NY. Maternal 
serum folate and B12 were analyzed by radio protein-binding assay (SimulTRAC-S; MP 
Biomedicals, Orangeburg, NY, USA). To determine folate concentrations, folic acid as 
pteroylglutamic acid was used for calibration, and its 125 I-labeled analog as the tracer. All 
samples were run on a Gamma counter (Perkin Elmer). Cys and Hcys were analyzed via a 
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HPLC  - fluorescent detector with 385nm excitation and 515nm emission26. OCM indicators 
deficiencies and/or sufficiency’s were determined for each woman as has previously been 
described27, and as in other iAs-exposed populations28. B12 deficiency was set at <150 pmol 
and ≥ 150 pmol for B12 sufficiency. Folate deficiency was set at <9 nmol and ≥ 9 nmol for 
folate sufficiency. Hyperhomocysteinemia (high Hcys) was defined by Hcys ≥ 10.4 nmol and 
normal Hcys was set at  < 10.4 nmol.  
Statistical analyses  
Spearman rank correlations (coefficients reported as rs) were calculated between the 
levels of arsenicals in both maternal urine and in neonatal cord serum. Spearman rank 
correlations were also calculated between the levels of arsenicals in both maternal urine and 
in neonatal cord serum and the OCM indicators, as well as for the individual OCM indicators 
to each other.  
Differences in the levels of arsenicals based on nutritional categories were calculated 
to compare those that were B12 sufficient (≥150 pmol) and deficient (<150 pmol), who had 
higher Hcys (hyperhomocysteinemia as defined in non-pregnant populations) (>10.4 nmol) 
and normal (<10.4 nmol) levels of Hcys using Wilcoxon Rank Sum tests, and between 
tertiles of folate for those who were in the lowest tertile (< 29.0 nmol), middle tertile (≥ 29.0 
nmol and < 47.0 nmol) and the upper tertile (≥ 47.0 nmol) using an ANVOA. The same 
comparisons for the individual OCM indicators by nutritional categories were calculated. 
These comparisons were not made for those who were deficient/sufficient in folate as there 
were not enough women who were deficient in folate for categorical comparisons.  
The relationship between the maternal biomarkers of B12, folate, Cys, and Hcys and 
maternal U-tAs and/or neonatal C-tAs was investigated via linear regression models. To 
improve model fit the independent variables (OCM indicators) and dependent variables (U-
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tAs, C-tAs) were log transformed, model fit was assessed by inspecting the normality of 
residuals. Regression assumptions of linearity and the homogeneity of residuals were 
evaluated by examination of appropriate residual plots. Beta regression models were used to 
examine the relationship between the percentages of iAs, MMAs, and DMAs and OCM 
indicators using a previously establish SAS macro29 These models were chosen because 
percentages of As metabolites are used an indication of metabolism efficiency, yet 
percentages can be problematic as dependent variables in traditional linear regression models 
because the outcome is only observed over the unit interval (i.e., 0,1). Beta regression 
modeling has been previously used for percentage-scaled dependent variables due as it is 
flexible for capturing various skewed unimodal and bimodal distributions, especially when 
normalizing and other transformations do not work well29. Beta regression models were also 
fitted to investigate the relationship between the arsenicals and nutritional categories based 
on B12 deficiency, folate tertiles, and for categories of Hcys. Regression coefficients were 
converted to a percentage and results are presented as the estimated percent difference in the 
log odds of %iAs, %MMA, and/or %DMAs with a one unit difference in B-12, folate, and/or 
Hcys. Potential confounders for all models were identified a priori based on their known or 
potential association with both the exposure (the individual OCM indicators) and the 
outcome (As or its methylated metabolites). To determine if maternal OCM indicators 
predicated maternal U-tAs and/or metabolism and neonatal levels of As all models were 
adjusted for maternal age (linear continuous), maternal education (categorical), maternal 
parity (categorical) and gestational age (linear continuous).   
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Results  
Demographic characteristics 
Selected characteristics of the BEAR cohort are presented in Table 4.1. The cohort 
has been previously described4. Briefly, all women were Hispanic and were an average age 
of 24 years at the time of delivery. Most of the women in this cohort had an educational level 
of high school or greater (74%). Almost all the women reported to take prenatal vitamins 
during pregnancy (96%), and for the majority of the women this was not their first pregnancy 
(65%).  
Exposure to iAs  
Levels of the arsenicals measured in drinking water, maternal urine, and neonatal 
cord serum are presented in Table 4.2. The mean level of DW-iAs was 24.7 μg/iAsL (range: 
0.33-235.6) and mean level of U-tAs was 37.5 μg/L (range: 4.3 to 319.7). DW-iAs was 
significantly positively correlated with U-tAs (rs= 0.60; p <0.001) (Table 4.3). The average 
levels of maternal metabolism arsenicals were 6.1% (range: 0.77% to 45.1%) for U-%iAs, 
6.4% (range: 1.3% to 24.9%) for U-%MMAs, 87.6% (range: 32.7% to 96.7%) for U-
%DMAs. For comparison to other studies, the ratios of U-MMAs/iAs and U-DMAs/MMAs 
are presented. 
The average level of C-tAs was μg/L (range: 0.0042 to 3.0). The mean levels for the 
neonatal cord serum metabolites were determined to be 0.038 μg/L (range: 0.00085 to 0.50) 
for C-iAs, 0.062 μg/L (range: 0.000042 to 0.56) for C-MMAs and 0.26 μg/L (range: 0.0031 
to 2.7) for C-DMAs. This corresponded to an average of 10.9% (range: 0.088 to 69.5) for 
%C-iAs, 16.7% (range: 0.032 to 51.8) for %C-MMAs and 72.5% (range: 21.6 to 97.8) for 
%C-DMAs. For comparison to other studies, the ratios of C-MMAs/iAs and C-
DMAs/MMAs are presented. 
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The totals and proportions of urinary arsenicals were compared to neonatal serum 
arsenicals using spearman rank correlation calculations and are presented in Table 4.3. 
Maternal total urinary arsenic was significantly positively correlated with neonatal total 
serum arsenic (rs= 0.60; p <0.001). The percentages and ratios of metabolites %U-MMAs 
and %C-MMAs (rs= 0.34; p <0.001) were significantly correlated as were %U-DMAs and 
%C-DMAs (rs= 0.17; p = 0.02). However, %U-iAs was not significantly correlated with %C-
iAs, (rs= 0.075; p = 0.3). While the proportions of metabolites were correlated in maternal 
and neonatal samples, the proportions of iAs and MMAs were higher in fetal cord serum in 
comparison to maternal urine. The levels of DMAs were lower in fetal cord serum in 
comparison to maternal urine (Table 4.2).  
One carbon metabolism indicators  
The levels of maternal serum nutritional biomarkers are presented in Table 4.4. The 
average maternal serum folate level was 40.6 nmol/L (range: 7.1 to 171.5). The average 
maternal serum B12 level was 127.4 pmol/L (range: 48.0 to 284.1). The average maternal 
serum Hcys level was 6.9 μmol/L (range: 4.1 to 19.4).  
B12 was not significantly correlated with folate (rs= -0.021; p= 0.7), or Hcys (rs= -
0.037; p= 0.6). Folate was significantly negatively correlated with Hcys (rs= -0.25; p= 
0.0005). 
The majority of women (n=195, 99%) were sufficient in folate, and only 2 (1%) 
women were deficient in folate (data not shown). A large proportion (n=145, 74%) of the 
pregnant women were deficient in B12 (Table 4.4). Only 15 women (8%) had 
hyperhomocysteinemia (Table 4.4). Levels of individual OCM indicators by nutritional 
categories are presented in Table 4.4. There were significant differences in the levels of Cys 
by Hcys status, where those who had higher Hcys also had higher mean levels of Cys. 
 74 
Furthermore, those in the lowest tertile of folate had the highest mean level of Hcys. There 
were no other statistically significant differences by categories of nutritional OCM indicators.  
Relationship among OCM indicators and the methylated iAs arsenicals 
Maternal urinary iAs was significantly negatively correlated with B12 (rs= -0.22; p= 
0.002), and positively correlated with Hcys (rs= 0.19; p= 0.19) (Table 4.5). There were no 
significant correlations between urinary markers of maternal metabolism (%U-iAs, %U-
MMAs, and %U-DMAs) and OCM indicators. However, the percentages of cord serum iAs 
were significantly positively correlated with maternal B12 (rs= 0.16; p= 0.02), and the 
percentages of cord serum MMAs were significantly negatively associated with folate (rs= -
0.15; p= 0.04) and positively correlated with Hcys (rs= 0.17; p= 0.01) (Table 4.5). 
Differences in the levels of maternal urinary or neonatal cord serum levels of 
arsenicals based on levels of maternal serum nutritional levels were calculated using 
Wilcoxon Rank Sum tests and are presented in Table 4.6. U-tAs was significantly (p<0.05) 
higher in those who were deficient in B12. There were no significant (p>0.05) differences in 
any of the other arsenicals and categories of B12. %U-iAs and %U-MMAs were higher in 
those that had a normal level of Hcys. %C-MMAs were significantly lower in the middle and 
highest tertile compared to the lowest tertile of folate. However, there were no other 
statistical differences in any of the other arsenicals by tertiles of folate. As higher levels of 
Hcys are associated with folate/B12 deficiencies, differences of hcys by B12 deficiencies 
and/or tertiles of folate were explored. There was no significant difference in Hcys levels by 
B12 deficiency status, however there was a significant difference (p<0.05) by tertiles of 
folate. Specifically, individuals in the lowest folate tertile had the highest levels of Hcys.  
Multivariable linear regression was used to determine if there was a relationship in 
the levels of maternal one carbon metabolism indicators and maternal and/or neonatal levels 
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of total iAs (tAs) (Table 4.7). Because the both the independent variables (OCM indicators) 
and dependent variables (U-tAs, C-tAs) were log transformed the betas are interpreted as a 
difference in the % of U-tAs or C-tAs based on a one percent difference of the OCM 
indicators. B-12 was significantly negatively associated with U-tAs where a one-unit 
difference in %B-12 pmol was associated with a -0.56% (95% CI: -0.31, -0.062) decrease in 
U-tAs. Hcys was also significantly associated with U-tAs where a one-unit difference in 
%Hcys was associated with a 0.44% (95% CI: 0.043, 0.83) increase in U-tAs. Furthermore, 
Hcys was significantly associated with C-tAs where a one-unit difference in %Hcys was 
associated with a 0.48% (95% CI: 0.054, 0.91) increase in C-tAs. There were no significant 
relationships in U-tAs or C-TAs and folate. Beta regression models were used to estimate the 
log difference in arsenicals based on OCM indicators. There were no significant relationships 
identified between maternal serum B12, folate. Interestingly, Hcys was significantly 
positively associated with neonatal serum %MMAs, where a 4.4 (95% CI: 0.89, 7.9) % 
increase in MMAs with for a one-unit difference in log Hcys. Even though the other 
relationships were not significant, B12 was positively associated with %U-iAs, %U-MMAs, 
%U-DMAs, %C-iAs, and %C-MMAs, and negatively associated with %C-DMAS. The 
relationship was positive with both folate and %MMAs, and %DMAs and negative 
relationships with %iAs although not statistically significant. Beta regression models were 
also performed to investigate the relationship between the arsenicals and nutritional 
categories based on B12 deficiency, tertiles of folate, and higher/lower Hcys (data not 
shown).  
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Discussion  
Exposure to inorganic arsenic (iAs) during pregnancy is associated with detrimental 
birth outcomes, and has been previously linked to maternal arsenic (As) metabolism 
capacity4-6. Metabolism capacity of As is influenced by nutrients and vitamins involved in 
one carbon metabolism (OCM). As the relationship between indicators of OCM and As 
metabolism in pregnant women is understudied, we set out to determine if levels of OCM 
indicators are associated with alterations in the levels of total As and metabolism of As in the 
Biomarkers of Exposure to ARsenic (BEAR) pregnancy cohort in Gómez Palacio, Mexico. 
In this region, iAs contaminates the drinking water, with levels up to 236 parts per billion4. In 
the present study we examined the levels of maternal serum nutritional biomarkers of OCM 
indicators (B12, folate, homocysteine) and contrasted these to maternal urinary markers and 
metabolism of iAs exposure and levels of neonatal cord serum iAs metabolites. We 
demonstrated that maternal and fetal cord serum levels of total As and As metabolites are 
significantly correlated. Almost all the pregnant women (99%) were folate sufficient yet, 
surprisingly, 74% of the women were deficient in B12. Additionally, a few (8%) of the 
women had hyperhomocysteinemia, as indicated by higher Hcys levels. Given that B12 is 
known to influence Hcys and methionine levels,30 we hypothesized such deficiencies would 
influence metabolism of iAs in pregnant women and the proportions of arsenic in neonatal 
cord serum. There were four major findings of this study. First, in contrast to our a priori 
hypothesis, we found that lower levels of serum B12 were not associated with differences in 
the metabolism of As as measured in maternal urine. However, elevated levels of serum B12 
were associated with lower levels of total arsenic in maternal urine (U-tAs). Second, elevated 
levels of Hcys were positively associated with total As in both maternal urine and neonatal 
cord serum. Third, maternal serum Hcys was positively associated with neonatal cord 
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%MMAs. Last, despite few of the women having folate deficiency, infants born to mothers 
in the lowest tertile of serum folate had significantly higher mean levels of %C-MMA as 
compared to those born to folate replete women. These data support that nutritional 
biomarkers involved in OCM are associated with biomarkers of total arsenic for both 
maternal and neonatal samples (urine and serum, respectively) and %MMAs in neonatal cord 
serum. 
We demonstrated a strong association between biomarkers of total As in maternal 
urine and both total As and metabolites in cord samples. The finding that maternal and fetal 
cord serum metabolites are significantly correlated is an indication that maternal-fetal 
transport of iAs and its metabolites across the placenta does indeed occur. Specifically, 
maternal total urinary arsenic was significantly positively correlated with neonatal total 
serum arsenic. Additionally, percentages of the As metabolites of MMAs and DMAs 
between maternal urine and neonatal cord serum were significantly positively correlated. 
Maternal-fetal correlations between As in maternal blood and neonatal samples have been 
supported by others16, 31, 32. Furthermore, the proportions of iAs, and MMAs were higher 
while DMAs were lower in fetal cord serum in comparison to maternal urine. Placental 
transfer of As is well established, however it is not known whether fetal metabolism of As 
occurs in utero16. Together, these findings suggest that the fetus is exposed to all of arsenic’s 
metabolites. 
Pregnant women in the BEAR cohort were folate sufficient, yet B12 deficient, and a 
small proportion of women had high Hcys levels (hyperhomocysteinemia). This relationship 
between B12 and folate is supported in several other studies with high rates of vitamin B-12 
insufficiency during pregnancy, where folate deficiency is estimated to be less than 10% (as 
 78 
reviewed in33). The sufficiency of folate is more than likely due to adequate dietary intake of 
folate and/or prenatal supplementation of folic acid33. This result is supported by the large 
number (96%) of women who reported taking prenatal vitamins. The causes of B12 
deficiencies during pregnancy are multifactorial, where deficiencies can occur due to dietary 
reasons, such as adhering to a vegetarian and specifically a lactovegetarian diet. Lower levels 
of vitamin B-12 during pregnancy could also be due to biological changes related to 
pregnancy including, hemodilution, active transport to the fetus, and changes in binding 
proteins34. Of concern, impaired vitamin B12 status alone during pregnancy has been 
associated with numerous adverse pregnancy outcomes, including intrauterine growth 
restriction, preterm delivery, neural tube defects (NTD)35, 36. B12 deficiency has also been 
linked to later in life health outcomes, including immune function impairment and 
neurological and cognitive functions in children37. Notably, a few women (8%) had clinically 
high levels of Hcys (hyperhomocysteinemia), however, the mean observed level of serum 
Hcys was 6.9 μmol/L, is in line with other populations with high rates of vitamin B-12 
insufficiency16, 38, 39. This is concerning as imbalances in Hcys is a well-established risk 
factor several adverse birth outcomes including, placental abruption, preeclampsia, and 
adverse pregnancy outcomes19. Taken together there is a concern for the levels and 
interactions of B12, folate, and Hcys in this cohort as they relate to birth outcomes, and later 
in life health.  
We demonstrated that higher levels of serum B12 are associated with lower levels of 
maternal U-tAs. In support of our findings, this inverse association between maternal levels 
of B12 has previously been observed, where the As+5 was in cord blood16. Given that 
maternal urinary arsenic has been used as an indicator of iAs exposure, these elevated levels 
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could suggest differences in the underlying exposure to iAs by those who have B12 
deficiencies.  In contrast to the B12 results, we demonstrate that elevated levels of Hcys were 
associated with elevated levels of total As in women’s urine and also with total As in 
neonatal cord serum. A similar relationship between Hcys and total As+5 in blood has been 
demonstrated in another cross-sectional pregnancy cohort.16 Given that As metabolism has 
been influenced by folate supplementation in adults,13 we hypothesized similar findings in 
this pregnancy cohort. Contrary to our hypothesis, we did not find any significant 
relationships between the B12, folate and the metabolites in maternal urine. Still, there were 
differences in %C-MMAs in association with levels of maternal folate and Hcys. 
Specifically, infants born to mothers in the lowest tertile of serum folate had significantly 
higher mean levels of %C-MMA as compared to those born to folate replete women. 
Additionally, higher maternal serum levels of Hcys were associated with higher neonatal 
serum levels of %MMAs. These results have not been previously identified for fetal cord 
serum. Conversely, in an adult population in Bangladesh plasma Hcys levels were positively 
associated with urinary %MMAs.40 The authors suggest that this positive association may be 
due to inhibition of the second methylation step by SAH, as OCM is a SAM-dependent 
methylation reaction producing SAH. SAH is hydrolyzed to homocysteine, a reversible 
process. Our results highlight that in folate sufficient, B12 deficient pregnant women 
maternal metabolism of As was not influenced by OCM, however maternal folate and Hcys 
levels may be an important factor for As metabolites in neonates. 
Several factors should be considered in the interpretation of the study results. Given 
the cross-sectional design, the maternal biomarkers of both serum OCM indicators markers 
and metabolism of As were measured once during pregnancy. However, changes in As 
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metabolism that occur differentially between trimesters of pregnancy would not influence 
interindividual shifts, as all samples represented urinary collection during the end of 
pregnancy immediately before delivery.41 Furthermore, a strength of our outcome assessment 
is the use individual markers of exposure, and in particular sensitive biomarkers of in utero 
exposure to As and its metabolites in both urine and neonatal cord serum. Serum levels of 
B12 decrease over the course of pregnancy, therefore the deficiency of B12 in this population 
as it relates to levels throughout should be interpreted with caution.33 There is currently no 
standard for determining differences of B12 over the course of pregnancy; however, 
measurements of serum B12 levels are currently the clinical standard to determine 
deficiencies, despite such variations42. Furthermore, the prevalence of vitamin B12 
deficiency observed here is potentially representative of the area, as data from the recent 
National Health and Nutrition Survey (Ensanut) demonstrate that B12 deficiency is at 40% 
and rising country-wide in Mexico for women of reproductive age, particularly in rural 
areas43. Additionally, any potential misclassification of either the exposure or the outcome 
would more than likely be non-differential, therefore would not influence the interpretation 
of our findings. Furthermore, other nutrients were not measured in this study that may not be 
required for OCM indicators but can contribute to the availability of methyl groups 
ultimately used in SAM biosynthesis including, betaine, choline, riboflavin, and serine. 
Additionally, we cannot rule out any potential unmeasured confounding between OCM 
indicators and the iAs biomarkers. While we did not find that any of the nutrients are 
associated with maternal metabolism of iAs in this cohort in Mexico, deficiencies in folate 
and/or B12 could still potentially influence methylation of As in other populations as they are 
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necessary in converting Hcys into methionine, and methionine is needed for the synthesis of 
SAM,14 therefore replication of this work is needed. 
In conclusion, this is among the first studies to assess B12, folate, and Hcys together 
on As metabolism in a folate sufficient pregnant population in Mexico. Our data highlight 
that pregnant women and their infants are exposed to iAs and that may necessitate further 
monitoring for B12 deficiencies. The findings from this study elucidate the need to 
investigate these relationships as they relate to disease etiologies associated with prenatal iAs 
exposure.  
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Table 4.1. Selected demographic characteristics of participants of the Biomarkers of 
Exposure to ARsenic (BEAR). 
Characteristic Total (n=197) 
 N (N%) 
Maternal age at delivery, yearsa 24 (5.5) 
Race/ethnicity (Hispanic) 197 (100) 
Educational level  
< High School 51 (25.9) 
High School 95 (48.2) 
> High School 51 (25.9) 
Smoking Status  
Non-smokers 184 (93.4) 
Current smokers 13 (6.6) 
Alcohol Consumption  
None 156 (79.2) 
Some 41 (20.8) 
Daily Prenatal Vitamin intake  
No  8 (4.1) 
Yes 189 (95.9) 
Seafood Consumption  
None  154 (78.2) 
Some 43 (21.8) 
Parity   
1st pregnancy  68 (34.5) 
More than 1 pregnancy 129 (65.5) 
Gestational Age, weeksa  39.3 (1.2) 
Newborn sex  
Male  103 (52.3) 
Female 94 (47.7) 
Birth weight (g) 3338.3 (481.7) 
a mean (standard deviation) 
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Table 4.2. Levels of arsenicals and one carbon metabolism indicators from participants+ of 
the Biomarkers of Exposure to ARsenic (BEAR) cohort. 
 Mean Median Range 
DW-iAs (μg As/L) 24.7 14.0 0.33-235.6 
    
Maternal Urinary arsenicals    
U-tAs (μg/L) 37.5 23.4  4.3-319.7 
U-iAs (μg/L) 2.1 1.3  0.14-23.0 
U-MMAs (μg/L) 2.3 1.3  0.082-18.2 
U-DMAs (μg/L) 33.1 20.8 1.4-292.5 
U-iAs (%) 6.1 5.3 0.77- 45.1 
U-MMAs (%) 6.4 5.9  1.3-24.9 
U-DMAs (%) 87.6 88.5 32.7- 96.7 
U-MMAs/iAs 1.2 1.2 0.13-5.5 
U-DMAs/MMAs 17.3 14.7  1.5-75.2 
    
Neonatal Cord Serum Arsenicals    
C-tAs (μg/L) 0.36 0.24 0.0042-3.0 
C -iAs (μg/L) 0.038 0.011 0.00085-0.50 
C -MMAs (μg/L) 0.062 0.044 0.000042-0.56 
C -DMAs (μg/L) 0.26 0.17 0.0031-2.7 
C -iAs (%) 10.9 4.5 0.088- 69.5 
C -MMAs (%) 16.7 16.7 0.032- 51.8 
C -DMAs (%) 72.5 74.9 21.6- 97.8 
C –MMAs/iAs 21.0 3.9  0.00075-249.4 
C -DMAs/MMAs 23.3 4.5  0.92-1768.1 
    
Maternal Serum One Carbon 
Metabolism Indicators 
   
Folate (nmol/L) 40.6 37.9  7.1-171.5 
B12 (pmol/L) 127.4 116.5 48.0-284.1 
Hcys (μmol/L) 6.9 6.4 4.1-19.4 
#Reported results are based upon a sample of 197 and 188, for measured values for urinary and neonatal cord 
serum arsenicals, respectively and 197 samples of maternal OCM indicators. 
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Table 4.3. Spearman rank correlation coefficients (rs) for the levels of in organic arsenic 
(iAs) in drinking water, maternal urinary arsenicals, and neonatal serum arsenicals.  
 C-tAs (μg/L) 
rs  (p-value) 
C -%iAs  
rs  (p-value) 
C -%MMAs 
rs  (p-value) 
C -%DMAs 
rs  (p-value) 
Drinking water iAs     
DW-iAs (μg As/L) 0.60 
(<0.001) 
-0.093 
(0.20) 
0.26 
(0.0004)* 
-0.14 
(0.06) 
Maternal urinary arsenicals     
U-tAs (μg/L) 0.60 
(<0.001) 
-0.27 
(0.0002)* 
0.19 
(0.010)* 
0.11 
0.1286 
U-%iAs  -0.049 
(0.50) 
0.075 
(0.3) 
0.17 
(0.018)* 
-0.11 
(0.12) 
U-%MMAs  -0.0068 
(0.92) 
0.011 
(0.87) 
0.34 
(<0.0001)* 
-0.18 
(0.012)* 
U-%DMAs  0.0012 
(0.98) 
-0.025 
(0.72) 
-0.32 
(<0.0001)* 
0.17 
(0.02)* 
*p-value<0.05 
  
 85 
Table 4.4. Levels of one carbon metabolism indicators by nutritional categories of carbon 
metabolism indicators from participants of the Biomarkers of Exposure to ARsenic (BEAR) 
cohort. 
 Maternal Serum One Carbon Metabolism Categories 
 B12 Homocysteine Folate 
One Carbon 
Metabolism 
Indicators 
Deficient 
(N=145, 
74%) 
 
Sufficient 
(N=52, 
26%) 
Normal 
(N=182, 
92%) 
High 
(N=52, 
8%) 
Lower 
Tertile 
(n=49) 
Middle 
Tertile 
(N=98) 
Upper 
Tertile 
(N=50) 
 Mean 
(sd) 
Mean  
(sd) 
Mean 
(sd) 
Mean  
(sd) 
Mean  
(sd) 
Mean  
(sd) 
Mean  
(sd) 
B12 104.4 
(23.6) 
192.0  
(38.2) 
127.3 
(46.1) 
129.1 
(65.1) 
134.0 
(53.1) 
123.5 
(44.6) 
128.7 
(48.0) 
Folate 40.6 
(18.9) 
40.8 
(26.0) 
41.4 
(21.1) 
31.9 
(14.6) 
20.8  
(5.4) 
38.0 
(4.9) 
65.2 
(25.2) 
Homocysteine 6.9 
(2.3) 
6.9 
(2.0) 
6.4 
(1.5) 
12.5 
(2.2)  
8.1* 
(2.9) 
6.5 
(1.7) 
6.6 
(2.0) 
*p-value<05, Wilcoxon Rank Sums Non parametric test for comparisons for B12 and Hcys and ANOVA for 
tertiles of folate.  
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Table 4.5. Spearman rank correlation coefficients (rs) for the nutritional biomarkers (B12, 
folate, and homocysteine) and exposure indicators of iAs in the BEAR cohort.  
 B12 
rs  
(p-value) 
Folate 
rs  
(p-value) 
Cys 
rs  
(p-value) 
Hcys 
rs  
(p-value) 
Drinking water iAs     
DW-iAs (μg As/L) -0.12 
(0.1) 
-0.020 
(0.7) 
-0.016 
(0.8) 
0.22 
(0.002)* 
Maternal urinary arsenicals     
U-tAs (μg/L) -0.22 
(0.002)* 
0.045 
(0.5) 
0.046 
(0.5) 
0.19 
(0.006)* 
U-iAs (μg/L) -0.22 
(0.001)* 
0.036 
(0.6) 
-0.044 
(0.5) 
0.11 
(0.1) 
U-MMAs (μg/L)  -0.17 
(0.01)* 
0.056 
(0.4) 
0.095 
(0.1) 
0.18 
(0.01) 
U-DMAs (μg/L)  -0.21 
(0.002)* 
0.044 
(0.5) 
0.054 
(0.4) 
0.20 
(0.005)* 
U-%iAs  0.047 
(0.5) 
-0.031 
(0.6) 
-0.17 
(0.01) 
-0.11 
(0.1) 
U-%MMAs  0.047 
(0.5) 
0.055 
(0.4) 
0.075 
(0.2) 
0.00049 
(0.9) 
U-%DMAs  -0.038 
(0.5) 
-0.0081 
(0.9) 
0.066 
(0.3) 
0.057 
(0.4) 
U-MMAs/iAs -0.0093 
(0.8) 
0.12 
(0.1) 
0.18 
(0.01)* 
0.071 
(0.3) 
U-DMAs/MMAs -0.049 
(0.4) 
-0.043 
(0.5) 
-0.063 
(0.3) 
0.0014 
(0.9) 
Fetal cord serum arsenicals     
C-tAs (μg/L) -0.0011 
(0.9) 
0.067 
(0.3) 
0.14 
(0.06) 
0.24 
(0.001)* 
C-iAs (μg/L) 0.15 
(0.03)* 
-0.037 
(0.6) 
-0.031 
(0.6) 
-0.030 
(0.6) 
C-MMAs (μg/L) 0.073 
(0.3) 
-0.021 
(0.7) 
0.11 
(0.1) 
0.30 
(<0.0001)* 
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C-DMAs (μg/L) -0.024 
(0.7) 
0.097 
(0.1) 
0.17 
(0.02)* 
0.25 
(0.0005)* 
C-%iAs 0.16 
(0.02)* 
-0.048 
(0.5) 
-0.11 
(0.1) 
-0.15 
(0.03)* 
C-%MMAs  -0.095 
(0.1) 
-0.15 
(0.04)* 
0.019 
(0.7)* 
0.17 
(0.01)* 
C-%DMAs  -0.073 
(0.3) 
0.11 
(0.1) 
0.10 
(0.1) 
0.0093 
(0.8) 
C-MMAs/iAs -0.16 
(0.03)* 
0.026 
(0.7) 
0.086 
(0.2) 
0.16412 
(0.02)* 
C-DMAs/MMAs 0.034 
(0.6) 
0.19 
(0.008)* 
-0.0024 
(0.9) 
-0.16 
(0.02)* 
B12 1 -0.021 
(0.7) 
0.16 
0.02* 
-0.037 
(0.6) 
Folate -0.021 
(0.7) 
1 -0.022 
(0.7) 
-0.25 
(0.0005)* 
Hcys  -0.037 
(0.6) 
-0.25 
(0.0005)* 
0.51 
(<0.0001)* 
1 
*p-value<0.05 
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Table 4.6. Levels of arsenicals by nutritional categories of one carbon metabolism indicators 
from participants of the Biomarkers of Exposure to ARsenic (BEAR) cohort. 
 Maternal Serum One Carbon Metabolism Categories  
 B12 Homocysteine Folate 
Arsenicals Deficient 
(N=145) 
Sufficient 
(N=52) 
Normal 
(N=182) 
High 
(N=52) 
Lower 
Tertile 
(n=49) 
Middle 
Tertile 
(N=98) 
Upper 
Tertile 
(N=50) 
 Mean 
(sd) 
Mean  
(sd) 
Mean 
(sd) 
Mean  
(sd) 
Mean  
(sd) 
Mean  
(sd) 
Mean  
(sd) 
Maternal 
Urinary Arsenic  
       
U-tAs (μg/L) 40.8* 
(45.9) 
37.7 
(25.1) 
37.5 
(44.2) 
28.5 
(32.5) 
38.4 
(40.3) 
33.5  
(39.9) 
44.7 
(50.8) 
%U-iAs 6.0 
(3.0) 
5.1 
(2.2) 
6.2* 
(4.0) 
6.4 
(5.8) 
6.0 
(2.5) 
5.9  
(2.8) 
6.7  
(6.2) 
%U-MMAs 6.3 
(2.9) 
5.9 
(2.9) 
6.4* 
(3.0) 
6.6 
(3.2) 
6.1  
(2.4) 
6.1  
(2.4) 
7.2 
(4.2) 
%U-DMAs 87.7 
(5.0) 
88.9 
(4.4) 
87.5 
(6.2) 
87.3 
(8.4) 
87.9  
(3.6) 
88.1 
(4.6) 
86.2 
(9.5) 
Neonatal Cord 
Serum Arsenic  
       
C-tAs (μg/L) 0.37 
 (0.43) 
0.33 
(0.21) 
0.36 
(0.42) 
0.33 
(0.33) 
0.36 
(0.39) 
0.34 
(0.43) 
0.40 
 (0.40) 
%C-iAs 10.2 
 (14.0) 
4.9 
(11.2) 
11.3 
(14.4) 
12.8 
(15.1) 
11.8 
(15.6) 
10.8 
(14.4) 
10.2 
(13.0) 
%C-MMAs 16.8 
(6.7) 
19.8 
(5.1) 
16.4 
(6.6) 
16.2  
(5.9) 
18.8* 
(6.4) 
15.9  
(7.1) 
16.1 
(5.0)  
%C-DMAs 73.0  
(12.8) 
75.3 
(9.8) 
72.3 
(13.5) 
70.9 
(14.8) 
69.4 
(14.2) 
73.3 
(13.3) 
73.7 
(12.4) 
*p-value<05, Wilcoxon Rank Sums Non parametric test for comparisons for B12 and Hcys and ANOVA for 
tertiles of folate. 
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Table 4.7. Multivariableτ relationship of arsenicals and one-carbon metabolism indicators 
from participants of the Biomarkers of Exposure to ARsenic (BEAR) cohort. 
 B-12 Folate Hcys 
 β (95% CI) 
[p-value] 
β (95% CI) 
[p-value] 
β (95% CI) 
[p-value] 
U-tAs+ -0.56 
(-0.86, -0.26) 
[0.0002]* 
0.027 
(-0.22, 0.27) 
[0.82] 
0.44 
(0.043, 0.83) [0.029]* 
%U-iAs++ 0.037  
(-0.11, 0.18) 
[0.6] 
-0.098  
(-0.44, 0.25) 
[0.57] 
2.1  
(-5.5, 1.2) 
[0.21] 
%U-MMAs++ 0.088 
(-0.041, 0.22) 
[0.18] 
0.097 
(-0.20, 0.39) 
[0.51] 
-0.29  
(-3.3, 2.7) 
[0.84] 
%U-DMAs++ 1.1 
(-1.9, 4.2) 
[0.48] 
0.017 
(-0.30, 0.33) 
[0.91] 
1.1 
 (-2.0, 4.1) 
[0.48] 
C-tAs+ -0.095 
(-0.43, 0.24) [0.57] 
0.096 
(-0.18, 0.37) 
[0.49] 
0.48 
(0.054, 0.91) 
[0.027]* 
%C-iAs++ 0.21  
(-0.076, 0.49)  [0.15] 
-0.025  
(-0.77, 0.72) 
[0.94] 
-5.0 
(-11.4, 1.5) 
[0.13] 
%C-MMAs++ 0.0562  
(-0.11, .22) 
[0.51] 
-0.17 
(-0.59, 0.25) 
[0.43] 
4.4 
(0.89, 7.9) 
[0.014]* 
%U-DMAs++ -0.090 
(-0.27, 0.092) 
[0.32] 
0.062  
(-0.39, 0.51) 
[0.78] 
0.32 
(-3.8, 4.4) 
[0.87] 
#Reported results are based upon a sample of 197 and 188, for measured values for urinary and neonatal cord 
serum arsenicals, respectively. 
τ All models adjusted for maternal age, gestational age, parity, and maternal education. 
+Beta values represent the estimated percent difference the arsenicals with a one percent difference in OCM 
indicators. 
++ Beta values represent the estimated percent difference in the log odds of the arsenicals with a one-unit 
difference in the log of OCM indicators.  
*p<0.05; 95% CI does not include the null of 0. 
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CHAPTER V: MATERNAL FOLATE LEVELS MODIFY THE RELATIONSHIP 
BETWEEN MATERNAL B12 LEVELS AND INTERACTIONS WITH MATERNAL 
ARSENIC METABOLISM ON INFANT BIRTHWEIGHT. 
Overview 
Inorganic arsenic (iAs) is metabolized in the body into mono- and di-methyl 
arsenicals (MMAs and DMAs, respectively). Metabolism of iAs can be influenced by 
nutrients involved in one carbon metabolism (OCM), and in fact, supplementation of OCM 
nutrients and/or vitamins in iAs exposed populations has been demonstrated to increase 
methylation of iAs. However, the role of OCM on arsenic metabolism during pregnancy and 
as it relates to birth outcomes has not been fully elucidated. In the present study, we estimate 
the relationship between OCM indicators of folate, B12, and homocysteine (hcys), iAs 
metabolism, and infant birthweight in a cross-sectional study from the Biomarkers of 
Exposure to ARsenic (BEAR) pregnancy cohort in Gómez Palacio, Mexico. 
We show that infant birthweight z-scores are negatively associated with B12 
deficiency, but only in the context of a lower folate status. Maternal metabolism of iAs was 
determined to not represent a mediator of the relationship between OCM indicators and 
infant birthweight, but instead may influence the proportion of the effect of OCM and 
birthweight via an interaction with OCM. These results indicate that maternal nutritional 
status of serum B12 and folate and maternal metabolism of arsenic may play an interactive 
role in infant’s birthweight. Such findings can inform future interventions to reduce the 
impacts of combined nutritional deficiencies in iAs exposed populations and associated 
adverse birth outcomes. 
 95 
Introduction  
Elucidating mechanisms that underlie adverse birth outcomes in relation to 
environmental factors is challenging due to the complex biological interactions from 
exposures during the prenatal period, as well as the practical and ethical limitations of 
studying pregnant women. This complexity is apparent in the interplay between maternal 
nutritional factors and exposure to environmental toxicants, as it is increasingly evident that 
both play a critical role in healthy fetal growth and development.  
A toxicant of particular concern for fetal growth is inorganic arsenic (iAs). Millions 
of people around the world are exposed to iAs from contaminated drinking water, and 
maternal exposure to iAs is associated with altered fetal growth. Specifically, in utero 
exposure to iAs is associated with reduced birthweight,1-5 height, and head circumference4. In 
fact, a recent meta-analysis identified an expected 53g reduction in birthweight from 
increasing prenatal iAs exposure across multiple studies6. Furthermore, maternal metabolism 
of iAs may have a greater impact on birthweight and other health outcomes than just 
exposure alone2, 4, 5. Drinking water iAs is metabolized in the body via a two-step 
methylation process, where it is methylated to monomethylated and dimethylated arsenicals 
(MMAs and DMAs, respectively). Efficiency of iAs metabolism, is characterized by the 
percentages of arsenicals in human tissues (i.e. %iAs, %MMAs, %DMAs).  
Metabolism of iAs can be influenced by nutrients involved in one carbon metabolism 
(OCM). This process occurs because the methyl group for the methylation of iAs is derived 
from S-adenosylmethionine (SAM), and synthesis of SAM is influenced by micronutrients 
involved in OCM, such as such as folate, cobalamin (vitamin B12), homocysteine (Hcys) 
vitamin B6, betaine and choline7. Interestingly, supplementation of OCM nutrients and/or 
vitamins in iAs exposed populations has been demonstrated to increase methylation of iAs. 
 96 
For example, folic acid supplementation was used to improve arsenic metabolism in adults 
exposed to iAs in contaminated drinking water in a recent randomized control trial (RCT)8. 
However, the role of OCM in iAs metabolism during pregnancy and as it relates to birth 
outcomes has not been fully elucidated.   
Adequate levels of nutrients involved in OCM for pregnant populations are also 
important for healthy fetal development. For example, folic acid supplementation during the 
prenatal period reduces neural tube defects and is required for healthy fetal growth.  
Specifically, folate can activate cell growth and biosynthetic processes that are essential over 
the course of pregnancy, and is critical for protein, DNA, and lipid synthesis, and is essential 
for epigenetic mechanisms9. This has led to a large public health effort to increase prenatal 
folic acid intake through the fortification of foods and prenatal vitamins. Vitamin B12 is also 
essential during pregnancy due to its role in folate dependent reactions, mitochondrial energy 
and lipid metabolic pathways, and normal cell growth10. Additionally, there is evidence that 
lower levels of maternal B12 is associated with reduced birthweight and increased 
susceptibility for metabolic diseases (as reviewed by 10).  Furthermore, deficiencies in either 
B12 or folate can influence OCM, where the regeneration of methionine is inhibited, 
resulting in increases in Hcys; such imbalances in Hcys levels are inversely associated with 
lower birthweight11. Despite these well-known impacts of deficiencies in OCM indicators, 
there is still little known about their interactions with one another. However, recent evidence 
suggests that imbalances in B12 and folate during pregnancy may influence birth outcomes 
more than one nutrient independently10, 12, 13. Investigations of interactions of various 
nutrients involved in OCM and arsenic metabolism during pregnancy as they relate to birth 
outcomes has been unexplored. 
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We recently demonstrated in the Biomarkers of Exposure to ARsenic (BEAR) cohort 
in Gómez Palacio, Mexico that 74% of the pregnant women displayed a B12 deficiency, yet 
were folate sufficient. Our work demonstrated that maternal serum markers of B12 and Hcys 
influenced total iAs in maternal urine (U-tAs), and folate and Hcys influenced the 
proportions of neonatal serum metabolites of %MMAs. Furthermore, we have also observed 
that inefficient maternal metabolism of iAs was negatively associated with infant 
birthweight2. In the present study, we assess the relationship between OCM indicators, 
maternal metabolism of iAs, and infant birthweight through mediation and interaction 
analyses. Specifically, we use a counterfactual approach to estimate the natural direct effects 
(NDE) of OCM indicators on infant birthweight, the natural indirect effects (NIE) through 
the mediated pathway of maternal metabolism of iAs and the total effects (TE) and controlled 
direct effects (CDE) of both OCM indicators and maternal metabolism of iAs on infant 
birthweight. This approach to investigate mediation allows for the exploration of non-linear 
models and potential important exposure-mediator interactions14. By estimating the natural 
direct and indirect effects, we can potentially clarify the underlying mechanisms15 of the 
relationship between OCM indicators and iAs metabolism as they relate to infant 
birthweight. Furthermore, by estimating the controlled direct effects, we can model how 
much birthweight would change on average when the mediator of arsenic metabolism is set 
at a predetermined level. This is important in understanding the underlying mechanisms of 
OCM indicators and arsenic metabolism, as it seems the interactions of OCM and iAs are 
most evident in nutrient poor environments8—a factor that we cannot ethically assign in 
human pregnant populations.   
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Materials and methods  
Study population 
The study population has been fully described previously2. Briefly, women were 
recruited at the time of the admission affiliated with their delivery from the General Hospital 
of Gómez Palacio. For women to be eligible for the study, participants must have met the 
following criteria: One-year minimum residence in the Gómez Palacio region, (urban 
locations of Gómez Palacio and surrounding rural locations), confirmation of a pregnancy 
without complications such as eclampsia or preeclampsia, and good overall health status (i.e., 
no signs of chronic or acute disease). The present study designed to analyze maternal serum 
levels of OCM indicators, iAs metabolism, and infant birthweight included a total of 197 
women. Demographic data was gathered from a clinical worker and included information on 
maternal age at delivery, education, occupation, time living at residence, smoking status and 
alcoholic beverage consumption during pregnancy, daily prenatal supplement intake, seafood 
consumption, source and daily consumption of drinking and cooking water, and participants 
previous pregnancies (number of pregnancies and number of previous pregnancy losses). 
Information on birth measures, including newborn birth weight, newborn length, gestational 
age, head circumference, placental weight, and 5-min Appearance, Pulse, Grimace, Activity, 
Respiration (APGAR) score was gathered at time of delivery by the physician and clinical 
staff. The outcome of infant birthweight was standardized by deriving z- scores that were 
calculated from the international infant growth charts of birthweight for gestational age at 
delivery (measured by last menstrual period)16. All procedures associated with this study 
were approved by the Institutional Review Boards of Universidad Juárez del Estado de 
Durango (UJED), Gómez Palacio, Durango, Mexico, and the University of North Carolina at 
Chapel Hill (UNC), Chapel Hill, North Carolina, U.S.A. 
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Determination of exposure to iAs  
To determine maternal exposure to iAs, maternal spot urine samples were collected at 
the hospital during the delivery admission for all participants, and immediately transferred to 
cryovials and placed in liquid nitrogen. Aliquots of urine samples were shipped on dry ice to 
UNC-Chapel Hill where concentrations of U-iAs, U-MMAs, and U-DMAs were determined 
by HG-AAS as described previously17-19. Maternal total urinary arsenic (U-tAs) was 
determined by summing U-iAs, U-MMAs and U-DMAs. Concentrations of U-iAs, U-
MMAs, and U-DMAs in each urine sample were adjusted for specific gravity as previously 
described20. Maternal metabolism efficiency of iAs was determined by calculating the 
proportions of the individual arsenicals iAs (%U-iAs), MMAs (%U-MMAs), and DMAs 
(%U-DMAs) relative to U-tAs. 
Determination of OCM indicators  
Banked maternal serum samples that were collected during the time of delivery 
admission for all participants and stored at -80°C were shipped on dry ice to Columbia 
University, New York, NY to measure OCM indicators. Maternal serum folate and B12 were 
analyzed by radio protein-binding assay (SimulTRAC-S; MP Biomedicals, Orangeburg, NY, 
USA), where folic acid as pteroylglutamic acid was used for calibration, and its 125 I-labeled 
analog as the tracer. All samples were run on a Gamma counter (Perkin Elmer). Hcys levels 
were analyzed via a HPLC- fluorescent detector with 385nm excitation and 515nm 
emission21. Deficiencies and/or sufficiency’s of the OCM indicators were determined for 
each woman as has previously been described22, and as in other iAs-exposed populations23. 
Because there were relatively few women (n=2) who had serum levels that indicated they 
were deficient in folate (<9 nmol), binary cutoffs for folate were created, where lower folate 
is defined as those women who had serum levels below the median level (37.9 nmol/L) and 
 100 
higher folate is defined as those women who had serum levels of folate above or equal to the 
median (37.9 nmol/L) levels of the cohort. B12 deficiency was set at <148 pmol and ≥ 148 
pmol for B12 sufficiency. Hyperhomocysteinemia (high Hcys) was defined by Hcys ≥ 10.4 
nmol and normal Hcys was set at  < 10.4 nmol. Four categories of combined B12 and folate 
status (B12/folate) were created based on the cutoffs of B12 deficiency or sufficiency and 
above or below the median levels of folate. Specifically, category I is defined as those 
women whose serum B12 levels were < 148 pmol and folate levels < 37.9 nmol; category II 
is defined as those women whose serum B12 levels were < 148 pmol and folate levels ≥ 37.9 
nmol; category III is defined as women whose serum B12 levels were ≥ 148 pmol and folate 
levels < 37.9 nmol, and category IV is defined as those women whose serum B12 levels were 
≥ 148 pmol and folate levels ≥ 37.9 nmol. 
Statistical analyses of the relationship of one carbon metabolism indicators with 
birthweight z-score  
All statistical comparisons and analysis were carried out using SAS v9.3. Differences 
in mean birth weight z-scores were determined based on the nutritional categories of OCM 
indicators using t-tests for two categorical comparisons of B12 deficiency and sufficiency, 
normal and high Hcys, and lower and higher folate levels. To compare mean levels of 
birthweight z-scores for the four categories of B12/folate (I, II, III, IV), ANOVA was used. 
Multivariable linear regression was used to determine the relationship between OCM 
indicators (continuous and based on nutritional categories) and birthweight z-score 
(continuous). All models were adjusted for a set of potential confounding variables selected a 
priori, including: maternal age (continuous), maternal education (categorized as below high 
school, high school, and above high school), and parity (dichotomized as one pregnancy or 
more than one previous pregnancy). Assumptions of linearity were assessed by examining 
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indicator variables for all modeled continuous variables (i.e. OCM indicators and maternal 
age) for the their linear relationship to infant birthweight z-score. Additionally, because of 
the potential interactions between folate and B12 during pregnancy on adverse birth 
outcomes, we were interested in determining if there was modification between the B12 
deficiency and folate levels on birthweight z-scores. To test the hypothesis that the estimates 
of B12 deficiency on birthweight z-score are modified by lower or higher folate levels, we 
modeled an interaction term of binary B12 deficient/sufficient (with sufficient B12 as the 
referent) and binary folate median levels (with higher than the median folate as the referent) 
as a full model and compared these results to a reduced model with no interaction term using 
a Likelihood Ratio test to assess statistical significance. We also presented these results in 
stratum specific effect estimates from a stratified multivariable regression analyses of the 
relationship of B12 deficiency on infant birthweight z-scores. Statistical significance was 
defined using p-values under 0.05.  
Mediation analysis  
Mediation analysis was carried out using methods and SAS code previously described 
by Valeri and Vanderweele24. In all models the variables are denoted as the following: 
A =exposure (OCM indicators), M =mediator (%U-iAs, %U-MMAs, %U-DMAs), 
Y =outcome (birthweight z-score), and C=covariates. The derivation of the specific 
regression models used to determine the estimates have been previously fully described 
elsewhere24.  In this study, the following regression equation was used to estimate the 
expected value of the potential mediator of arsenicals, given the exposure of OCM indicators 
and covariates: E [M|a,c]=β0+β1a+β’2c. The following regression equation was used to 
estimate the expected value of the outcome of infant birth weight z-scores, given the 
exposure of OCM indicators, the potential mediators of arsencials, and covariates: E 
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[Y|a,m,c]=θ0+θ1a+θ2m+ θ3am + θ’4c. Covariates were selected a priori and all models were 
adjusted for a set of potential confounders of the main exposure to outcome (OCM indicators 
to birthweight z-score), the mediator to outcome (birthweight z-score to the arsenicals), and 
the mediator to the main exposure (arsenicals to OCM indicators). Final models were 
adjusted for maternal age (continuous), maternal education (coded as an indicator variable), 
and parity (dichotomized). For specific parameters estimated for the potential effects of 
OCM indicators and iAs metabolism on infant birthweight, denote a reference (baseline) 
level of maternal serum OCM indicators, a0, and a new level, a1; and M as the mediator (e.g 
%U-iAs, %U-MMAs, and %U-DMAs) for both a natural and a set level to estimate all of the 
following: the natural direct effect (NDE), which can be interpreted as how much the 
outcome of birthweight z-score would change if the exposure of OCM indicators were set to 
a new level of exposure (a1) but the mediator of arsenicals (M) is kept at a level it would 
have taken at level a0 of exposure; the natural indirect effect (NIE), which can be interpreted 
as how much the outcome of birthweight z-score would change on average if the exposure 
(OCM indicators) were controlled at level a1 but the mediator (arsenicals) were changed 
from the level they would have taken if a0 to the level it would have taken if a1; the total 
effect (TE), which estimates how much the outcome of birthweight z-score would change 
overall for a change in the exposure of OCM indicators from level a0 to a1; the controlled 
direct effect (CDE), which estimates how much the outcome of birthweight z-score would 
change on average if the mediator of arsenicals were controlled at a set level (assigned), and 
the percent proportion mediated (PM)25. These parameters are represented by the following 
equations:   
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CDE=(θ1-θ3m) (a-a*)  
NDE= {θ0+θ3 (β0 +β1a*+β’2c)} (a-a*)  
NIE= (θ2β1+ θ3β1a) (a-a*) 
PM= NIE/TE x 100  
To estimate the relationship of OCM indicators on infant birthweight, we modeled the 
OCM indicators (a) as a population that would be in an adverse nutritional state (indicated by 
the previously mentioned serum cutoffs) by setting (a0) to a positive nutritional status (i.e. 
sufficient for B12, higher folate median levels, and lower Hcys levels) and setting (a1) to a 
poorer nutrient status (i.e. deficient for B12, lower folate median levels, and higher Hcys 
levels). The coding of variables for the specific model parameters is displayed in Table 5.1. 
Specifically, estimates for the relationship between OCM indicators on the outcome of infant 
birthweight z-score were assessed using the following models for categories of OCM 
indicators: Model 1 B12 sufficiency/deficiency was assessed, Model 2 examined folate as 
lower or higher than the median level; Model 3 examined Hcys categorized as normal or 
higher. Models were run with and without an interaction term of iAs metabolism and OCM 
indicators to measure OCM indicators on infant birthweight z-score through the path of the 
potential mediator of iAs metabolism. The levels that the mediators of each of the indicators 
for iAs metabolism were set to are presented in Table 5.1. Specifically, the population was 
set at the median levels of the arsenicals previously found in the cohort where %U-iAs were 
set at 5.3%, %U-MMAs were set at 5.9%, and %U-DMAs were set to 88.7% (models 1a, 2a, 
3a, and 4a). We were also interested in examining these associations when the population 
arsenicals were set at the poorest metabolism of iAs found in the cohort, therefore we also 
modeled maternal metabolism of iAs to the population’s respective 90th percentile for %U-
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iAs at 9.5% and %U-MMAs at 9.6%, and the 10th percentile for %U-DMAs at 88.1% 
(models 1b, 2b, 3b, and 4b). To assess whether the arsenical proportions (e.g. %U-iAs, %U-
MMAs, %U-DMAs) may mediate or interact with B12 in the context of modification by 
folate levels of the relationship between B12 and infant birthweight, models 1a and 1b were 
carried out but stratified by binary folate median levels (represented by models 4a and 4b). 
Results 
The demographic characteristics for the study subjects are presented in Table 5.2. 
Briefly, all women were of Hispanic decent, and most had at least a high school education or 
greater (48% and 26%, respectively). Nearly all (96%) women reported that they took 
prenatal vitamins during pregnancy. The mean birthweight adjusted for gestational age z-
score was -0.29 with a range of -2.6, 2.8. Nutritional levels of OCM indicators, as measured 
in maternal serum and biomarkers of As exposure, are presented Table 5.2 and have been 
previously described.  
Differences in unadjusted mean birthweight z-scores are presented in Table 5.3. 
There were no significant differences in mean birthweight z-score between those that were 
B12 deficient compared to those who were sufficient in B12. There were also no significant 
differences in mean birthweight z-scores for newborns born to women who had above or 
below median serum folate levels. Similarly, there were no differences in mean birthweight 
z-scores between newborns born to mothers who had high or normal serum Hcys levels. 
Conversely, when analyzed in the context of the B12/folate categories, there were significant 
differences in the comparisons of mean birthweight z-score (p=0.0037) for the unadjusted 
models. Specifically, newborns born to mothers in category III (sufficient B12/lower folate) 
displayed higher mean levels birthweight z-score, while those born to women in categories I 
and II of deficient B12/lower or higher folate were similarly low (-0.43, -0.31, respectively). 
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However, newborns born to mothers in category IV (sufficient B12/higher folate) had the 
lowest mean birthweight z-score of -0.52 (Table 5.3).  
The adjusted multivariable linear regression models quantifying relationships 
between each individual OCM indicators and birthweight z-score are presented in Table 5.4. 
There were no significant linear relationships in birthweight z-score from examining the 
multivariable regression analyses for levels of maternal B12, folate, or Hcys. Specifically, 
infants born to those women who were B12 deficient had a mean difference of birthweight z-
score of -0.26 (95%CI of -0.57, 0.047) compared to those infants who were born to mothers 
who were B12 sufficient. Additionally, infants born to those women who had serum levels of 
folate below the median value of 37.9 pmol had a mean difference of birthweight z-score of -
0.11 (95%CI of -0.38, 0.17) compared to infants born to mothers who had serum folate levels 
above the median level. Furthermore, infants born to those women who had high Hcys levels 
had a mean difference of birthweight z-score of -0.24 (95%CI of -0.75, 0.28) compared to 
those born to mothers with low Hcys levels. 
We next assessed whether there was a relationship between B12 status and 
birthweight stratified by folate status, as there are known interactions between these two in 
relation to infant birth outcomes14. Modification of the relationship between B12 status and 
birthweight z-score by folate levels was assessed using the likelihood ratio test, where 
models were fit with (e.g. the full model) and without an interaction term (reduced model). 
The likelihood ratio test statistic p-value of p <0.05 indicates the presence of effect measure 
modification by median folate levels (Table 5.5). Stratified estimates of the relationship of 
B12 deficiency and folate are presented in Table 5.5. When maternal serum folate is lower, 
the beta estimate was -0.74 (95% CI: -1.2, -0.31; p=0.008). This indicates average 
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birthweight z-score is -0.74 lower for newborns born to women who are deficient in B12 and 
with lower folate relative to those sufficient in B12. In the higher folate strata, the estimate 
was 0.29 (95% CI: -0.70, 0.13; p=0.17) (Table 5.5).  
We next set out to describe potential mediation of the relationships between all OCM 
indicators and birthweight, by maternal arsenic metabolism. Results of the mediation analysis 
assessing the categories of OCM indicators, with iAs metabolism on infant birthweight for 
categories of B12 are presented in Table 5.6, for categories of folate are presented in Table 
5.7, and for Hcys are presented in Table 5.8. When allowing the exposure of B12 and 
mediator of %U-DMAs to interact, a significant estimate was observed for the controlled 
direct effect (CDE) of B12 deficiency on infant birth weight z-scores when %U-DMAs was 
set at the median level of (88.7%) (Table 5.6). Specifically, when the population was 
modeled to change their exposures from B12 sufficiency to B12 deficiency and all have %U-
DMAs set at 88.7%, the difference between B12 deficiency to birthweight z-score to is -0.43 
(95% CI: -0.83, -0.018; p-value= 0.040) (Table 5.6). There were no statistically significant 
natural direct or indirect effects for any of the arsenicals on the relationships between folate 
and birthweight z-score (Table 5.7). When contrasting higher Hcys to lower Hcys when %U-
iAs was set at the 90th (higher %iAs) percentile, the controlled direct effect (CDE) was 
estimated to be a -1.3 (95% CI: -2.6, -0.049; p=0.041) difference in infant birth weight z-
score (Table 5.8).  
Folate levels modified the association between B12 deficiency and infant birth weight 
z-scores in the stratified regression analysis, therefore we sought to modification of folate in 
the estimations of mediation by maternal metabolism of iAs of the relationship of B12 
deficiency on infant birthweights in strata of median folate, allowing for an interaction 
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between B12 and the mediator of maternal iAs metabolism (Table 5.9) and for non-
interaction of B12 and iAs metabolism (Table 5.9b). The estimates for the natural direct 
effect (NDE), natural indirect effect (NIE), and total effect (TE) for the linear effects of B12 
deficiency on birthweight z-score for all mediation analyses of maternal metabolism of iAs, 
were negative when stratified by lower folate levels, and positive when stratified by higher 
folate levels (Table 5.9, 5.10). When folate was lower the percent mediated (PM) was small, 
yet differed by mediator interaction/non-interaction models with increases in the percent 
mediated when allowing for the mediator of maternal metabolism of arsenic and B12 
interaction. Furthermore, the estimated NIEs were not statistically significant; however, they 
did increase when modeling the mediators with interaction with B12 (Table 5.9). 
Additionally, when modeling the mediators of maternal metabolism of iAs as an interaction 
with B12, the CDEs changed based on the levels that the percentages of maternal arsenical 
were set when folate was low and/or high. Specifically, the controlled direct effects (CDE) of 
the estimated effect of B12 deficiency on birthweight z-scores were significant in the stratum 
of lower folate when setting the mediator of %U-iAs, %U-MMAs, and %U-DMAs to their 
median values, and to percentiles to simulate a poorer iAs metabolism (%U-iAs and %U-
MMAs to their 90th percentile and %U-DMAs to its 10th percentile). Specifically, in this 
stratum when the arsenicals were set at the median level, the controlled direct effect for B12 
deficiency on infant birthweight %iAs was estimated to be -0.61 (95% CI: -1.07, -0.51), %U-
MMAs was estimated to be -0.72 (95% CI: -1.2, -0.27), and for %U-DMAs the estimated 
effect was -0.71 (95% CI: -1.2, -0.27). Similarly, in the lower folate stratum when %iAs and 
%U-MMAs were set at 90th percentile, the estimated controlled direct effect was -1.4 (95% 
CI: -2.2, -0.56) and -0.65 (95% CI: -1.5, -0.20), respectively, and when %DMAs were set at 
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90th percentile, the estimated effect was -1.04 (95% CI: -2.0, -0.13). However, when folate 
was high, the controlled direct effect estimates of the relationship between B12 deficiency 
with the mediators of %U-iAs, %U-MMAs, and %U-DMAs were all positive (Table 5.9).  
Discussion  
We previously demonstrated that differences in maternal metabolism of iAs, as 
indicated by %U-iAs, %U-MMAs and %U-DMAs in urine, was associated with lower infant 
birth weight in the Biomarkers of Exposure to ARsenic (BEAR) pregnancy cohort2. Since 
metabolism of iAs can be influenced from nutritional supplementation of nutrients and 
vitamins involved in one carbon metabolism (OCM), we analyzed the relationships between 
OCM indicators and metabolism of iAs, and found associations between OCM indicators and 
iAs metabolites in fetal cord serum (Chapter IV of this thesis). Given the potential for OCM 
indicators to influence iAs metabolism and fetal growth, and inefficient metabolism of iAs to 
influence neonatal growth, we sought to clarify these potential biological mechanisms using 
a causal mediation approach. Here we show that maternal imbalances in B12 and folate 
together influence birthweight adjusted for gestational age z-scores, whereas independently 
there is no effect. In the causal mediation analysis, maternal iAs metabolism was not found to 
mediate the relationships between OCM indicators and birthweight z-score. However, there 
is evidence of interaction between iAs metabolism and B12 on the estimates of the 
relationship between levels of B12 and changes in infant birthweight. These results suggest 
that both folate levels and maternal arsenic metabolism interact in the relationship between 
B12 deficiency during pregnancy and infant birthweight. These complex biological 
interactions have not been previously identified in iAs exposed pregnant populations. 
Stratified estimates of B12 deficiency displayed that when pregnant women have 
lower folate serum levels, there is a negative association with birthweight z-score and for 
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those that have higher folate serum levels, there is a positive association with birthweight z-
score. These data suggest that independent of iAs exposure, maternal folate serum levels 
modify the impacts of B12 deficiency on infant birthweight z-score in this population. 
Previous studies have also indicated that imbalances in folate/vitamin B12 ratios identified in 
blood during and at the end of pregnancy have been associated with lower birth weight, 
spontaneous abortion, placental abruption and congenital malformations13, 26, 27. However, it 
also important to note that when mean levels of birthweight z-scores were compared across 
four subcategories of B12/folate, the women in the higher B12 and higher folate levels had 
newborns with the lowest mean birthweight z-score. These results are supported from 
another study that demonstrated lower fetal growth due to a higher folate/vitamin B12 ratio 
from serum levels in the third trimester28. While the precise mechanisms of these B12/folate 
imbalances on fetal growth are unknown, this effect could potentially occur because both 
folate and B12 deficiencies can influence maternal-fetal metabolism, and effect methyl 
transfers in the mother and the fetus29, which can lead to vascular compromise to the fetus 
and insufficient placental development in the early embryonic period30. Taken together, these 
results suggest that the effect of B12 on infant birthweight is different across levels of folate 
and is imperative to investigate this modification rather than levels of B12 and folate 
independent of one another.  
Given that we found significant modification by folate for the relationship of B12 
deficiency on birthweight z-score, we focused part of our mediation analyses on these 
relationships. Specifically, we estimated the effects of potential mediation and/or interaction 
by maternal arsenic metabolism on B12 deficiency stratified by lower and higher folate 
serum levels. Interestingly, these results indicate that the natural direct effect, which 
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represents the change in birthweight z-score while allowing %U-iAs, %U-MMAs, and %U-
DMAs to be kept at a level that it would have taken in absence of the B12 deficiency, was 
negative for %U-iAs, %U-MMAs, and %U-DMAs, and positive in the lower folate 
categories. These data support the direct relationship between B12 deficiency and 
birthweight, where birthweight is lower when pregnant women have lower levels of serum 
folate. To quantify the proportion of mediation explained by maternal metabolism of iAs for 
the relationship of B12 deficiency to infant birth weight z-score, we estimated both the 
natural indirect effect (NIE) of the arsenicals on infant birthweight z scores and calculated 
the proportion mediated (PM) for the potential mediators %U-iAs, %U-MMAs, and %U-
DMAs. We found that the proportion mediated by maternal metabolism was rather small, and 
none of the natural indirect effects were significant. These results suggest that the effect of 
B12 deficiency on birthweight z-score is not mediated by arsenical urinary proportions.  
Conversely, there was evidence of potential interactive effects (estimated by the 
controlled direct effects), indicating that the relationship of B12 on infant birthweight 
changes depending on the levels of the modeled maternal arsenicals. Whereby, when the 
levels of maternal arsenicals were set to levels of either the median and/or the 90th percentile 
(for %U-iAs, and %U-MMAs) and 10th percentile for %U-DMAs to simulate altered 
maternal metabolism of iAs, we find that there is evidence of potential interaction of %U-
iAs, %U-MMAs, and %U-DMAs with B12 deficiency on infant birthweight. In particular, 
among those with lower folate levels, the controlled direct effect for the B12-birthweight 
association becomes significantly more negative when %iAs is higher (90th percentile) than 
when allowed to naturally vary or set to the median level. This models a condition of poorer 
metabolism during pregnancy where one would accumulate higher levels of %U-iAs. 
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Similarly, when %U-DMAs were set to the 10th percentile, thus simulating a potential poorer 
metabolism of arsenic, the controlled direct effect for B12-birthweight association becomes 
significantly more negative than when allowing %U-DMAs to naturally vary. While the 
effect on B12 associated changes in infant birthweight with a modeled high proportion of U-
MMAs was not statistically significant, a similar trend for birthweight was observed. When 
folate was higher, there were no statistically significant controlled direct effects of the 
relationship between B12 deficiency and infant birthweight z-scores for any of the modeled 
arsenicals; however, the estimates between B12 deficiency and infant birthweight z-scores 
remained positive, regardless of the levels of arsenicals. These simulated findings from the 
present study are interesting as previous research from a clinical trial indicates that folate can 
increase arsenic metabolism8. However, the comparison of our results to this previous study 
is not fully comparable as the supplementation in the previous study was carried in adults of 
both gender (i.e. not pregnant women) and excluded those who were deficient in B12. 
Together, these data suggest the relationship between B12 deficiency and infant birthweight 
z-score is not only modified by folate, but there is the potential for an interaction between 
OCM and metabolism of iAs on infant birthweight. 
There are several limitations to this study that should be kept in mind when 
interpreting these findings. First, both OCM indicators and maternal arsenicals were 
measured at the time of delivery, thus we do not have longitudinal exposure information. 
This is important for the measurement of B12 deficiency, as serum levels decrease over the 
course of pregnancy10. However, despite such variations, measurements of biomarkers for 
B12, Hcys, and folate are currently the standard for estimating deficiencies, as biomarker 
data can be more accurate and precise than questionnaire data, and daily B12 and folic acid 
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intakes are positively correlated with predictors of serum B1231. Second, interpretations of 
the change in birthweight z-scores do not represent a low birthweight phenotype. Therefore, 
the outcome interpretation represents a population shift in average birthweight z-score, 
instead of low infant birthweight. We did not categorize birthweights to explore typical 
cutoffs, such as small for gestational age or large for gestational age phenotypes, as this 
reduces the power to detect small associations between fetal exposures and birth weight32. In 
support of the methodology employed in the present study, a continuous measurement of 
birthweight-z score to examine the entire distribution of birthweights is beneficial to detect 
variation within the majority of newborns that are average for gestational age and may be 
more generalizable to many populations32. Third, causal interpretations from these analyses 
require strong assumptions. In particular, for causal interpretation of mediation analyses, we 
need to assume that there is no unmeasured confounding between the relationships of the 
main exposure to outcome (OCM indicators to birthweight z-score), the mediator to outcome 
(birthweight z-score to the arsenicals), and the mediator to the main exposure (arsenicals to 
OCM indicators). While we cannot rule out unmeasured confounding, we were careful in the 
selection of confounders based on a priori knowledge. Furthermore, the study population 
(i.e., women in a single town in Mexico) is fairly homogenous compared to national or 
international studies of birth weight, thus reducing the potential for residual confounding by 
restriction to women residing in a single town. However, sensitivity analysis will need to be 
further explored33. Lastly, because we found modification of the main exposures of B12 and 
folate, we targeted the mediation analysis to describe effects of iAs metabolism within these 
different strata. This further reduced our sample size and limited the ability to detect 
statistical mediation. This study is limited by only being able to explore dichotomous 
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categorization of folate levels, as further categorization reduced our sample size. Therefore, it 
will be important to analyze the relationship of B12 deficiency on infant birthweight across 
other cutpoints of folate. Replication of these findings in other populations will be important, 
as there is still potential that the relationship between OCM indicators and infant birthweight 
could be mediated through maternal iAs metabolism. This is particularly important in regard 
to the estimation of the total effects, as the association with the exposure in a given 
population depends on the population prevalence of the mediator,34 and despite the effort to 
simulate poorer metabolism, we were limited in our ability to do such, as most women in this 
population were efficient at metabolizing iAs. One major strength of this study is the 
estimation of potential causal effects, especially since we found evidence of potential 
interaction between the OCM indicators and iAs metabolism on infant birthweight. Another 
major strength of this work lies in the modeling of interactions between the exposure and 
mediator. In many mediation analysis that are carried out not using causal methods (e.g. the 
classical product method for estimating indirect effects), there is the assumption that the 
exposure and mediator do not interact, and this corresponds to misleading assumptions of 
effect homogeneity and that causal effects are constant across all individuals25. 
In conclusion, in the study of the cohort in Gomez Palacio Mexico who are exposed 
to iAs from drinking water, we observe the population is B12 deficient, yet folate sufficient. 
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Across the cohort, the newborn birthweight z-scores were negatively associated with B12 
deficiency when analyzed in the context of folate status. Additionally, there is evidence of 
potential interaction between iAs metabolism and B12 on the estimates of the relationship 
between levels of B12 and shifts in infant birthweight. These findings may inform future 
interventions to reduce the impacts of both nutritional imbalances and exposures to toxic 
substances.  
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Table 5.1. Coding of variables used for mediation models to estimate the relationships 
between one carbon metabolism indicators, arsenicals, and infant birthweight.   
Model:  
OCM indicator 
Baseline 
exposure 
New exposure Mediator 
 a0 a1 %U-iAs %U-MMAs %U-DMAs 
Model 1: B12      
1a Sufficient 
<148 pmol/L 
Deficient 
≥148 pmol/L 
Median 
5.3 
Median 
5.9 
Median 
88.5 
1b Sufficient 
<148 pmol/L 
Deficient 
≥148 pmol/L 
90th 
percentile 
9.3 
90th 
percentile 
9.5 
10th percentile 
81.7 
Model 2: 
Folate 
     
2a Higher  
≥ 37.9 nmol/L 
Lower  
<37.9 nmol/L 
Median 
5.3 
Median 
5.9 
Median 
88.5 
2b Higher  
≥ 37.9 nmol/L 
Lower  
<37.9 nmol/L 
90th 
percentile 
9.3 
90th 
percentile 
9.5 
10th percentile 
81.7 
Model 3: 
Homocysteine 
     
3a Lower  
<6.4 μmol/L 
Higher 
≥6.4 μmol/L 
Median 
5.3 
Median 
5.9 
Median 
88.5 
3b Lower  
<6.4 μmol/L 
Higher 
≥6.4 μmol/L 
90th 
percentile 
9.3 
90th 
percentile 
9.5 
10th percentile 
81.7 
Model 4: B12+      
4a Sufficient 
<148 pmol/L 
Deficient 
≥148 pmol/L 
Median 
5.3 
Median 
5.9 
Median 
88.5 
4b Sufficient 
<148 pmol/L 
Deficient 
≥148 pmol/L 
90th 
percentile 
9.3 
90th 
percentile 
9.5 
10th percentile 
81.7 
+Model estimates are presented as stratified below and above median folate levels. 
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Table 5.2. Selected demographic characteristics, levels of arsenicals, and one carbon 
metabolism indicators of participants of the Biomarkers of Exposure to Arsenic (BEAR).  
 N (N%) or Mean, Median [range] 
Maternal age at delivery, years 24.0, 23 [18-41] 
Race/ethnicity (Hispanic) 197 (100) 
Educational level  
  < High School 51 (25.9) 
     High School 95 (48.2) 
   > High School 51 (25.9) 
Daily Prenatal Vitamin intake  
No  8 (4.1) 
Yes 189 (95.9) 
Parity   
1st pregnancy  68 (34.5) 
More than 1 pregnancy 129 (65.5) 
Newborn sex  
   Male  103 (52.3) 
   Female 94 (47.7) 
Birth weight (g) 3338.7, 3340.0 [1800-5120.00] 
Gestational Age, weeks 39.3, 40 (34-42) 
Birth weight (z-score) -0.29, -0.37 (-2.6, 2.7)  
Maternal Urinary arsenicals 197 (100%)  
U-tAs (μg/L) 37.5 23.4 [4.3-319.7] 
U-iAs (μg/L) 2.1, 1.3 [0.14-23.0] 
U-MMAs (μg/L) 2.3, 1.3 [0.082-18.2] 
U-DMAs (μg/L) 33.1, 20.8 [1.4-292.5] 
U-iAs (%) 6.1, 5.3 [0.77- 45.1] 
U-MMAs (%) 6.4, 5.9 [1.3-24.9] 
 117 
U-DMAs (%) 87.6, 88.5 [32.7- 96.7] 
One Carbon Metabolism Indicators 197 (100%) 
B12 (pmol/L) 127.4, 116.5 [48.0-284.1] 
 Deficient (< 148) 145 (74%) 
 Sufficient (≥ 148) 52 (26%) 
Folate (nmol/L) 40.6, 37.9 [7.1-171.5] 
 < Median (37.9)  98 (50%) 
  ≥ Median (37.9)  99 (50%) 
Homocysteine (μmol/L) 6.9, 6.4 [4.1-19.4] 
  Normal (<10.4) 182 (92%) 
  High (≥ 10.4) 15 (8%) 
B12/Folate Interaction categories  
  I: B12 deficient /<median folate 70 (36%) 
  II: B12 deficient /≥ median folate  75 (38%) 
  III: B12 sufficient /<median folate 28 (13%) 
  IV: B12 sufficient /≥ median folate 24 (12%) 
 
  
1
1
8
 
Table 5.3. Mean birth weight-for-gestational age z-score by categories of maternal serum one carbon metabolism indicators (OCM 
indicators). 
 B12 Folate Hcys B12/Folate categories 
Categories+ 
N 
Deficient   
(145) 
Sufficient 
(52) 
<Median  
(98) 
≥Median 
(98) 
Normal 
(182) 
High 
(15) 
I 
(70) 
II 
(75) 
III 
(28) 
IV 
(24) 
 Mean (sd) Mean (sd) Mean (sd) Mean (sd) Mean (sd) Mean (sd) Mean (sd) Mean (sd) Mean (sd) Mean (sd) 
birthweight  
z-score 
-0.36 
(0.99) 
-0.064 
(1.01) 
-0.21 
(1.1) 
-0.36 
(0.94) 
-0.27 
(1.01) 
-0.51 
(0.90) 
-0.43 
(0.95) 
-0.31 
(1.02) 
0.33  
(1.1) 
-0.52  
(0.61) 
p-value  0.067  0.29  0.33    0.0037 
+B12 categories are set at deficient <148 pmol and sufficient ≥ 148 pmol for maternal serum B12 levels.  
Folate categories are set at above or below the median of 37.5 nmol for maternal serum folate levels.   
Normal homocysteine (Hcys) was set at < 10.4 nmol and high hcys was was set ≥ 10.4 nmol for maternal serum hcys levels.   
B12/folate categories were created based on deficient/sufficient B12 status and median levels of folate.  
I: Deficient B12 (<148 pmol)/higher folate (≥37.9 nmol). 
II: Deficient B12 (<148 pmol)/lower folate (< 37.9 nmol). 
III: Sufficient B12 (≥148 pmol)/lower folate (< 37.9 nmol). 
IV: Sufficient B12 (≥148 pmol)/higher folate (≥ 37.9 nmol).  
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Table 5.4. Multivariable# linear regression models testing relationships between each 
individual OCM indicators and birthweight z-score.  
 B12  Folate Hcys 
Categories of OCM+ 
 
Beta estimate 
[95 % CI]  
(p-value) 
Beta estimate 
[95 % CI]  
(p-value) 
Beta estimate 
[95 % CI]  
(p-value) 
Birthweight z-score -0.26 
[-0.56, 0.047] 
(0.096) 
-0.10 
[-0.38, 0.18] 
(0.47) 
-0.24 
[-0.75, 0.28] 
(0.37) 
#All models were adjusted for maternal age (continuous), maternal education (coded as an indicator variable), 
and parity (dichotomized). 
^ Referent for B12 is sufficient, for folate >the median level, and for homocysteine <normal level  
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Table 5.5. Multivariable# linear regression to determine effect measure modification of B12 
to birth weight-for-gestational age z-score by categories of folate. 
B12 deficiency to birth weight z-score Beta 
Estimate for B12 
deficient ^ 
[95% CI] 
(p-value) 
Test for 
modification+ 
Reduced model -0.26 
 
[-0.56, 0.051] 
(0.10) 
 
Full model with an interaction term of 
folate and B12 
-0.72 [-1.1, -0.31] 
(0.006) 
 
 
Stratified estimates    
Estimate for B12 deficiency with 
Lower Folate 
-0.74  
 
[-1.2, -0.31] 
(0.0008) 
 
Estimate for B12 deficiency with    
Higher Folate 
0.29 
 
[0.70, -0.13] 
(0.17) 
10.1 
(0.0015) 
#All models were adjusted for maternal age (continuous), maternal education (coded as an indicator variable), 
and parity (dichotomized). 
^reference of B12  sufficient for all models; for interaction model reference is the lower folate level  
+ LRT test statistic and p-value  
 
  
1
2
1
 
Table 5.6. Mediation analysis of Model 1#, to estimate the relationship between B12 deficiency with and without interaction between 
the potential mediators of maternal iAs metabolism and B12 (%U-iAs, %U-MMAs, %U-DMAs) on infant birthweight z-scores. 
 %U-iAs %U-iAs %U-MMAs %U-MMAs %U-DMAs %U-DMAs 
Model 1+ B12 with interaction B12 without 
interaction 
B12 with interaction B12 without interaction B12 with interaction B12 without 
interaction 
NDE -0.29 
[-0.61, 0.033] 
(0.078) 
-0.27 
[-0.58, 0.044] 
(0.093) 
-0.27 
[-0.58, 0.044] 
(0.091) 
-0.27 
[-0.58, 0.042] 
(0.091) 
-0.28 
[-0.59, 0.039] 
(0.086)  
-0.27 
[-0.58, 0.043] 
 (0.090) 
NIE 0.024 
[-0.046, 0.093 
(0.50) 
0.0075 
[0.58, -0.019] 
(0.033)* 
0.0074 
[-0.029, 0.044] 
(.69) 
0.0080  
 [-0.031,0.046] 
 (0.68) 
0.015 
 [-0.045,0.076] 
 (0.62) 
0.0085 
[-0.026, 0.043] 
 (0.63) 
TE -0.26 
[-0.58, 0.050] 
(0.099) 
-0.26 
[-0.57, 0.052] 
(0.10) 
-0.26  
[-0.58, 0.054] 
(0.10)  
-0.26 
[-0.57, 0.053] 
(0.10) 
-0.26 
[-0.57, 0.052] 
(0.10)  
-0.26 
[-0.57, 0.053] 
(0.10) 
PM -2.9% -8.9% -2.8% -3.1% -2.8 -3.1 
CDE       
Model 1a++ -0.20 
[-0.52, 0.13] 
(0.23) 
N/A -0.27 
[-0.59, 0.043] 
(0.090) 
 
N/A 
-0.43 
[-0.83 -0.018] 
(0.040)* 
 
N/A 
Model 1b 
+++ 
-0.20 
[-0.52, 0.13] 
(0.23) 
N/A -0.24 
[-0.71, 0.24] 
(0.32) 
 
N/A 
-0.24  
[-0.56, 0.073] 
(0.13) 
 
N/A 
#All models were adjusted for maternal age (continuous), maternal education (coded as an indicator variable), and parity (dichotomized). 
+ B12 a0 set to sufficient <148 pmol/L, B12 a1 set to deficient ≥148 pmol/L and modeled with an without an interaction for B12 and arsenicals 
NDE: Natural direct effect, interpreted as how much birthweight z-score would change if the exposure of B12 was changed from sufficient to deficient and the 
mediator of arsenicals is kept at a level it would’ve taken in absence of B12 deficient exposure. 
 NIE: Natural indirect effect, interpreted as how much birthweight z-score would change on average if the exposure of B12 was changed from sufficient to 
deficient but the mediator (arsenicals) were changed from the level it would’ve taken in absence of B12 deficiency. 
TE: total effect, estimates how much birthweight z-score would change overall for a change in the exposure of B12 sufficient to deficient  
PM: proportion mediated (PM) that was calculated by the following formula: NIE/TE x 100. 
CDE: the controlled direct effect estimates how much the outcome of birthweight z-score would change on average if the mediator of arsenicals were controlled 
at the set level (assigned). 
++Mediator set at the 50th percentile (median value), set at 5.3 %U-iAs, 5.9 %U-MMAs, and 88.5 % U-DMAs . 
+++ Mediator set at 90th percentile for %U-iAs (9.5) and %U-MMAs (9.6), and 10th percentile for %U-DMAs (81.7). 
  
  
1
2
2
 
Table 5.7. Mediation analysis of Model 2#, to estimate the relationship between folate levels with and without interaction between the 
potential mediators of maternal iAs metabolism and folate (%U-iAs, %U-MMAs, %U-DMAs) on infant birthweight z-scores. 
 %U-iAs %U-iAs %U-MMAs %U-MMAs %U-DMAs %U-DMAs 
Model 2+ Folate with interaction Folate without 
interaction 
Folate with 
interaction 
Folate without 
interaction 
Folate with interaction Folate without 
interaction 
NDE 0.11 
[-0.18, 0.39] 
(0.48) 
0.10 
[-0.18, 0.39] 
(0.48) 
0.076 
[-0.21, 0.36] 
(0.60) 
0.079 
[-0.20, 0.36] 
(0.58) 
0.087 
[-0.20, 0.37] 
(0.54)  
0.093 
[-0.19, 0.37] 
(0.52)  
NIE 0.00010 
[-0.028, 0.028] 
(0.99) 
0.00006 
[-0.017, 0.017] 
(0.99) 
0.026 
[-0.037, 0.088] 
(0.41) 
0.023 
[-0.020, 0.065] 
(0.29) 
0.015 
[-0.037,0.068] 
(0.56) 
0.0092 
[-0.021,0.040] 
(0.55) 
TE 0.10 
[-0.18, 0.38] 
(0.48) 
0.10 
[-0.18, 0.38] 
(0.48) 
0.10 
[-0.18, 0.38] 
(0.48) 
0.10 
[-0.18, 0.38] 
(0.48) 
0.10 
[-0.18, 0.38] 
(0.48) 
0.10 
[-0.18, 0.38] 
(0.48) 
PM 
0.10% 0.06% 26% 23% 15% 9% 
CDE       
Model 2a++ 0.12 
[-0.18, 0.42] 
(0.44) 
 
N/A 
0.082 
[-0.20, 0.37] 
(0.57) 
 
N/A 
0.0094 
[-0.42, 0.43] 
(0.96) 
 
N/A 
Model 2b 
+++ 
0.049 
[-0.37, 0.47] 
(0.81) 
N/A 0.052 
[-0.42, 0.52] 
(0.82) 
 
N/A 
0.10 
[-0.18, 0.39] 
(0.47) 
 
N/A 
#All models were adjusted for maternal age (continuous), maternal education (coded as an indicator variable), and parity (dichotomized). 
+Folate a0 set to lower than the median folate level of <37 nmol/L, Folate a1 was set to higher than the median folate level of ≥37 nmol/L and modeled with an 
without an interaction for folate and arsenicals. 
NDE Natural direct effect, interpreted as how much birthweight z-score would change if the exposure of B12 was changed from sufficient to deficient and the 
mediator of arsenicals is kept at a level it would’ve taken in absence of B12 deficient exposure. 
NIE Natural indirect effect, interpreted as how much birthweight z-score would change on average if the exposure of B12 was changed from sufficient to 
deficient but the mediator (arsenicals) were changed from the level it would’ve taken in absence of B12 deficiency. 
TE total effect, estimates how much birthweight z-score would change overall for a change in the exposure of B12 sufficient to deficient  
PM proportion mediated (PM) that was calculated by the following formula: NIE/TE x 100. 
CDE the controlled direct effect estimates how much the outcome of birthweight z-score would change on average if the mediator of arsenicals were controlled 
at the set level (assigned). 
++Mediator set at the 50th percentile (median value), set at 5.3 %U-iAs, 5.9 %U-MMAs, and 88.5 % U-DMAs . 
+++ Mediator set at 90th percentile for %U-iAs (9.5) and %U-MMAs (9.6), and 10th percentile for %U-DMAs (81.7). 
  
  
1
2
3
 
Table 5.8. Mediation analysis of Model 3#, to estimate the relationship between Homocysteine (Hcys) status (higher vs. normal) with 
and without interaction between the potential mediators of maternal iAs metabolism and Hcys (%U-iAs, %U-MMAs, %U-DMAs) on 
infant birthweight z-scores. 
 %U-iAs %U-iAs %U-MMAs %U-MMAs %U-DMAs %U-DMAs 
Model 3+ Hcys with 
interaction 
Hcys without 
interaction 
Hcys with interaction Hcys without 
interaction 
Hcys with interaction Hcys without 
interaction 
NDE -0.48 [-1.1, 0.11] 
(0.11)  
-0.25 [-0.78, 0.28]  
(0.35) 
-0.31 [-0.84, 0.22] 
(0.25) 
-0.26 [-0.78,0.27] 
(0.33) 
-0.41 [-0.96, 0.15] 
(0.14)  
-0.26 [-0.78,0.27] 
(0.33) 
NIE 0.22 [-0.31, 0.75] 
(0.40) 
0.016 [0.033,0.064] 
(0.53) 
0.071 [-0.17, 0.32] 
(0.57) 
0.022 [-0.040, 0.084] 
(0.49) 
0.16 [-0.26,0.58] 
(0.45) 
0.022 [-0.040,0.084] 
(0.48) 
TE -0.25 [-0.95, 0.44] 
(0.47) 
-0.24 [-0.76, 0.29] 
(0.38) 
-0.24 [-0.81, 0.33] 
(0.40)  
-0.24  [-0.76, 0.29] 
(0.38) 
-0.2 [-0.89, 0.40] 
(0.44)  
-0.24 [-0.76, 0.29] 
(0.38) 
PM -88.4% -6.7 -29.5 -9.4% -64.7 -9.4% 
CDE+       
Model 3a++ -0.22 [-0.74, 0.31] 
(0.42) 
N/A -0.25 [-0.77, 0.27] 
(0.34)  
N/A -1.04 [-2.04, -0.035] 
(0.042) * 
N/A 
Model 3b 
+++ 
-1.3 [-2.6, -0.049] 
(0.041) * 
N/A -0.71 [-1.6, 0.20] 
(0.12) 
N/A -0.30 [-0.82, 0.22] 
(0.26) * 
N/A 
# Hcys a0 set to normal < 10.4 nmol, Hcys  a1 was set to higher ≥10.4 nmol and modeled with an without an interaction for Hcys and arsenicals 
NDE: Natural direct effect, interpreted as how much birthweight z-score would change if the exposure of Hcys was changed from normal to higher and the 
mediator of arsenicals is kept at a level it would’ve taken in absence of Hcys exposure. 
NIE: Natural indirect effect, interpreted as how much birthweight z-score would change on average if the exposure exposure of Hcys was changed from below 
the median to above the median value (6.4) but the mediator (arsenicals) were changed from the level it would’ve taken in absence of higher Hcys. 
TE: total effect, estimates how much birthweight z-score would change overall for a change in the exposure of exposure of Hcys was changed from normal to 
higher. 
PM: proportion mediated (PM) that was calculated by the following formula: NIE/TE x 100. 
CDE: the controlled direct effect estimates how much the outcome of birthweight z-score would change on average if the mediator of arsenicals were controlled 
at a set level (assigned). 
++Mediator set at the 50th percentile (median value), set at 5.3 %U-iAs, 5.9 %U-MMAs, and 88.5 % U-DMAs . 
+++ Mediator set at 90th percentile for %U-iAs (9.5) and %U-MMAs (9.6), and 10th percentile for %U-DMAs (81.7). 
  
  
1
2
4
 
Table 5.9. Mediation analysis to model the effects of B12 deficiency in strata of above or below the median levels of maternal serum 
folate, allowing for an interaction between the potential mediators of maternal iAs metabolism and B12 (%U-iAs, %U-MMAs, %U-
DMAs). 
 %U-iAs %U-iAs %U-MMAs %U-MMAs %U-DMAs %U-DMAs 
Est# Folate  
Low 
Folate  
High  
Folate  
Low 
Folate  
High  
Folate  
Low 
Folate  
High  
NDE -0.74 
[-1.2, -0.26] 
(0.0027) * 
0.22  
[-0.24, 0.67] 
(0.34) 
-0.73  
[-1.2, -0.27] 
(0.0016) * 
0.25 
[-0.19, 0.68] 
(0.27) 
-0.72  
[-1.2, -0.27] 
(0.0018) * 
0.23  
[-0.22, 0.67] 
(0.32) 
NIE -0.010 
[-0.076, 0.056] 
(0.76) 
0.070  
[-0.082, 0.22] 
(0.37) 
-0.011 
[-0.060, 0.038] 
(0.65) 
0.045  
[-0.052, 0.14] 
(0.36) 
-0.020  
[-0.090, 0.048] 
0.56 
0.064 
[-0.070, 0.20] 
(0.34) 
TE -0.75  
[-1.2, -0.29] 
(0.0016)* 
0.29 
[0.19, -0.14] (0.71) 
-0.74 
[-1.2, -0.29] 
(0.0013) * 
0.29 
 [-0.14, 0.72] 
(0.18) 
-0.74  
[-1.2, -0.29] 
(0.0012) * 
0.29  
[-0.14, 0.72] 
(0.18) 
PM 1.3% 24% 1.5% 16% 2.7% 22% 
INT -0.19 
(0.072)  
-0.065 
(0.14) 
0.021 
(0.83) 
-0.052 
(0.87) 
0.048 
(0.74) 
0.036 
(0.16) 
CDE+       
 50th++ -0.61 
[-1.07, -0.15] 
(0.0091) * 
0.33 
[-0.10, 0.77] 
(0.13) 
-0.72 
[-1.2, -0.27] 
(0.0016) * 
0.33 
[-0.13, 0.78] 
(0.16) 
-0.71  
[-1.2, -0.27] 
(0.0018) * 
0.33  
[-0.11, 0.76] 
(0.14) 
 90th 
 or 
10th +++ 
-1.4 
[-2.2, -0.56] 
(0.0016) * 
0.063 
[-0.47, 0.58] 
(0.81) 
-0.65 
[-1.5, 0.20] 
(0.13) 
0.13 
[-0.38, 0.64] 
(0.60) 
-1.04 
[-2.0, -0.13] 
(0.025) * 
0.079  
[–0.43, 0.58] 
(0.75) 
  
  
1
2
5
 
Table 5.10. Mediation analysis to model the effects of B12 deficiency in strata of above or below the median levels of maternal serum 
folate, without interaction between the potential mediators of maternal iAs metabolism and B12 (%U-iAs, %U-MMAs, %U-DMAs).  
 %U-iAs %U-iAs %U-MMAs %U-MMAs %U-DMAs %U-DMAs 
 Folate  
Low 
Folate  
High  
Folate  
Low 
Folate  
High  
Folate  
Low 
Folate  
High  
NDE -0.73 
[-0.79, -0.035] 
(0.0012)* 
0.28  
[-0.15, 0.71] 
(0.20) 
-0.72 
[-1.2, -0.27] 
(0.0015)* 
0.26 
[-0.17, 0.68] 
(0.24) 
-0.72  
[-1.2, -0.27] 
(0.0015)* 
0.27  
[-0.16, 0.70] 
(0.22) 
NIE -0.0043 
[-0.035, 0.026] 
(0.78) 
0.0066  
[-0.047,0.060] 
(0.80) 
-0.013 
[-0.062, 0.036] 
(0.60) 
0.029  
[-0.043, 0.10] 
(0.42) 
-0.014  
[-0.066, 0.037] 
0.59 
0.018 
[-0.043, 0.079] 
(0.55) 
TE -0.74 
[-1.2, -0.29] 
(0.0012)* 
0.29 
[-0.14, 0.72] (0.19) 
-0.74 
[-1.2, -0.28] 
(0.0012)* 
0.29 
 [-0.14, 0.72] 
(0.19) 
-0.74  
[-1.2, -0.29] 
(0.0012)* 
0.29  
[-0.14, 0.72] 
(0.19) 
PM 0.58% 2.3% 1.7% 10% 1.9% 6.4% 
#All models were adjusted for maternal age (continuous), maternal education (coded as an indicator variable), and parity (dichotomized). 
+ B12 a0 set to sufficient <148 pmol/L, B12 a1 set to deficient ≥148 pmol/L and modeled with an without an interaction for B12 and arsenicals 
NDE: Natural direct effect, interpreted as how much birthweight z-score would change if the exposure of B12 was changed from sufficient to deficient and the 
mediator of arsenicals is kept at a level it would’ve taken in absence of B12 deficient exposure. 
NIE: Natural indirect effect, interpreted as how much birthweight z-score would change on average if the exposure of B12 was changed from sufficient to 
deficient but the mediator (arsenicals) were changed from the level it would’ve taken in absence of B12 deficiency. 
TE: total effect, estimates how much birthweight z-score would change overall for a change in the exposure of B12 sufficient to deficient  
PM: proportion mediated (PM) that was calculated by the following formula: NIE/TE x 100. 
INT: the interaction coefficient and p-value from the interaction of B12 and arsenicals to birthweight. 
CDE: the controlled direct effect estimates how much the outcome of birthweight z-score would change on average if the mediator of arsenicals were controlled 
at the set level (assigned). 
++Mediator set at the 50th percentile (median value), set at for 5.3 %U-iAs, 5.9 %U-MMAs, and 88.5 % U-DMAs . 
+++ Mediator set at 90th percentile for %U-iAs (9.5) and %U-MMAs (9.6), and 10th percentile for %U-DMAs (81.7). 
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CHAPTER VI: LOW LEVELS OF EXPOSURE TO INORGANIC ARSENIC IN 
DRINKING WATER MAY MODIFY THE RELATIONSHIP BETWEEN 
MATERNAL SERUM LEVELS OF HOMOCYSTEINE, AND INFANT 
BIRTHWEIGHT. 
Overview 
Exposure to inorganic arsenic (iAs) from contaminated drinking water is a 
widespread global public health problem, and is particularly harmful during sensitive 
windows of exposure such as the prenatal period. Nutrients involved in one carbon 
metabolism (OCM) may play an important role in metabolism of iAs and is associated with 
changes in birthweight. Additionally, the levels of exposure to iAs may modify the 
associations between OCM, iAs metabolism, and infant birthweight. This work focuses on 
the impacts of the levels of drinking water iAs below, or at and above the World Health 
Organization (WHO) guideline level of 10ppb on OCM metabolism, iAs metabolism, and 
infant birthweight.  Mediation analysis was carried out to estimate the effects of indicators of 
OCM, namely maternal serum B12, folate, and Homocysteine (Hcys) on infant birthweight 
and potential mediation by maternal arsenic metabolism (percentages of iAs, mono and di 
methylated arsenicals) stratified by iAs drinking water levels. We find that drinking water 
levels are marginally correlated with maternal metabolism of iAs, and that maternal serum 
Hcys is correlated with drinking water levels. The levels of drinking water did not modify the 
association between maternal B12, folate and infant birthweight. However, there was 
evidence of potential modification between higher Hcys exposure and infant birthweight 
when exposure to iAs in drinking water was below the WHO guideline level. There was no 
indication of mediation by iAs metabolism of the relationship between OCM and birthweight 
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regardless of drinking water levels. These data indicate that lower levels of iAs in drinking 
water might play a role in the relationship between maternal one carbon metabolism and iAs 
associated alterations in birthweight. 
Introduction 
Exposure to inorganic arsenic (iAs) from contaminated drinking water is a 
widespread global public health problem, and particularly for populations that may be most 
sensitive and susceptible to exposure such as the developing fetus. In utero exposure to iAs is 
associated with several adverse birth outcomes, including lower birth weight, preterm birth, 
reduced height and head circumference, increased susceptibility to infection, including 
inflammation and infectious disease, and later in life cancers1.  There are many factors that 
influence risks of iAs-associated birth outcomes. Of particular importance are differences in 
pregnant women’s ability to metabolize iAs, as this may influence risks for adverse birth 
outcomes, such as alterations in fetal growth and increased risks for later in life disease2-5. 
Inorganic arsenic is metabolized in the body into mono- and di-methyl arsenicals (MMAs 
and DMAs, respectively).   
Recently, there is interest in reducing iAs-associated diseases by increasing 
individuals’ capacity to metabolize iAs6. Two modifiable factors that may be of importance 
for influencing iAs metabolism from a potential intervention approach are nutrition and the 
levels of exposure to iAs from drinking water. Specifically, metabolism of iAs may be 
influenced by nutrients involved in one carbon metabolism (OCM), and in fact, 
supplementation of OCM nutrients and/or vitamins in iAs exposed populations has been 
demonstrated to increase methylation of iAs6, 7. Another factor that may contribute to 
metabolism of iAs, and therefore increases in risks for iAs-associated diseases, are the levels 
of exposure in drinking water. This has been demonstrated in previous studies where, with 
 131 
increasing exposure to levels of iAs in drinking water, the urinary proportions of iAs and 
MMAs in increased and the proportions of DMAs decreased8, 9. However, in other studies the 
amount of iAs levels in drinking water were not associated with metabolism of iAs8. 
Furthermore, it is unclear whether individuals who are exposed above and below the 
regulatory guidelines, e.g. the World Health Organization (WHO) recommended guideline, 
display differences in metabolism of iAs. For example, in pregnant populations exposed to 
iAs, there is evidence of increases in %MMA (an indicator of inefficient iAs metabolism) at 
even very low levels of iAs10. 
Knowing how this modifiable factor of exposure to levels of iAs from drinking water 
influences metabolism of iAs may be important for environmental regulation of iAs. This 
could identify populations at a higher risk for iAs-associated diseases. This is particularly 
important since regulations vary by region and are continually being reexamined. For 
example, WHO and Australia have a set guideline level of 10 ppb (μg/L) for iAs in drinking 
water, and the U.S. Environmental Protection Agency’s (EPA) maximum contaminant level 
(MCL) is 10 ppb. Additionally, some states have set limits of exposure to lower levels, such 
as 5ppb. However, in many countries (e.g. Bangladesh) 50 μg/L is still the commonly 
adopted guideline, and in Mexico, the MCL is set at 25 μg/L. It has been suggested that these 
differences in regulation may primarily be due to the difficulties in remediating iAs below 
the designated MCLs11. Furthermore, despite guidelines, there is still widespread exposure 
from iAs in drinking water. For example, there are several areas in the U.S. that have 
exposure to iAs in drinking water from unregulated private wells supplied with groundwater. 
Specifically, contaminated groundwater with elevated iAs is prevalent in the West, Midwest, 
parts of Texas, the Northeast and the South 12-14.   
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 The impacts of the levels of iAs in drinking water on maternal metabolism of iAs in 
relation to birth outcomes have not been fully elucidated. Furthermore, whether exposure 
levels of iAs in drinking water modify the relationship between metabolism of nutrients 
involved in OCM, related to iAs methylation, and associated birth outcomes has not been 
previously studied. The aim of this work was to investigate the direct effects of maternal 
levels indicators of one carbon metabolism (B12, folate, cysteine, homocysteine) on infant 
birthweight stratified by different levels of drinking water iAs, and the indirect effects of this 
relationship in the context of potential mediation by maternal metabolism of iAs in the 
Biomarkers of exposure to arsenic (BEAR) cohort. We hypothesized that the levels of iAs in 
drinking water influence the effect of maternal nutritional biomarkers and infant birthweight, 
as iAs in drinking water is the primary source of exposure to iAs in this cohort.3 Knowing 
how OCM indicators influence birthweight across different levels of exposure could inform 
important biological mechanisms of in utero exposure.   
Materials and methods  
Study population 
The study population has been fully described previously3. Briefly, women were 
recruited at the time of the admission affiliated with their delivery from at the General 
Hospital of Gómez Palacio. The present study designed to analyze maternal serum levels of 
OCM indicators, iAs metabolism, and infant birthweight by levels of exposure to iAs via 
drinking water included a total of 197 women. Demographic data was gathered by a clinical 
worker and included information on maternal age at delivery, education, occupation, time 
living at residence, smoking status and alcoholic beverage consumption during pregnancy, 
daily prenatal supplement intake, seafood consumption, source and daily consumption of 
drinking and cooking water, and participants previous pregnancies (number of pregnancies 
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and number of previous pregnancy losses). Information on birth measures including newborn 
birth weight, newborn length, gestational age, head circumference, placental weight, and 5-
min Appearance, Pulse, Grimace, Activity, Respiration (APGAR) score was gathered at time 
of delivery by the physician and clinical staff. The outcome of infant birthweight was 
standardized by deriving z- scores that were calculated from the international infant growth 
charts of birthweight for gestational age at delivery (measured by last menstrual period)15. 
All procedures associated with this study were approved by the Institutional Review Boards 
of Universidad Juárez del Estado de Durango (UJED), Gómez Palacio, Durango, Mexico, 
and the University of North Carolina at Chapel Hill (UNC), Chapel Hill, North Carolina, 
U.S.A. 
Assessing the levels of inorganic arsenic in drinking water  
The methods for drinking water sampling have been described previously3. Briefly, 
within 4 weeks of newborn delivery, a drinking-water sample was collected by the research 
team at the homes of each of the study participants. The concentrations of iAs in drinking 
water (micrograms As/L; DW-iAs) were measured at UJED, Mexico, using hydride 
generation–atomic absorption spectrometry (HG-AAS) supported by a FIAS-100 flow 
injection accessory system as described previously16. The Trace Elements in Water standard 
reference material (SRM 1643e) (National Institute of Standards and Technology, 
Gaithersburg, MD) was used for quality control. The limit of detection (LOD) for iAs in 
drinking water by HG-AAS was 0.46 μg As/L. For this present study, drinking water iAs 
(Dw-iAs) levels were categorized into binary values of participants’ drinking water levels 
being either < or ≥ WHO guideline level of 10ppb. This included 92 (47%) women who had 
Dw-iAs below the WHO guideline level of 10 ppb and 105 (53%) women who had Dw-iAs 
equal to and/or above 10ppb (Table 6.2).  
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Determination of inorganic arsenic metabolism   
Maternal metabolism of inorganic arsenic was determined from spot urinary samples 
collected at the hospital during the delivery admission for all participants. These samples 
were immediately aliquoted, transferred to cryovials, and placed in liquid nitrogen. Aliquots 
of urine samples were shipped on dry ice to UNC-Chapel Hill where concentrations of U-
iAs, U-MMAs, and U-DMAs were determined by HG-AAS as described previously16-18.  
Maternal total urinary arsenic (U-tAs) was determined by summing U-iAs, U-MMAs and U-
DMAs. Concentrations of U-iAs, U-MMAs, and U-DMAs in each urine sample were 
adjusted for specific gravity as previously described19. Metabolism efficiency was 
determined by calculating the proportions of the individual arsenicals iAs (%U-iAs), MMAs 
(%U-MMAs), and DMAs (%U-DMAs) relative to U-tAs. 
Determination of OCM indicators  
Banked maternal serum samples that were collected during the time of delivery 
admission for all participants and stored at -80° were shipped on dry ice to Columbia 
University, New York, NY to measure OCM indicators. Maternal serum folate and B12 were 
analyzed by radio protein-binding assay (SimulTRAC-S; MP Biomedicals, Orangeburg, NY, 
USA), where folic acid as pteroylglutamic acid was used for calibration, and its 125 I-labeled 
analog as the tracer. All samples were run on a Gamma counter (Perkin Elmer). Hcys levels 
were analyzed via a HPLC- fluorescent detector with 385nm excitation and 515nm 
emission20. OCM indicators deficiencies and/or sufficiencies were determined for each 
woman as has previously been described21, and as in other iAs-exposed populations22. 
Because there were relatively few women (n=2) who had serum levels that indicated they 
were deficient in folate (<9 nmol), binary cutoffs for folate were created, where lower folate 
is defined as those women who had serum levels below the median level (37.9 nmol/L) and 
 135 
higher folate is defined as those women who had serum levels of folate above or equal to the 
median (37.9 nmol/L) in the cohort. B12 deficiency was set at <148 pmol and ≥ 148 pmol for 
B12 sufficiency. Hyperhomocysteinemia (high Hcys) was defined by Hcys ≥ 10.4 nmol and 
normal Hcys was set at  < 10.4 nmol.  
Statistical analyses of the relationship of the drinking water levels of inorganic arsenic 
(iAs) to metabolism of iAs and one carbon metabolism indicators.  
All statistical comparisons and analysis were carried out using SAS v9.3. Spearman 
rank correlations coefficients (rs) were calculated between the levels of arsenicals in maternal 
urine including total maternal urinary arsenic (U-tAs), %U-iAs, %U-MMAs, and %U-
DMAs, and maternal one carbon metabolism (OCM) indicators of B12, folate, and Hcys, 
across all women and by stratified levels of Dw-iAs (< or ≥ WHO guideline level of 10ppb). 
Differences in mean levels of maternal urinary arsenicals, maternal serum OCM indicators, 
and differences in infant birthweight z-scores were determined based on Dw-iAs levels 
below or above the WHO guideline level of 10 ppb using a two sided t-test. 
Mediation methods  
Mediation analysis for OCM indicators, iAs metabolism, and infant birthweight were 
carried out using mediation methods and SAS code previously described by Valeri and 
Vanderweele23. Specifically, these mediation analysis were carried out for each strata of 
drinking water iAs levels, where the women were stratified by their drinking water iAs levels 
of < or ≥ WHO guideline level of 10ppb. This analysis aimed to address whether the 
arsenical proportions (e.g. %U-iAs, %U-MMAs, %U-DMAs) are mediators of the 
relationship between B12, folate or Hcys and birthweight z-score. In all models, the variables 
are denoted as the following: A =exposure (OCM indicators), M =mediator (%U-iAs, %U-
MMAs, %U-DMAs), Y =outcome (birthweight z-score), and C=covariates. The derivation of 
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the specific regression models used to determine the estimates have been previously fully 
described elsewhere23.  Specifically for this current study, the following regression equation 
was used to estimate the expected value of the potential mediator of arsenicals, given the 
exposure of OCM indicators and covariates: E [M|a,c]=β0+β1a+β’2c. The following 
regression equation was used to estimate the expected value of the outcome of infant birth 
weight z-scores, given the exposure of OCM indicators, the potential mediators of arsencials, 
and covariates: E [Y|a,m,c]=θ0+θ1a+θ2m+ θ3am + θ’4c. Covariates were selected a priori, and 
all models were adjusted for a set of potential confounders of the main exposure to outcome 
(OCM indicators to birthweight z-score), the mediator to outcome (birthweight z-score to the 
arsenicals), and the mediator to the main exposure (arsenicals to OCM indicators). Final 
models were adjusted for maternal age (continuous), maternal education (coded as an 
indicator variable), and parity (dichotomized). For the specific parameters estimated for the 
potential effects of OCM indicators, iAs metabolism and infant birthweight, denote a 
reference (baseline) level of maternal serum OCM indicators, a0, and a new level, a1; and the 
mediator or maternal arsenicals (e.g %U-iAs, %U-MMAs, and %U-DMAs) for both a natural 
and a set level to estimate: the natural direct effect (NDE), which can be interpreted as how 
much the outcome of birthweight z-score would change if the exposure of OCM indicators 
were set to a new level of exposure (a1) but the mediator of arsenicals (M) is kept at a level it 
would have taken at level a0 of exposure; the natural indirect effect (NIE), which can be 
interpreted as how much the outcome of birthweight z-score would change on average if the 
exposure (OCM indicators) were controlled at level a1, but the mediator (arsenicals) were 
changed from the level they would have taken if a1; the total effect (TE), which estimates 
how much the outcome of birthweight z-score would change overall for a change in the 
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exposure of OCM indicators from level a0 to a1; the controlled direct effect (CDE), which 
estimates how much the outcome of birthweight z-score would change on average if the 
mediator of arsenicals were controlled at a set level (assigned), and the percent proportion 
mediated (PM)24. These parameters are represented by the following equations:  
CDE=(θ1-θ3m) (a-a*)  
NDE= θ0+θ3 (β0 +β1a*+β’2c) (a-a*)  
NIE= (θ2β1+ θ3β1a) (a-a*) 
PM= NIE/TE x 100  
To estimate the relationship of OCM indicators on infant birthweight, we modeled the 
OCM indicators (a) as a population that would be in an adverse nutritional state (indicated by 
the previously mentioned serum cutoffs) by setting (a0) to a positive nutritional status (i.e., 
sufficient for B12, higher folate median levels, and lower Hcys levels) and setting (a1) to a 
poorer nutrient status (i.e., deficient for B12, lower folate median levels, and higher Hcys 
levels). Coding of variables for the specific model parameters are displayed in Table 6.1. 
Specifically, estimates for the relationship between OCM indicators on the outcome of infant 
birthweight z-score were assessed using the following models for categories of OCM 
indicators where, Model 1 B12 sufficiency/deficiency was assessed, Model 2 examined 
folate as lower or higher than the median level; and Model 3 examined Hcys categorized as 
normal or higher. Models were run with and without an interaction term of the iAs 
metabolism and the OCM indicators to estimate the effect of OCM indicators on infant 
birthweight z-score through the path of iAs metabolism. The levels that the individual 
arsenicals were set to are presented in Table 6.1. Specifically, the population was set at the 
median levels of the arsenicals previously found in the cohort where %U-iAs were set at 
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5.3%, %U-MMAs were set at 5.9%, and %U-DMAs were set to 88.7% (models 1a, 2a, 3a). 
We were also interested in examining these associations when the population arsenicals were 
set at the poorest metabolism of iAs found in the cohort; therefore, we also modeled maternal 
metabolism of iAs to the population’s respective 90th percentile for %U-iAs at 9.5% and %U-
MMAs at 9.6%, and the 10th percentile for %U-DMAs at 88.1% (models 1b, 2b, 3b). 
Results 
The demographic characteristics for the study subjects are presented in Table 6.2. 
Briefly, all women identified as being Hispanic, and most had at least a high school 
education or greater (48% and 26%, respectively). Nearly all (96%) women reported that 
they took prenatal vitamins during pregnancy. The mean birthweight adjusted for gestational 
age z-score was -0.29 with a range of -2.6 to 2.8. The mean level of iAs in drinking water 
samples was 24.6ppb with a range of 0.46-236.0 ppb. Nutritional levels of OCM indicators, 
as measured in maternal serum and biomarkers of As exposure as measured in maternal 
urine, are presented Table 6.2.  
Correlations of maternal urinary arsenicals and maternal OCM indicators across the 
entire the cohort and stratified by below or at/above the World Health Organization’s (WHO) 
guideline level are presented in Table 6.3. Across the entire cohort, Dw-iAs was significantly 
correlated with U-tAs (rs= 0.60, p <0.001), and this was the same for the correlation of U-tAs 
and Dw-iAs in the context of the stratum where Dw-iAs was above the WHO guideline level 
(rs= 0.39, p <0.001). However, U-tAs was not correlated with Dw-iAs in the context of the 
stratum where Dw-iAs was below the WHO guideline level. Hcys was significantly 
correlated with drinking water levels among all women (rs =0.22, p= 0.0025), but not when 
stratified by Dw-iAs WHO guideline levels. There were no other statistically significant 
correlations between OCM indicators and Dw-iAs (Table 6.3). 
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Differences in mean maternal urinary arsenicals and maternal OCM indicators 
stratified by below or above the WHO guideline level are presented in Table 6.3. U-tAs was 
significantly higher for women whose drinking water levels of iAs was above the WHO 
guideline level (p <0.001). There were no statistically significant differences in the mean 
levels of %U-iAs, %U-MMAs, or %U-DMAs between the women who were categorized as 
below or at/above the Dw-iAs WHO guideline. Mean birthweight adjusted for z-score for 
infants whose mothers had drinking water levels of iAs below the WHO guideline was -0.41 
with a standard deviation of 0.94, and for those infants who mother’s had drinking water 
levels of iAs at or above the WHO guideline, mean birthweight z-score was -0.18 with a 
standard deviation of 1.04. The difference between these means was not statistically 
significant (p >0.05) (data not shown). 
We next set out to describe potential mediation of the relationships between all OCM 
indicators on birthweight, through the path of maternal arsenic metabolism stratified by iAs 
drinking water levels (< or ≥ WHO guideline level of 10ppb). Results of the mediation 
analysis assessing the categories of OCM indicators, with iAs metabolism on infant 
birthweight for categories of B12 are presented in Table 6.3, for categories of folate in Table 
6.4, and for Hcys in Table 6.5.  
Beta estimates for the natural direct effect (NDE) and total effect (TE) that represent a 
one unit difference in birthweight z-scores based on B12 deficiency compared to sufficiency 
were negative and similar in magnitude of effect, regardless of the stratification by drinking 
water levels (Table 6.3a, 6.3b). When Dw-iAs was lower, the percent mediated (PM) by all 
arsenicals was small, yet differed by mediator interaction/non-interaction models for the 
relationship between B12 and infant birthweight. Furthermore, the estimated natural indirect 
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effects (NIEs) were not statistically significant, and were close to the null value of 0. When 
modeling the mediator of all %U-iAs as an interaction with B12, the controlled direct effect 
(CDE) estimate became more negative for the relationship of B12 on infant birthweight for 
%U-iAs when the mediator was fixed at both the median and 90th percentile, when levels 
were below the recommended guideline than the natural direct effect. However, such 
relationships were not observed for %U-MMAs or %U-DMAs when they were fixed at their 
respective median and/or 90th percentile (Table 6.3a).  
All estimated effects for the comparison of the estimated change in infant birthweight 
with the exposure of below the median serum levels of folate to above the serum folate levels 
in strata below or at/above the WHO guideline level were not significant. This observation 
was true when allowing for an interaction between the mediator of maternal iAs metabolism 
with folate and for non mediator interaction models (Table 6.4, 6.5).  
We modeled the effects of being below the median serum levels of Hcys in strata of 
above or below the WHO guideline level, allowing for an interaction between the mediator 
of maternal iAs metabolism and for non mediator interaction. The estimates for the natural 
direct effect (NDE), natural indirect effect (NIE), and total effect (TE) for the linear effects 
of higher Hcys on birthweight z-score for all mediation analyses of maternal metabolism of 
iAs were negative and similar in the magnitude of effect when stratified by levels below the 
WHO guideline level, and positive when stratified by levels above the WHO guideline level 
(Table 6.6, 6.7). When Dw-iAs was lower, then the WHO guideline level percent mediated 
(PM) was small, yet differed by mediator interaction/non-interaction models with increases 
in the percent mediated when allowing for mediator Hcys interaction; however, these 
estimates were very imprecise. Furthermore, the estimated natural indirect effects (NIE) were 
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not statistically significant (Table 6.7). When modeling %iAs, allowing for interaction with 
Hcys, the CDE weakened, -0.41 [-0.82, -0.0049] in the strata below the WHO guideline level 
of 10ppb when %iAs was set at the median.  However, when modeling %MMAs to represent 
a poorer state of iAs metabolism (i.e. setting them to the 90th percentile) and allowing for 
interaction with Hcys, the estimate for the controlled direct effect (CDE) for of Hcys on 
infant birthweight becomes more negative than when allowing %U- MMAs to naturally vary 
(i.e. the natural direct effect)  
Discussion  
In previous work, differences in maternal metabolism of iAs as indicated by %U-iAs, 
%U-MMAs and %U-DMAs in urine was associated with lower infant birth weight in the 
Biomarkers of Exposure to ARsenic (BEAR) pregnancy cohort3. Given that metabolism of 
iAs can be influenced from nutritional supplementation of nutrients and vitamins involved in 
one carbon metabolism (OCM)6, 25, we analyzed the relationships between OCM indicators, 
maternal metabolism of iAs, and impacts on infant birthweight. Specifically, we sought to 
clarify these potential biological mechanisms using a causal mediation approach and 
stratified our analysis by drinking water levels below or at/above the World Health 
Organization (WHO) guideline level of 10ppb-, as the relationship between OCM and iAs 
metabolism on infant birthweight may differ by exposure levels to iAs in drinking water. 
Maternal iAs metabolism was not found to mediate the relationships between OCM 
indicators and birthweight z-score when stratified by levels of iAs in drinking water by the 
WHO standard of below or at/above 10ppb. Interestingly, homocysteine (Hcys) was 
significantly correlated with levels of iAs in drinking water, and in mediation analysis, higher 
Hcys levels had a negative association with infant birthweight z-scores for those women with 
drinking water levels of iAs below the WHO guideline level of 10ppb, but not for those that 
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who had drinking water levels of iAs higher than the WHO guideline level. Additionally, the 
controlled direct effect of Hcys on infant birthweight, when allowed to interact with 
%MMAs indicated that there was a negative relationship with infant birthweight. These data 
suggest the interaction of Hcys and metabolism of iAs may be particularly important at lower 
levels of exposure to iAs from drinking water. These complex biological interactions in the 
context of a dose response to iAs exposure have not been previously identified in iAs 
exposed pregnant populations.  
We found that Dw-iAs was significantly correlated with U-tAs across the entire 
cohort 0.60 (<0.001) (as previously reported), suggesting that drinking water is the primary 
source of exposure to iAs in this population3 . This positive correlation remained strong for 
those women whose iAs levels in drinking water were above the WHO guideline level, 
however this was not observed for those with exposure to Dw-iAs below the WHO guideline 
level. Urinary proportions of metabolites were not significantly associated with Dw-iAs 
water across the cohort. Although not statistically significant (p=0.07), %U-MMAs were 
negatively correlated with drinking water levels in all women, and %iAs was marginally 
significantly (i.e. p-value slightly greater than 0.05) negatively correlated for those women 
with Dw-iAs above the WHO guideline level. A marginal association between Dw-iAs and 
maternal metabolism of iAs has been previously reported – where the effect of the dose of 
iAs in drinking water on the methylation efficiency seems to be small across a multitude of 
studies8. The reasons for such variation include that there are many influences to metabolism 
of iAs, including but not limited to, the level of exposure to iAs in drinking water or food, 
age, gender, pregnancy, nutritional status of folate, homocysteine, and protein, creatine, and 
genotype for arsenic 3 methyltransferase (AS3MT)8, 9. This was emphasized by a recent study 
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that biological and behavioral factors were more significant predictors of absolute and 
relative levels of iAs, MMAs, and DMAs in urine8.  However, the role that drinking water 
iAs levels have on metabolism of iAs is debated. Together, these results indicate that 
drinking water levels may be an important predictor for some of proportions of the 
metabolites and in particular for %iAs when drinking water levels are above the WHO 
guideline level.  
We estimated the effects of potential mediation and/or interaction by maternal arsenic 
metabolism on the relationship of maternal B12, folate, and Hcys levels stratified by < or ≥ 
the WHO guideline level of 10ppb. The relationship of B12 deficiency on infant birthweight 
did not differ by levels of iAs in drinking water when iAs was allowed to naturally vary 
(natural direct effect). There was an observed increase in the estimated controlled direct 
effect for the estimate of B12 deficiency on differences in infant birthweight z-scores as 
compared to the natural direct effect when metabolism of %iAs was set at 90th percentile and 
when %U-MMAs was set to the median level in the lower strata of iAs drinking water levels. 
This finding is interesting in that there is evidence that lower levels of maternal B12 is 
associated with reduced birthweight and increased susceptibility for metabolic diseases (as 
reviewed by 26).  These results indicate that there could be potential shifts in infant 
birthweights for those that are B12 deficient even at low levels of exposure to Dw-iAs, but 
only in the context of when maternal metabolism is also poorer.  
A surprising finding was that there were interactions between Hcys and maternal 
metabolism of arsenic on infant birthweight when women had lower levels of drinking water 
exposure. Specifically, the natural direct effects for a change in Hcys to a higher level was 
negatively associated with infant birthweights when women had drinking water levels below 
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the WHO guideline level. Additionally, this effect may be worsened by an interaction with 
maternal metabolism of iAs. This is exemplified when %U-MMAs were set to represent 
poorer metabolism of iAs and the estimate (controlled direct effect) for a difference in 
birthweight with exposure to Hcys became more negative than when %U-MMAs were 
allowed to vary naturally (the natural direct effect) in the strata of drinking water iAs levels 
below the WHO guideline level. Previous work has indicated that the linear dose response 
between increases of serum Hcys and decrease in birthweight occur with increases in Hcys of 
around 31g for 1-SD increase in maternal total homocysteine27. Potential biological 
mechanisms of this relationship include that Hcys may directly cause impaired fetal growth 
or via its effect on placental growth and function via its vascular effects; however, this has 
not been elucidated in studies in human28. These results indicate that Hcys levels may 
influence infant birthweights, and are modified by levels of drinking water iAs. 
This study is not without limitations that may influence the interpretations of these 
findings. The first limitation of this work is in the context of the statistical estimation of the 
relationship between drinking water levels of iAs and the proportions of metabolites in 
maternal urine. Specifically, we did not find that all the proportions of maternal urinary 
arsenicals were associated with drinking water levels from correlation tests. This lack of 
correlation should be interpreted with caution as there are many other factors that may 
confound this relationship and here these were modeled in a bivariate assessment without the 
inclusion of other key predictors. Future studies will need to model these relationships in a 
manner that would account for potential confounders of drinking water exposure and 
metabolism of iAs that were not included here and examine the potential for linear and/or 
non-linear trends. The second limitation of this work is that both OCM indicators and 
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maternal arsenicals were measured at the time of delivery, thus we do not have longitudinal 
exposure information, limiting the causal interpretations. Additionally, causal interpretations 
from mediation analyses require strong assumptions. In particular, we need to assume that 
there is no unmeasured confounding between the relationships of the main exposure to 
outcome (OCM indicators to birthweight z-score), the mediator to outcome (birthweight z-
score to the arsenicals), and the mediator to the main exposure (arsenicals to OCM 
indicators). While we cannot rule out unmeasured confounding, we were careful in the 
selection of confounders based on a priori knowledge. Sensitivity analysis will need to be 
further explored29. Lastly, the targeted mediation analysis to describe effects of iAs 
metabolism within different strata of exposure to iAs in drinking water further reduced our 
sample size and limited the ability to detect statistical mediation and this led to imprecise 
estimates, particularly for the estimates within drinking water levels of iAs above the WHO 
guideline. Replication of these findings in other populations will be important to extrapolate 
findings for potential regulatory purposes.  
Despite these limitations, there are many strengths of this study, including a strong 
correlation between exposure to iAs in drinking water and the maternal biomarker of urinary 
total arsenic. Therefore, attempts to elucidate dose–response still remain important as these 
relationships can influence policies regarding exposure, as exposure to iAs is widespread. 
The exact number of households affected by contaminated drinking water is largely 
unknown; however, an EPA study in 2001 found that approximately 13 million U.S. 
residents are drinking water from private wells that exceed the federal drinking water 
standard for iAs 30. Additionally, this is of local concern as demonstrated previously by our 
 146 
lab.  Out of 63,000 private drinking water wells tested, 1,436 wells had iAs concentrations 
greater than the WHO guideline level, and a maximum level of 806 µg/L was found31. 
In conclusion, we find that drinking water levels of iAs are correlated with maternal 
metabolism of iAs, specifically %U-iAs. There could be potential shifts in infant 
birthweights for those that are B12 deficient, even at low levels of exposure to Dw-iAs. This 
relationship may be even more important in the context of poorer maternal metabolism of iAs 
(e.g. where %U-MMAs are elevated). Additionally, there was modification between higher 
Hcys exposure and differences in infant birthweight when drinking water levels were below 
the WHO recommended guideline level. These results indicate that the levels of exposure to 
iAs may need to be considered in the relationship of B12 and Hcys on infant birthweight. 
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Table 6.1. Coding of variables used for mediation models to estimate the relationships 
between one carbon metabolism indicators, arsenicals, and infant birthweight.   
Model+ 
OCM indicator 
Baseline 
exposure 
New exposure Mediator 
 a0 a1 %U-iAs %U-MMAs %U-DMAs 
Model 1: B12      
1a Sufficient 
<148 pmol/L 
Deficient 
≥148 pmol/L 
Median 
5.3 
Median 
5.9 
Median 
88.5 
1b Sufficient 
<148 pmol/L 
Deficient 
≥148 pmol/L 
90th percentile 
9.3 
90th percentile 
9.5 
10th percentile 
81.7 
Model 2: Folate      
2a Higher  
≥ 37.9 nmol/L 
Lower  
<37.9 nmol/L 
Median 
5.3 
Median 
5.9 
Median 
88.5 
2b Higher  
≥ 37.9 nmol/L 
Lower  
<37.9 nmol/L 
90th percentile 
9.3 
90th percentile 
9.5 
10th percentile 
81.7 
Model 3: 
Homocysteine 
     
3a Lower  
<6.4 μmol/L 
Higher 
≥6.4 μmol/L 
Median 
5.3 
Median 
5.9 
Median 
88.5 
3b Lower  
<6.4 μmol/L 
Higher 
≥6.4 μmol/L 
90th percentile 
9.3 
90th percentile 
9.5 
10th percentile 
81.7 
+All model estimates are presented as stratified as < or ≥ WHO guideline level of 10ppb  
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Table 6.2. Selected demographic characteristics, levels of arsenicals, and one carbon 
metabolism indicators of 197 participants of the Biomarkers of Exposure to Arsenic (BEAR) 
cohort study from 2011 to 2012. 
 N (N%) or Mean, Median [range] 
Maternal age at delivery, years 24.0, 23 [18-41] 
Race/ethnicity (Hispanic) 197 (100) 
Educational level  
  < High School 51 (25.9) 
     High School 95 (48.2) 
   > High School 51 (25.9) 
Daily Prenatal Vitamin intake  
No  8 (4.1) 
Yes 189 (95.9) 
Parity   
1st pregnancy  68 (34.5) 
More than 1 pregnancy 129 (65.5) 
Newborn sex  
   Male  103 (52.3) 
   Female 94 (47.7) 
Birth weight (g) 3338.7, 3340.0 [1800-5120.0] 
Gestational Age, weeks 39.3, 40 (34-42) 
Birth weight (z-score) -0.29, -0.37 (-2.6, 2.7)  
Drinking water levels (μg/L) 24.6, 13.0 [0.46-236.0] 
Maternal Urinary arsenicals 197 (100%)  
U-tAs (μg/L) 37.5 23.4 [4.3-319.7] 
U-iAs (μg/L) 2.1, 1.3 [0.14-23.0] 
U-MMAs (μg/L) 2.3, 1.3 [0.082-18.2] 
U-DMAs (μg/L) 33.1, 20.8 [1.4-292.5] 
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U-iAs (%) 6.1, 5.3 [0.77- 45.1] 
U-MMAs (%) 6.4, 5.9 [1.3-24.9] 
U-DMAs (%) 87.6, 88.5 [32.7- 96.7] 
One Carbon Metabolism Indicators 197  (100%) 
B12 (pmol/L) 127.4, 116.5 [48.0-284.1] 
 Deficient (< 148) 145 (74%) 
 Sufficient (≥ 148) 52 (26%) 
Folate (nmol/L) 40.6, 37.9 [7.1-171.5] 
 < Median (37.9)  98 (50%) 
  ≥ Median (37.9)  99 (50%) 
Homocysteine (μmol/L) 6.9, 6.4 [4.1-19.4] 
  Normal (<10.4) 182 (92%) 
  High (≥ 10.4) 15 (8%) 
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Table 6.3. Spearman rank (rs) and mean level comparison of drinking water inorganic 
arsenic (iAs) levels to maternal urinary arsenicals and maternal one carbon metabolism 
indicators (OCM) in the entire Biomarkers of Exposure to Arsenic (BEAR) cohort study and 
stratified by below or equal to/above the World Health Organization (WHO) recommended 
guideline for allowable levels of inorganic arsenic in drinking water (10ppb). 
 Drinking water-iAs 
Entire Cohort 
n=197 
Below WHO  
n=92 
Above WHO  
n=105 
  
 rs 
(p-value) 
Mean  
Stdv 
rs 
(p-value) 
Mean  
Stdv 
rs 
(p-value) 
Mean  
Stdv 
Drinking Water 
(Dw-iAs) 
- 24.7 
(41.7) 
- 1.7 
(2.4) 
- 44.0 
(48.8) 
Maternal Urinary 
arsenicals 
      
U-tAs (μg/L) 0.60 
(<0.001)* 
37.5 
(43.0) 
0.20 
(0.065) 
21.4 
(13.7) 
0.39 
(<0.001)* 
51.7* 
(53.8) 
U-%iAs  -0.049 
(0.49) 
6.1 
(3.9) 
-0.021 
(0.84) 
6.0 
(2.7) 
-0.19  
 (0.051)  
6.3 
(4.8) 
U-%MMAs  -0.13 
(0.074) 
6.4  
(3.0) 
-0.0034 
(0.97) 
6.6 
(2.5) 
-0.12  
(0.21) 
6.3 
(3.3) 
U-%DMAs  0.058  
(0.43) 
87.6 
(6.1) 
-0.069 
(0.52) 
87.7 
(4.3) 
0.14  
(0.16) 
87.5 
(7.3) 
Maternal OCM 
indicators 
      
B12  -0.12 
 (0.11) 
127.4 
(47.6) 
-0.023 
(0.83) 
132.5 
(48.0) 
-0.039 
 (0.69) 
123.0 
(47.0) 
Folate -0.02014 
(0.78) 
40.6 
(20.8) 
-0.069 
(0.52) 
40.4 
(20.3) 
-0.043 
(0.66) 
40.9 
(21.4) 
Hcys 0.22 
(0.0025)* 
6.9 
(2.2) 
0.14 
(0.19) 
6.7 
(2.2) 
0.11 
 (0.26) 
7.1 
(2.3) 
rs= Spearman's rank correlation coefficient 
*p<0.05 
 
  
1
5
1
 
Table 6.4. Mediation analysis to model the effects of B12 deficiency in strata of above or below the World Health Organization’s 
recommended guideline for allowable levels of inorganic arsenic in drinking water (10ppb), allowing for an interaction between the 
potential mediators of maternal iAs metabolism and B12 (%iAs, %MMAs, %DMAs). 
 %U-iAs %U-iAs %U-MMAs %U-MMAs %U-DMAs %U-DMAs 
Est# <10ppb >10ppb <10ppb >10ppb <10ppb >10ppb 
NDE -0.63 
[-1.10, -0.15] 
(0.00099) * 
-0.12 
[-0.59, 0.35] 
(0.24)  
-0.61 
[-1.05, -0.17] 
(0.0067) * 
-0.074  
[-0.53, 0.38] 
(0.74)  
-0.60 
[-1.03, -0.17] 
(0.0068)* 
-0.11 
[-0.57, 0.36] 
(0.64) 
NIE -0.0089 
[-0.052,0.034] 
(0.68) 
0.073  
[-0.080, 0.23] 
(0.35) 
0.00020  
[-0.014, 0.015] 
(0.97) 
0.023  
 [-0.053, 0.099] 
(0.54) 
-0.0053 
[-0.039, 0.028] 
(0.75) 
0.061 
[-0.071, 0.19] 
(0.36) 
TE -0.64 
[-1.10 -0.17] (0.0073) 
* 
-0.042  
[-0.49, 0.41] 
(0.85) 
-0.61  
[-1.04, -0.17] 
(0.0067) * 
-0.051 
[-0.50, 0.40] 
(0.82)  
-0.60 
[-1.04, -0.17] 
(0.0067)* 
-0.049 
[-0.50, 0.40] 
(0.83)  
PM 1.41% -173.2% 1.4% -151% -51% -125% 
INT -0.19 
(0.067) 
-0.063 
(0.79)  
0.081 
(0.31) 
-0.021 
(0.75) 
0.034 
(0.21) 
-0.00052 
(0.99) 
CDE+       
 50th++ -0.54 
[-0.98, -0.11] 
(0.014) * 
0.0074 
[-0.45, 0.47] 
(0.97)  
-0.67  
[-1.12,  -0.22] 
(0.0034) 
-0.059  
 [-0.51, 0.40] 
(0.80)  
-0.60 
[-1.04, -0.16] 
(0.0075) * 
-0.028  
[-0.48, 0.43] 
(0.90)  
 90th 
 or 
10th +++ 
-1.4  
[-2.3, -0.45] 
(0.0032) * 
-0.26 
[-0.78, 0.27] 
(0.33)  
-0.37  
[-1.1, 0.26] 
(0.25) 
-0.13 
[-0.75, 0.48] 
(0.67) 
-0.60 
[-1.4, 0.21] 
(0.14)  
-0.28 
[-0.79, 0.28] 
(0.34)  
  
1
5
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Table 6.5. Mediation analysis to model the effects of B12 deficiency in strata of above or below the World Health Organization’s 
recommended guideline for allowable levels of inorganic arsenic in drinking water (10ppb), without interaction between the potential 
mediators of maternal iAs metabolism and B12 (%iAs, %MMAs, %DMAs).  
 %U-iAs %U-iAs %U-MMAs %U-MMAs %U-DMAs %U-DMAs 
Est# <10ppb >10ppb <10ppb >10ppb <10ppb >10ppb 
NDE -0.61 
[1.04, -0.17] 
(0.0063) * 
-0.066 
[-0.52, 0.39] 
(0.77)  
-0.61 
 [-1.04, -0.176] 
(0.0058) * 
-0.069  
[-0.52, 0.38] 
(0.76)  
-0.60 
[-1.03, -0.17] 
(0.0068)* 
-0.074  
[-0.52, 0.37] 
(0.74) 
NIE 0.00076  
[-0.023, 0.025] 
(0.95) 
0.017 
[-0.044, 0.078] 
(0.58) 
0.0047 
[-0.034, 0.043] 
(0.81) 
0.020  
[-0.046, 0.086] 
(0.54) 
-0.0053 
[-0.037, 0.026] 
(0.73) 
0.025 
[-0.042, 0.092] 
(0.46) 
TE -0.60 
[-1.04, -0.17]  
(0.0063) * 
-0.049  
[-0.50, 0.40] 
(0.83) 
-0.604 
[-1.04, -0.17] 
(0.0063) * 
-0.049 
[-0.50, 0.40] 
(0.83)  
-0.60 
[-1.04, -0.17] 
(0.0063)* 
-0.049 
[-0.50, 0.40] 
(0.83)  
PM -.13% -35% -.77% -42% -51% 0.88% 
#NDE Natural direct effect, interpreted as how much birthweight z-score would change if the exposure of B12 was changed from sufficient to deficient and the 
mediator of arsenicals is kept at a level it would’ve taken in absence of B12 deficient exposure. 
NIE Natural indirect effect, interpreted as how much birthweight z-score would change on average if the exposure of B12 was changed from sufficient to 
deficient but the mediator (arsenicals) were changed from the level it would’ve taken in absence of B12 deficiency. 
TE total effect, estimates how much birthweight z-score would change overall for a change in the exposure of B12 sufficient to deficient  
PM proportion mediated (PM) that was calculated by the following formula: NIE/TE x 100. 
INT the interaction coefficient and p-value from the interaction of B12 and arsenicals to birthweight. 
CDE the controlled direct effect estimates how much the outcome of birthweight z-score would change on average if the mediator of arsenicals were controlled 
at fixed level (assigned). 
++Mediator fixed at the 50th percentile (median value). Fixed at for 5.3 %U-iAs, 5.9 %U-MMAs, and 88.5 % U-DMAs . 
+++ Mediator fixed at 90th percentile for %U-iAs (9.5) and %U-MMAs (9.6), and 10th percentile for %U-DMAs (81.7). 
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Table 6.6. Mediation analysis to model the effects of folate in strata of above or below the World Health Organization’s 
recommended guideline for allowable levels of inorganic arsenic in drinking water (10ppb), allowing for an interaction between the 
potential mediators of maternal iAs metabolism and B12 (%iAs, %MMAs, %DMAs). 
 %U-iAs %U-iAs %U-MMAs %U-MMAs %U-DMAs %U-DMAs 
Est# <10ppb >10ppb <10ppb >10ppb <10ppb >10ppb 
NDE 0.12 
[-0.29, 0.53] 
(0.56)  
-0.056 
[-0.48, 0.36] 
(0.79) 
0.097 
[-0.31, 0.50] 
(0.63) 
-0.054 
[-0.47, 0.36] 
(0.79) 
0.093 
[-0.33, 0.52] 
(0.67)  
-0.042 
[-0.46, 0.38] 
(0.84) 
NIE 0.021 
[-0.072, 0.11] 
(0.65) 
-0.0011 
[-0.085, 0.083] 
(0.97) 
0.056 
[-0.13, 0.24] 
(0.55) 
-0.0011 [-0.019, 0.017] 
(0.90) 
0.049 
[-0.11, 0.21] 
(0.54) 
-0.0015 
[-0.099, 0.070] 
(0.73) 
TE 0.14 
[-0.26, 0.54] 
(0.49) 
-0.057 
[-0.47, 0.35] 
(0.78) 
0.14 
[-0.26, 0.55] 
(0.49) 
-0.056 
[-0.47, 0.36] 
(0.79) 
0.14 
[-0.26, 0.54] 
(0.49) 
-0.056 
[-0.47, 0.36] 
(0.78) 
PM 15% 1.9% 40% 2.0% 35% 2.7% 
CDE+       
 50th++ 0.14 
 [-0.27, 0.55] 
(0.50) 
-0.056 
[-0.48, 0.36] 
(0.79)  
0.096 
[-0.31, 0.50] 
(0.64)  
-0.071 
[-0.49, 0.35] 
(0.73) 
0.024 
[-0.61, 0.66] 
(0.94) 
0.0028 
[-0.73, 0.74] 
(0.99) 
 90th 
 or 
10th +++ 
0.067 
[-0.26, 0.55] 
(0.49)  
-0.056 
[-0.78, 0.67] 
(0.88) 
0.055 
[-0.65, 0.76] 
(0.87) 
0.034 
[-0.62, 0.69] 
(0.92) 
0.12 
[-0.29, 0.53] 
(0.56) 
-0.042 
[-0.46, 0.38] 
(0.84) 
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Table 6.7. Mediation analysis to model the effects of folate deficiency in strata of above or below the World Health Organization’s 
recommended guideline for allowable levels of inorganic arsenic in drinking water (10ppb), without interaction between the potential 
mediators of maternal iAs metabolism and B12 (%U-iAs, %U-MMAs, %U-DMAs).  
 %U-iAs %U-iAs %U-MMAs %U-MMAs %U-DMAs %U-DMAs 
Est# <10ppb >10ppb <10ppb >10ppb <10ppb >10ppb 
NDE 0.13 
[-0.27, 0.53] 
(0.51)  
-0.056 
[-0.48, 0.36] 
(0.79) 
0.097 
[-0.31, 0.50] 
(0.63) 
-0.055 
[-0.46, 0.35] 
(0.79) 
0.12 
[-0.29, 0.53] 
(0.56)  
-0.039 
[-0.45, 0.38] 
(0.84) 
NIE 0.090 
[-0.030, 0.048] 
(0.65) 
-0.0011 
[-0.085, 0.083] 
(0.97) 
0.045 
[-0.044, 0.13] 
(0.48) 
-0.0022 
[-0.033, 0.028] 
(0.88) 
0.024 
[-0.041, 0.089] 
(0.46) 
-0.0018 
[-0.085, 0.049] 
(0.59) 
TE 0.14 
[-0.26, 0.54] 
(0.48) 
-0.057 
[-0.47, 0.35] 
(0.78) 
0.14 
[-0.26, 0.54] 
(0.48) 
-0.057 
[-0.47, 0.35] 
(0.78) 
0.14 
[-0.26, 0.54] 
(0.48) 
-0.057 
[-0.47, 0.35] 
(0.78) 
PM 64% 1.9% 32% 3.9% 17% 3.2% 
#NDE Natural direct effect, interpreted as how much birthweight z-score would change if the exposure of Hcys was changed from below the median to above the 
median value (6.4) and the mediator of arsenicals is kept at a level it would’ve taken in absence of B12 deficient exposure. 
NIE Natural indirect effect, interpreted as how much birthweight z-score would change on average if the exposure exposure of Hcys was changed from below the 
median to above the median value (6.4) but the mediator (arsenicals) were changed from the level it would’ve taken in absence of B12 deficiency. 
TE total effect, estimates how much birthweight z-score would change overall for a change in the exposure of exposure of Hcys was changed from below the 
median to above the median value (6.4) . 
PM proportion mediated (PM) that was calculated by the following formula: NIE/TE x 100. 
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Table 6.8. Mediation analysis to model the effects of Hcys deficiency in strata of above or below the World Health Organization’s 
recommended guideline for allowable levels of inorganic arsenic in drinking water (10ppb), allowing for an interaction between the 
potential mediators of maternal iAs metabolism and B12 (%iAs, %MMAs, %DMAs). 
 %U-iAs %U-iAs %U-MMAs %U-MMAs %U-DMAs %U-DMAs 
Est# <10ppb >10ppb <10ppb >10ppb <10ppb >10ppb 
NDE -0.43 
[-0.83, -0.018] 
(0.040)*  
0.020 
[-0.40, 0.44] 
(0.93)  
-0.43 
[-0.83, -0.018] 
(0.040)* 
0.11 
[-0.28, 0.50] 
(0.59)  
-0.40 
[-0.81, 0.0081] 
(0.054)  
0.051 
[-0.35, 0.45] 
(0.80) 
NIE -0.0052 
[-0.040, 0.030] 
(0.76) 
0.093  
[-0.096, 0.28] 
(0.33) 
-0.0052 
[-0.040, 0.030] 
(0.76) 
0.0087 
[-0.078, 0.096] 
(0.84) 
-0.028 
[-0.11, 0.055] 
(0.50) 
0.062 
[-0.074, 0.20] 
(0.37) 
TE -0.43 
[-0.84, -0.024] 
(0.038)* 
0.11 
[-0.28, 0.50] (0.57)  
-0.43 
[-0.83, -0.023] 
(0.038)*  
0.11 
[-0.27, 0.50] 
(0.56)  
-0.43 
[-0.84, -0.026] 
(0.037)* 
0.11 
[-0.28, 0.51] 
(0.56) 
PM 1.2% 83% 8.7% 7.6% 6.6% 55% 
INT -0.063 
(0.26)  
-0.045 
(0.54) 
-0.066 
(0.26) 
-0.077 
(0.33) 
0.040 
(0.17) 
0.038 
(0.42) 
CDE+       
 50th++ -0.41 
[-0.82, -0.0049] 
(0.047)* 
0.11 
[-0.28, 0.51] 
(0.57)  
-0.36 
[-0.78, 0.059] 
(0.091)  
0.13 
[-0.25, 0.52] 
(0.49) 
-0.65 
[-1.3, 0.04] 
(0.067)  
-0.14 
[-0.66, 0.37] 
(0.58) 
 90th 
 or 
10th +++ 
-0.59 
[-1.25, 0.075] 
(0.082)  
-0.13 
[-0.69, 0.43] 
(0.64)  
-0.65 
[-1.3, -0.024] 
(0.041)* 
-0.11 
[-0.65, 0.43] 
(0.68) 
-0.39  
[-0.81, 0.0183] 
(0.061)  
0.13 
[-0.26, 0.52] 
(0.52)  
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Table 6.9. Mediation analysis to model the effects of Hcys deficiency in strata of above or below the World Health Organization’s 
recommended guideline for allowable levels of inorganic arsenic in drinking water (10ppb), without interaction between the potential 
mediators of maternal iAs metabolism and B12 (%U-iAs, %U-MMAs, %U-DMAs).  
 %U-iAs %U-iAs %U-MMAs %U-MMAs %U-DMAs %U-DMAs 
Est# <10ppb >10ppb <10ppb >10ppb <10ppb >10ppb 
NDE -0.43 
[-0.83, -0.023] 
(0.038)*  
0.095 
[-0.30, 0.49] 
(0.63)  
-0.42 
[-0.82, -0.0087] 
(0.045)* 
0.11 
[-0.28, 0.49] 
(0.58)  
-0.42 
[-0.82, -0.011] 
(0.044) * 
0.092 
[-0.30, 0.48] 
(0.64) 
NIE 0.00013 
[-0.019, 0.019] 
(0.98) 
0.016 
[-0.048, 0.079] 
(0.63) 
-0.012 
[-0.068, 0.045] 
(0.68) 
0.0049 
[-0.045, 0.054] 
(0.86) 
-0.0096  
[-0.066, 0.047] 
(0.74) 
0.019 
[-0.035, 0.074] 
(0.49) 
TE -0.43 
[-0.83, -0.023] 
(0.038)* 
0.11 
[-0.28, 0.50] (0.57)  
-0.43 
[-0.83, -0.023] 
(0.038)*  
0.11 
[-0.28, 0.50] 
(0.57)  
-0.43 
[-0.83, -0.023] 
(0.038)* 
0.11 
[-0.28, 0.50] 
(0.57) 
PM -0.030% 14% 4.4% -1.1% 0.88% 2.24% 
INT -0.063 
(0.26)  
-0.045 
(0.54) 
-0.066 
(0.26) 
-0.077 
(0.33) 
0.040 
(0.17) 
0.038 
(0.42) 
#NDE Natural direct effect, interpreted as how much birthweight z-score would change if the exposure of Hcys was changed from below the median to above the 
median value (6.4) and the mediator of arsenicals is kept at a level it would’ve taken in absence of B12 deficient exposure. 
 NIE Natural indirect effect, interpreted as how much birthweight z-score would change on average if the exposure exposure of Hcys was changed from below 
the median to above the median value (6.4) but the mediator (arsenicals) were changed from the level it would’ve taken in absence of B12 deficiency. 
TE total effect, estimates how much birthweight z-score would change overall for a change in the exposure of exposure of Hcys was changed from below the 
median to above the median value (6.4) . 
PM proportion mediated (PM) that was calculated by the following formula: NIE/TE x 100. 
INT the interaction coefficient and p-value from the interaction of B12 and arsenicals to birthweight. 
CDE the controlled direct effect estimates how much the outcome of birthweight z-score would change on average if the mediator of arsenicals were controlled 
at fixed level (assigned). 
++Mediator fixed at the 50th percentile (median value). Fixed at for 5.3 %U-iAs, 5.9 %U-MMAs, and 88.5 % U-DMAs . 
+++ Mediator fixed at 90th percentile for %U-iAs (9.5) and %U-MMAs (9.6), and 10th percentile for %U-DMAs (81.7) 
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CHAPTER VII: CONCLUSIONS 
The research presented in this thesis focuses on a population exposed to arsenic (As) 
prenatally. The emphasis on this developmental window of exposure is of public health 
importance as the prenatal period represents a critical window of susceptibility to As 
exposure for the developing fetus. Moreover, exposure to As is a significant global public 
health problem as millions are exposed to elevated levels of As from inorganic arsenic (iAs) 
in drinking water. Of local importance, this exposure is also present in North Carolina from 
contaminated wells1.  
Individuals metabolize iAs differently, and importantly inter-individual differences in 
pregnant women’s metabolism of iAs influences risk for adverse birth outcomes2-4. Once 
ingested, iAs undergoes hepatic methylation generating mono- and di-methyl arsenicals 
(MMAs and DMAs, respectively) – a process that facilitates urinary iAs elimination. Recent 
public health interventions have been investigating the use of nutritional supplementation of 
nutrients involved in one carbon metabolism (OCM) in an effort to facilitate metabolism of 
iAs, and thus reduce iAs-associated disease burden,  5-7.  
OCM is the nutritionally regulated pathway essential for supplying methyl groups and 
may play an important role in both iAs methylation and in utero development. Because of 
these potentially important interactions between these nutritional factors and exposure to iAs 
during the prenatal period, the central hypothesis of this research was that nutrients 
involved in one-carbon metabolism (B12, folate, and homocysteine) influence arsenic 
metabolism and birth outcomes.  
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To investigate this hypothesis, I used existing data of biomarkers of iAs exposure and 
metabolism of iAs and collected new data of OCM biomarkers from banked maternal serum 
samples within the Biomarkers of Exposure to ARsenic (BEAR) pregnancy cohort in Gómez 
Palacio, Mexico. This work was established based on previous studies in our lab where we 
demonstrated that pregnant women are exposed to potentially harmful levels of iAs from 
drinking water, with levels up to 236 ppb3. This finding is alarming as these drinking water 
samples greatly exceed the World Health Organization’s (WHO) recommended guideline of 
10 ppb. Furthermore, maternal urinary concentrations and proportions of MMAs (potentially 
representing maternal metabolism of iAs) were negatively associated with newborn 
birthweight3. The studies presented in this thesis, further investigated these relationships and 
included a key factor of maternal nutritional biomarkers of OCM within three study aims. 
The conclusions, strengths, limitations, and future directions are detailed below for each of 
the three aims investigated in this work.  
Major findings of Chapter IV 
The primary goal of the first aim of the thesis in this cross-sectional analysis was to 
examine the associations among the levels of maternal serum indicators of OCM and iAs. 
Specifically for the iAs measurements, maternal urinary markers of total iAs exposure, 
metabolism of iAs and the levels of neonatal cord serum iAs metabolites (both collected at 
delivery) were assessed. The hypothesis to be tested was that maternal nutritional 
biomarkers of OCM indicators would be associated with both maternal and neonatal 
biomarkers of exposure to iAs and its metabolites. To determine if maternal serum OCM 
indicators were associated with maternal exposure to iAs and maternal metabolism of iAs, 
there was a total of 197 pregnant women included in the analysis. Maternal exposure to iAs 
was assessed using the total amount of iAs in urine (U-tAs). Pregnant women’s estimated 
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efficiency for metabolism of iAs was calculated using the percentages of the individual 
metabolites out of total iAs (i.e. %U-iAs, %U-MMAs, and %U-DMAs). For the assessment 
of neonatal exposure to iAs, there were 188 infants included, with exposure estimated based 
on neonatal cord serum total iAs (C-tAs) and cord serum metabolites, calculated from the 
percentages of the individual metabolites in neonatal cord serum out of the total iAs in 
neonatal cord serum (%C-iAs, %C-MMAs, and %C-DMAs). OCM indicators were defined 
by the levels of maternal serum B12, folate, and homocysteine (Hcys) from serum samples 
collected at the time of admission for delivery. Cutoffs of OCM indicators in maternal serum 
samples were used to determine pregnant women’s nutritional status. Specifically, estimates 
for B12 deficiency/sufficiency were defined as <148 pmol, and ≥148 pmol (respectively), 
hyperhomocysteinemia/normal Hcys was defined as ≥10.4 and <10.4 nmol (respectively), 
and folate deficiency/ sufficiency was defined as <9 nmol and ≥ 9 nmol (respectively). 
The first major finding from Chapter IV was that maternal urinary and fetal cord 
serum metabolites were significantly correlated, indicating that maternal-fetal transport of 
iAs and its metabolites across the placenta did indeed occur. Correlations between iAs in 
maternal blood and neonatal samples of cord blood and other tissues has been supported by 
others7-9. An additional finding of this work that may be of concern for iAs- related toxicity 
in that the average percentages of MMAs in neonatal cord serum were higher than the 
averages of %MMAs in maternal urine; this finding may require further investigation as 
higher proportions of MMAs are associated with an increased risk for iAs-associated 
diseases10. Additionally, the finding of overall higher proportions of the DMAs present in 
cord serum support that with increased methylation of iAs in the last trimester, majority of 
excreted As in urine is in the form of methylated DMAs, and therefore is the major 
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proportion of arsenicals transferred to the developing fetus in utero. This finding of higher 
proportions of DMAs relative to other iAs metabolites has been demonstrated previously in 
cord blood7. It is not yet known if the levels of arsenicals in cord serum represent a signature 
of elevated exposure or how they relate to health outcomes, as at the time of this report these 
results are the only ones of neonatal cord serum biomarkers of iAs and its metabolites. Taken 
together, the levels of iAs and its metabolites found in cord serum indicate that this tissue 
may serve as a biomarker of potential in utero exposure to iAs and its metabolites.  
The second major finding from Chapter IV was that majority of the pregnant women 
in the cohort displayed folate sufficiency, yet B12 deficiency. Specifically, there was a high 
prevalence of folate sufficiency in the cohort, with 99% of the pregnant women having serum 
folate levels ≥ 9 nmol/L. This finding is likely due to majority of the women reporting that 
they took prenatal supplements during pregnancy (96%), and because of mandatory folic acid 
supplementation of both corn and flour products in Mexico. Hyperhomocysteinemia was 
relatively low, where 8% of women had Hcys levels ≥ 10.4 μmol/L. The finding that 74% of 
the women displayed a deficiency in B12 (serum levels < 148 pmol/L) was surprising. The 
potential causes of these deficiencies may be multifactorial. The most common reason for 
B12 deficiencies during pregnancy occur due to dietary reasons, such as adhering to a 
vegetarian and specifically a lactovegetarian diet11-15. Additional contributions of the B12 
deficiencies found here may be due to intestinal parasite infections, as this is a growing 
concern in many areas, and particularly for those living in developing countries. 
Furthermore, standards of B12 deficiencies are the same across pregnancy, yet there are 
many biological changes that occur over the course of pregnancy including, hemodilution, 
active transport to the fetus, and changes in binding proteins, potentially contributing to 
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lower levels of B1216. However, the high rate of B12 deficiency is alarming and will need to 
be further addressed. This will be important for the health of the women, children in this 
study, and for any future intended pregnancies – as B12 deficiency is associated with 
numerous adverse pregnancy outcomes, including intrauterine growth restriction, preterm 
delivery, neural tube defects (NTD)17, 18.  Additionally, exposure to B12 deficiencies in utero 
are also associated with later in life health outcomes in children, including immune function 
impairment, and neurological and cognitive functions, among others19. Furthermore, the 
results presented in this work are valuable in their overall contribution to the limited 
knowledge of B12 levels in pregnant women and the prevalence of B12 deficiencies in 
Mexico, as there are no global estimates for deficiencies for both B12 and folate.  
The third major finding from Chapter IV is that contrary to what might be expected 
with such a high prevalence of B12 deficiency, such deficiencies were not associated with 
maternal metabolism of iAs. However, levels of B12 were associated with maternal total (U-
tAs). Additionally, despite an overall high prevalence of folate sufficiency in pregnant 
women, children born to women in the lowest tertile of serum folate had significantly higher 
%C-MMA as compared to those born to folate replete women. This finding is interesting as it 
represents a potential dose response relationship between maternal serum folate levels and 
cord serum MMAs. Furthermore, maternal Hcys levels were positively associated with both 
total As and percentages of MMAs in neonatal cord serum. Higher levels of biomarkers of 
%MMAs in association with higher levels of Hcys biomarkers have been observed in other 
iAs exposed populations 7. This finding could be related to the fact that with a moderate 
elevation in total homocysteine, there is a positively associated parallel increase in S-
adenosylhomocysteine (SAH) concentrations, and it is known that SAH accumulation is a 
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strong inhibitor of methyltransferases6, in particular S- Adenosylmethionine (SAM)20. 
Therefore, inhibition of SAM would lead to decreased methylation of iAs, resulting in higher 
proportions of MMAs. These findings are concerning as higher levels Hcys and higher levels 
of maternal percentages of MMAs are both associated with adverse birth outcomes. 
However, it is not yet known how potential alterations of cord serum arsenicals with 
increases in Hcys levels could influence neonatal health outcomes. The results from this 
study indicate that maternal OCM status may influence neonatal metabolites of iAs and 
warrant further investigation of these relationships as they relate to neonatal health. 
Limitations of Chapter IV 
There are several limitations from Chapter IV that may influence the interpretations 
and generalizability of these results. These include, two broad limitations: the first relates to 
the use of serum markers for estimates of OCM, and the second relates to potential residual 
confounding. 
The first limitation from Chapter IV is that data regarding the nutritional biomarkers 
is limited by both partial nutritional information from the questionnaire data (as the original 
study was not designed to fully elucidate dietary data), and by a one-time measurement of the 
serum markers of the OCM indicators measured at delivery. These limitations could result in 
possible exposure misclassification, potentially underestimating the relationship between 
OCM indicators and maternal metabolism. Because levels of OCM indicators can change 
over the course of pregnancy21, the findings here of deficiencies in B12, a general lack of 
folate deficiencies, and few women who had high Hcys levels should be interpreted with 
caution and warrant follow-up. However, despite potential variations in these serum levels, 
measurements of biomarkers for B12, folate, and Hcys are currently the standard for 
estimating deficiencies in clinical settings. Additionally, biomarkers in serum can be more 
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accurate and precise than other commonly used assessments of nutritional status such as 
dietary recall data and/or food frequency data collected from surveys, questionnaires, and/or 
interviews. Furthermore, in support of the biomarker data as they relate to potential dietary 
intake of the nutrients, a recent study determined that among women who were of 
reproductive age, daily B12 and folic acid intakes were positive predictors of levels of serum 
B12 and folate22. Despite such correlations, without knowing the sources of foods that 
contribute to the levels of OCM indicators measured in this study, we are limited in our 
ability to extrapolate information regarding public health recommendations to potentially 
reduce and mitigate nutritional imbalances for pregnant women in this area. In the likelihood 
of having full dietary data, extrapolations of deficiencies would have their own limitations, 
including inconsistencies in self-reporting of nutritional data, which could potentially 
introduce recall bias. Furthermore, it would be difficult to fully elucidate the causes of the 
deficiencies found in this study without further information as B12 and folate deficiencies are 
multifactorial, and can be due to inadequate nutrient intake from foods, overall poor diet 
quality, low bioavailability and/or gastrointestinal infections, differences in metabolism 
based on genetic factors, and other factor11, 23. Therefore, future investigators will need to 
consider all factors that may influence B12 deficiencies in this area and for other populations 
during the prenatal period. 
The second limitation from Chapter IV is that we did not capture other potential 
biomarkers involved in OCM or other nutrients/nutritional statuses that may influence iAs 
metabolism, as there are many interactions that can influence this process. This could 
potentially underestimate the influence of OCM on iAs metabolism in this cohort, as OCM 
depends on adequate intakes of multiple nutrients. For example, previous studies in iAs 
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exposed populations have found associations between the levels of urinary selenium and 
plasma α-tocopherol, folate, and cysteine with proportions of arsenic species in urine, and 
that dietary protein, iron, zinc, and niacin are associated with urinary MMAs and DMAs (as 
reviewed by 24). In addition, there are other mechanisms of nutritional regulation of iAs 
metabolism, including influences of nutrients on oxidative stress and epigenetic regulation. 
For example, previous work has suggested that antioxidant levels in the body could protect 
against arsenic-induced toxicity, as toxic effects were reduced with the administration of 
ascorbic acid, a-tocopherol plant extracts, flavonoids, polyphenols, and/ or selenium (as 
reviewed by 24). Such considerations will need to be factored into future study designs to 
fully elucidate the many nutritional associations with iAs metabolism. 
The last limitation from Chapter IV is that we cannot rule out any potential residual 
and/or unmeasured confounding of the relationship between OCM indicators and shifts in 
iAs metabolism. An example of a potential unmeasured confounder is the influence of 
polymorphic variations in genes that may regulate metabolism of both nutrients involved in 
OCM and iAs. However, this is a limitation that we plan to address within this cohort (see 
future studies). Important to the findings of this work are that in attempts to reduce any 
residual confounding, adjustments were made for the available demographic data and 
included key factors that may influence both OCM and iAs metabolism, as were identified 
based on previous studies and a DAG. Furthermore, careful attention was made to assess 
changes in estimates based on the covariates added to the model, therefore the models are 
well specified. Another factor that could limit any residual confounding is that there was 
overall homogeneity within the population studied. 
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Given the potential for a large prevalence of B12 deficiency in this pregnant 
population and the possibility for adverse health impacts for both the mother and any future 
pregnancies from these deficiencies, these limitations will need to be considered for future 
studies.  
Strengths of Chapter IV 
There are many strengths of the work carried out in Chapter IV of this thesis that aide 
in informing potential biological mechanisms of how nutrients involved in one carbon 
metabolism influence the levels of iAs and may inform future studies and potential 
interventions of iAs-associated diseases. 
The first strength of the work in Chapter IV is the use of two different matrices for 
biomarkers of prenatal iAs exposure, which supports that infants born to these women were 
exposed to iAs during a sensitive developmental period. Furthermore, the use of urinary 
markers for metabolism of iAs are well established biomarkers for exposure, and is non-
invasive. Additionally, identifying metabolism of iAs represents key biological mechanisms 
of potential detoxification. While it is known that shifts in iAs metabolism occur in 
pregnancy with increases in metabolism efficiency towards the end of pregnancy, any 
differences between trimesters of pregnancy would not influence individual shifts, as all 
samples represented urinary collection immediately before delivery, therefore would likely 
not influence our findings. Furthermore, there was likely little misclassification of the 
implied source of exposure to iAs, as the women had high levels of iAs in their drinking 
water samples, and there was significant correlation between iAs in drinking water and iAs 
levels in urine (rs=0.51, p<0.001). This is supported from previous research in the study area 
that also concluded that drinking water is the main source of iAs exposure in this area25-28. 
While other studies have demonstrated that dietary sources can influence iAs levels, a 
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previous assessment of dietary iAs exposures in this region estimated that most of iAs 
exposure that did occur from foods, rather was dependent on the amount of water used and 
cooking time, as most foods were boiled or cooked with water before consumption. 
Furthermore, any contamination from seafood would be minimal as marine foods are not 
usually consumed in this area29. This is also supported by the finding that few women (22%) 
consumed seafood in this cohort. Therefore the exposure data collected here represent a vast 
matrix of exposure classification via the levels of iAs from drinking water, maternal 
metabolites of iAs in urine, and fetal cord serum iAs with little potential of differential 
exposure misclassification. 
The second strength of the work in Chapter IV is in the ability to generalize our 
results to a large population of pregnant women – for most of the women in the study were 
sufficient in folate. This is similar to many other pregnant populations, specifically in the US 
and other populations living in the western world where foods are highly supplemented with 
folic acid. This filled a significant research gap, as the only other previous studies to examine 
pregnant women’s OCM indicators status and iAs metabolism are from two populations in 
Bangladesh where their exposure levels to iAs from drinking water is extremely high and the 
women were severely malnourished.  
The third major strength is that this study was conducted in a relative “low exposure” 
to iAs population, therefore results may be more generalizable to several populations that are 
exposed to iAs globally- particularly in the U.S, where low level exposures to iAs are 
common.  
The last major strength of the work in Chapter IV is in the statistical methods used to 
investigate the differences in iAs metabolism as outcome. Previous studies have modeled iAs 
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metabolism without addressing the concern of applying traditional linear regression models 
to these types of data with boundaries of the interval (i.e., 0 or/and 1). We used beta 
regression modeling, which has been previously been used for percentage-scaled dependent 
variables due to its flexibility in capturing various skewed unimodal and bimodal 
distributions, especially when normalizing and other transformations do not work well30.  
Future directions related to Chapter IV 
Future directions of research to investigate the relationship between OCM and iAs 
metabolism that goes beyond the scope of this work incudes utilizing existing data and/or 
banked samples to identity other nutritional impacts of iAs metabolism, addressing potential 
unmeasured confounding, integrating existing OMICs data into the data presented here, and 
identifying potential sources of deficiencies for future preventions of OCM deficiency 
associated outcomes. There is need to further investigate the relationships described in this 
present study, as despite our findings that many of the OCM indicators were not strongly 
associated in this cross-sectional analysis with maternal metabolism of iAs, we cannot rule 
out that OCM does not impact iAs metabolism in pregnant populations. Additionally, 
because we found associations with OCM indicators and fetal metabolites, further analysis 
within this dataset of these relationships is warranted. Given that there is potential to increase 
methylation capacity with OCM indicators (e.g. increases in %U-DMAs), thus reducing 
tissue exposures and concentrations of iAs and iAs-associated toxicity, investigations are 
important for future studies. 
The first future direction for the research related to Chapter IV includes incorporating 
existing data that has been previously collected that may influence iAs metabolism in the 
BEAR cohort. Specifically, there is data on the levels of other metals that may act as either a 
co-toxicant or as other important nutritional markers, including selenium and manganese as 
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measured in maternal urinary samples. Selenium is another nutritional factor known to 
influence iAs metabolism. Furthermore, there is data on urinary creatinine concentrations, 
which has previously been used as a proxy of macronutrient status, as it is related to muscle 
mass and intake of meat – as protein intakes are known to influence iAs metabolism6. 
Previous studies observed that urinary creatinine was a strong predictor of As methylation,31 
and individuals exposed to iAs in drinking water with lower urinary creatinine levels are at 
increased risk for As-induced skin lesions32. Combining these data with the nutritional serum 
markers described in Chapter IV could be used to create a more complete nutritional profile 
of the women in the BEAR cohort and will be interesting to analyze, especially with the high 
prevalence of B12 deficiency.  
The second future direction for research in relation to the findings of Chapter IV, 
would address genetic differences that may underlie the relationship between OCM and iAs 
metabolism, by genotyping the mothers for known polymorphisms that may influence both 
OCM and iAs metabolism. For example, it is well known that common polymorphisms in the 
gene that regulates enzymes for methylenetetrahydrofolate reductase MTHFR (C677T) play a 
critical role in OCM. Previous work has identified that individuals with the MTHFR 677TT 
genotype have 70% reduced activity of MTHFR in comparison to the MTHFR 677CC 
genotype, resulting in the reduction of the rate of 5-methylTHF production33. Additionally, 
previous studies have indicated that MTHFR influences iAs metabolism in adults34. 
Furthermore, in studies of mice, maternal genotype contributed to the sensitivity of iAs 
embryotoxicity – measured by implantation, resorption, congenital malformation and fetal 
birth weight in a MTHFR mouse model35. It has also been hypothesized that individuals with 
a genotype associated with less efficient methylation of arsenic, such as variants inorganic 
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arsenic methyltransferases (AS3MT) may be more sensitive to interactions of iAs metabolism 
with poor nutrition24. We have genotyped both the moms and infants in the BEAR cohort for 
variants of AS3MT, and therefore can investigate the relationship between genotype for 
AS3MT and OCM indicators, as well as OCM indicators associated genes such as MTHFR 
and AS3MT for gene-gene interactions. The support for the role of genotype of both OCM 
indicators and other iAs-associated genes in influencing iAs metabolism in human pregnancy 
cohorts has not been fully elucidated. 
The third future direction for research in relation to Chapter IV would be to explore 
potential relationships between OCM indicators and OMICs data, as other studies within the 
BEAR cohort have focused on OMICs data. In a subsample of participants, there is data on 
the epigenome, transcriptome, proteome, and metabolome. We will estimate the influence 
OCM indicators on these OMICs biomarkers in relationship to iAs exposure and metabolism 
in this cohort. Interestingly, in preliminary data, I investigated the overlap of expressed 
microRNAs in neonatal cord blood in the BEAR cohort to B12 and folate and %U-MMAs, 
and there is evidence of shared microRNAs between %U-MMAs, folate, and B12. 
Specifically, the expression of microRNAS was negatively associated with B12 and 
positively associated with U-tAs (data not shown). Additionally, in preliminary 
investigations of a targeted analysis to examine the relationship between KCNQ1 methylation 
and B12, we found that as the levels of B12 decrease, expression of KCNQ1 also decreases, 
and as levels of U-TAs increase, expression of KCNQ1 increases (data not shown). These 
preliminary results are fascinating; methylation of KCNQ1, a maternally imprinted gene 
known to regulate birthweight – thus KCNQ1 may be a candidate gene influencing iAs-
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associated shifts in birthweight. Given these preliminary findings, further investigations of 
these relationships are warranted. 
The last future direction for research in relation to Chapter IV would be to investigate 
other sources of B12 deficiency that would also influence iAs-associated diseases. 
Specifically, from pilot data in this cohort of measurements of maternal exposure to 
mycotoxins (aflatoxin), results suggest that some of the women in the BEAR cohort may 
have been exposed to aflatoxin – likely via contaminated corn and corn products. There is the 
potential to investigate this further as it relates to the levels of OCM indicators, as 
mycotoxins are also known to influence B vitamins and B12 deficiencies.  
Such integration of these findings in the context of other data could represent an 
exciting and unique ability to investigate interactions between multiple mechanisms of OCM 
indicators, other nutritional data, genetic and epigenetic mechanisms, and other toxicants in 
relation to iAs exposure and metabolism. Results would significantly strengthen the 
investigations of biological mechanisms that underlie iAs metabolism, reduce any potential 
unmeasured confounding, and could be applied to better understand iAs-associated diseases.  
Major findings of Chapter V 
The second aim of the thesis builds off of both the findings presented here in Chapter 
IV and previously published work in our lab that maternal metabolism of iAs (%U-iAs and 
%U-MMAs) was associated with infants’ birthweight in the Biomarkers of Exposure to 
Arsenic (BEAR) pregnancy cohort. Furthermore, it is known that nutrients involved in one 
carbon metabolism (OCM) can influence both iAs metabolism5, 36, 37 and fetal growth12, 21, 38-
43. Therefore, the work in this chapter sought out to clarify these two potential biological 
mechanisms on shifts in infant birthweights using a causal mediation approach. This work 
addressed two sub aims. The originally proposed aim of this work (Aim 2a) was to estimate 
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the total effect of maternal nutritional biomarkers involved in one carbon metabolism (B12, 
folate, homocysteine) as measured in maternal serum at delivery on infant birthweight, where 
the total effect is any effect that operates through the path of maternal nutritional biomarkers 
involved in one carbon metabolism (B12, folate, homocysteine), iAs metabolism, and 
birthweight. To address this aim using a causal mediation approach, we estimated the total 
effect (TE) as proposed, and the natural direct effects (NDE), of OCM indicators on infant 
birthweight, and controlled direct effects (CDE) of both OCM indicators and maternal 
metabolism of iAs on infant birthweight. The hypothesis of this work was that levels of 
maternal serum OCM indicators would be associated with changes in overall infant 
birthweights, independent of iAs exposure. Specifically, deficiencies in both folate and 
B12 and increases in Hcys were predicted to be negatively associated with infant birthweight. 
The original proposed Aim 2b was to estimate the indirect effect of maternal nutritional 
biomarkers involved in one carbon metabolism (B12, folate, cysteine, homocysteine), as 
measured in maternal serum at delivery, on infant birthweight that operated through iAs 
metabolism. To estimate this, the natural indirect effects (NIE) and proportions mediated 
(PM) by the arsenicals were estimated. The hypothesis of this aim was that the effects of 
maternal nutritional biomarkers involved in one carbon metabolism (B12, folate, 
homocysteine) on birthweight operated via the pathway of iAs metabolism for changes 
in infant birthweights. The investigation of these mechanisms in a causal framework had 
not previously been demonstrated. 
The first major finding from Chapter V was that B12, folate, and Hcys when 
examined independently of one another, did not have a statistically significant effect on 
infant birthweight z-scores. However, maternal imbalances in B12 and folate together 
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influence birthweight adjusted for gestational age z-scores, where there were differences in 
mean birthweight z-scores across the four categories representing the interactions of lower 
and higher B12 and folate. Furthermore, this relationship was supported from tests for effect 
measure modification by median folate levels. Specifically, the average birthweight z-score 
was -0.74 [95% CI: -1.2, -0.31] lower for newborns born to women who were deficient in 
B12 relative to those born to women who were sufficient in B12-specifically for women who 
also had lower folate serum levels. These results suggest that the relationship between B12 
deficiency and infant birthweight z-scores is modified by folate levels; therefore, future 
studies should consider this important biological factor in the relationship of B12 deficiency 
and infant birthweight. Specifically, not including this important modifier (folate) of the 
relationship of B12 deficiency and infant birthweights could lead to incorrect estimates and 
effects of the relationship of maternal levels of B12 on infant birthweight. 
The second major finding from Chapter V was that there were significantly stronger 
effects of B12 deficiency on infant birthweight z-scores when folate was lower, but not when 
folate was higher from the mediation analysis. Specifically, the natural direct effect estimates 
for B12 deficiency was a strong predictor of a negative association with birthweight z-scores 
when folate was lower (total effect of -0.74) compared to when folate was higher (total effect 
of 0.29). This is interesting as in the mediation analysis, without the consideration of folate, 
there was no evidence of statistically significant direct effects of B12 deficiency (total effect 
of -0.29). This finding further supports that levels of folate modify the effects of B12 
deficiency on infant birthweights. Taken together these two major findings suggest that 
independent of iAs exposure, maternal folate serum levels modify the impacts of B12 
deficiency on infant birthweight z-score in this population. Previous studies have also 
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indicated that imbalances in folate/vitamin B12 ratios identified in maternal red blood cells 
during and at the end of pregnancy have been associated with lower birth weight, 
spontaneous abortion, placental abruption and congenital malformations14.  
The third major finding from Chapter V was that results from the causal mediation 
analysis demonstrated that while there were no statistically significant mediated effects by 
maternal iAs metabolism in the relationship between OCM indicators and birthweight z-
score, there is evidence of interaction between OCM indicators and iAs metabolism. These 
results suggest that within a B12 deficient population, maternal arsenic metabolism may 
interact with B12 levels, thus changing the effect of the B12 on birthweight z-score, with this 
effect further amplified when folate levels are lower. Specifically, when the levels of 
maternal arsenicals were set to levels of either the median and/or the 90th percentile (for %U-
iAs, and %U-MMAs) and 10th percentile for %DMAs to simulate altered maternal 
metabolism of iAs (the controlled direct effect), we find that there is evidence of potential 
interaction of %U-iAs, %U-MMAs, and %U-DMAs and B12 deficiency on infant 
birthweight. These simulated findings are interesting as previous research from a clinical trial 
indicates that folate can increase arsenic metabolism5. These findings could have vast public 
health impacts in iAs exposed populations as they demonstrate that there are interactions 
between pregnant women’s nutritional status and maternal metabolism of arsenic on infant 
birthweights. These complex biological interactions have not been previously identified in 
iAs exposed pregnant populations.  
These estimated shifts of infant birthweight are ever important as they may lead to 
early life and later in life health effects. These susceptibilities to later in life diseases from 
prenatal exposures (e.g. fetal origins of adult disease (FOAD)) has been theorized to have 
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major impacts from birth and throughout the life course, and has been supported by several 
studies 44. Additionally, while low birthweight is not the phenotype measured in this work, 
the data do represent potential shifts in birthweight that could indicate that lower birthweight 
could occur on a population level. While not assessed here, shifts in infant birthweights could 
be followed by “catch-up growth”, a term that refers to exponential childhood growth – with 
associated increased risks for metabolic syndrome, obesity, insulin resistance, dyslipidemia, 
and hypertension44-48. This is a particular concern for the study population that this cohort 
represents, as the prevalence of both low birthweight and small for gestational age (SGA) is 
relatively high (~10%) in Mexican populations49. Additionally, shifts in birthweights on the 
other end of the spectrum can also represent impacts from being born bigger and/or large for 
gestational age (LGA), and these are associated with increased risks for diseases, including 
obesity and insulin resistance. Given the potential for a multitude of lifetime health effects 
from shifts in birthweights, establishing the underlying causes are critical in reducing these 
large public health burdens. Therefore, the results of this work may add critical information 
of some of the potential underlying mechanisms of birthweight shifts in this population in 
Mexico. With replication and further support, these results could influence public health 
interventions. 
Limitations of Chapter V 
Limitations of the work presented in Chapter V also encompass the limitations of the 
work for Chapter IV of this thesis (discussed above). However, specific to the results 
presented in this chapter, there are additional limitations in the exposure, mediator, and 
outcome assessment. These include limitations surrounding using OCM indicators as a proxy 
for nutritional data, the measurement of maternal metabolism of iAs as a potential mediator, 
 178 
and birthweight as an outcome. The second area of these limitations surrounds the causal 
interpretations of the findings, especially given the design of the study.  
The first limitation of Chapter V is in the use of OCM indicators as a proxy of overall 
one carbon metabolism. This limits public health recommendations and the application of our 
findings for future interventions. From the literature, there is little data on the correlation of 
the levels of serum markers of these OCM indicators to extrapolate to the potential levels of 
nutritional supplements or diets that may have contributed to the serum levels of OCM 
indicators examined, particularly during the prenatal period. However, a recent study 
indicates that among women who were of reproductive age, daily intake of B12 and folic 
acid were positive predictors of serum B12 and serum folate22. Therefore, these data 
presented in this work likely represent what would have been current intakes of B12, folate, 
and their combined effects on the levels of Hcys. Furthermore, we can broadly make 
recommendations for women in this cohort to further examine their diets and nutritional 
status. As previously mentioned in the discussion of Chapter V, we cannot conclude that 
these levels are representative of the levels of serum OCM indicator levels over the course of 
pregnancy, as it is known that there are shifts in these markers – leading to potential 
misclassification. These shifts could not only influence our findings (as previously 
mentioned), but also our ability to make recommendation to remediate these potential 
nutritional deficiencies. However, currently, serum markers are the standard for OCM 
indicators and in determining deficiencies, regardless of trimester for pregnant women. 
Future studies, particularly for mediation analyses, would benefit from repeated measures of 
the OCM indicators over the course of pregnancy and to gather nutritional intake data to 
capture the amounts of nutrients foods and/or vitamin intake that contribute to serum OCM 
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indicators. Such correlations could be applied to associations with infant birthweights to 
make public health recommendations for pregnant women. 
The second limitation of Chapter V that may influence the interpretations of causality 
are related to the study design. The cohort was developed to be a prospective cohort, and 
there is potential for follow up in this study; however, in the context of this work, the 
samples that contributed to the measurements of maternal serum estimates of exposure to 
OCM indicators, the mediator of maternal metabolism of iAs, and the outcome of infant 
birthweight were measured at the time of admission to the hospital for delivery and after 
delivery – therefore, the data are cross-sectional by design. This reverse causality between 
the mediator and the exposure cannot be fully dismissed, and therefore results should be 
interpreted with caution, as the causal criterion of temporality may be a factor that is not met 
by these data. However, the exposure of OCM indicators was measured in maternal serum, 
an indicator of recent OCM nutritional intake, and the potential mediator was iAs metabolism 
in maternal urine – also an indicator of recent iAs exposure, therefore it would be highly 
unlikely that the levels of iAs in urine would influence the OCM indicators in serum. 
Additionally, while the biomarkers of exposure and mediators were measured at the same 
time of the outcome of infant birthweight, indicators of exposure would precede the outcome. 
Furthermore, given that we did not find mediation of the relationship between B12 deficiency 
and infant birthweight by iAs metabolism, and instead potential evidence of interaction of 
iAs and B12, the simultaneous measurements may relax strict assumptions of temporality 
regarding mediation. Additionally, because recall bias (i.e. for typical questionnaire 
assessments for nutritional data) and potential measurement error (i.e. of the nutritional 
serum markers) is a major concern in using cross-sectional data (and in particular for 
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mediation analysis), such concerns would not be a factor in the interpretation of our findings 
by using biomarker data of the nutritional OCM indicators. However, if there are changes in 
OCM indicators and metabolism of iAs, the mediation of such could be underestimated, 
especially if this occurs more readily in the first trimester of pregnancy. Given these 
limitations, we acknowledge that the biological interpretations of the exposure-mediator 
relationship are limited and assumptions of temporality in terms of measurements for 
exposures and potential mediators are unlikely to accurately reflect longitudinal mediation 
effects. Therefore, future studies will need to consider these limitations in study design and 
attempt to obtain repeat measurements. While the design of a prospective cohort study to 
gather repeat measures would be beneficial, would in itself introduce further complexity (to 
intervene), as it would be unethical to not inform women of their exposures levels for both 
OCM indicators and iAs.  
The third limitation of Chapter V is in the assumption made that there is no 
unmeasured confounding in regards to application of causal inference methods used here – 
this could have potentially biased the results, and influence the interpretation of the findings 
of Chapter V. Specifically, the estimation of direct and indirect effects, and subsequent 
causal interpretations require that there be no unmeasured exposure-outcome, mediator-
outcome, or exposure-mediator confounders50. Some of the potential exposure-outcome 
mediators that could be missing are mentioned above (e.g. other nutritional measures not 
captured in this study); however, there may be others as well. There may also be unmeasured 
potential confounders of the mediator-outcome relationship, and specific to these findings, 
this can lead to biased estimates for the controlled direct effect51.  
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The fourth limitation of Chapter V is in the small sample size of the study to detect 
statistically significant mediation and/or interaction. Furthermore, because we found 
modification of the main exposures of B12 and folate, we targeted the mediation analysis to 
describe effects of iAs metabolism within the different strata of B12/folate;  this further 
reduced our sample size, limited our ability to detect statistical mediation and led to 
imprecise estimates, with very wide confidence intervals. Therefore the results should be 
interpreted with caution and replication in larger cohorts is warranted. This will be 
particularly important in the estimation of the total effect, as the association with the 
exposure in a given population depends on the population prevalence of the mediator, and 
despite the effort to simulate poorer metabolism, we were limited as in this population, most 
women were efficient at metabolizing iAs (a good thing). Additionally, because of the high 
prevalence of the exposure of B12 deficiency, this limited the ability to effectively model the 
data as a potential positive exposure change, specifically modeling shifts from B12 
deficiency to sufficiency on the impacts for increased methylation capacity of iAs. Given the 
potential importance of interaction between OCM indicators and iAs metabolism on infant 
birthweight, future studies would benefit from modeling potential mediation of improved 
nutritional status on iAs metabolism as it relates to birth outcomes.  
The last limitation of Chapter V surrounds the use of birthweight adjusted for z-
scores as an outcome. Specifically, there is the potential for measurement error, and there are 
limitations in the interpretability of estimates that measure shifts of birthweight that are 
adjusted for z-scores. The benefits of using z-score birthweights is that it can counter issues 
surrounding adjusting for unstandardized birthweight. However, a caution for the use of z-
scores in birthweight adjustments is that there could still be confounding the of coefficients 
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and there is a loss of interpretability52. There is also the potential of the misclassification of 
gestational age, which would influence the outcome of gestational age adjusted for z-scores. 
In this study, gestational age was estimated using the women’s last menstrual period (LMP) 
verses other methods that may be more precise (such as ultrasound measurements). Therefore 
there may be some measurement error, and misclassification in the birthweight for z-score 
gestational ages used for our outcome. However, any estimates in this would likely be non-
differential, thus potentially driving the estimates towards the null. Strengths for the use of 
birthweight for-gestational age z-score are that they do allow for comparison with other 
cohorts, domestic and international. 
Given these limitations, the results and conclusions from the work in Chapter V 
should be interpreted with caution. In particular, from this work we may not be able to draw 
conclusions of causality, given the above limitations; therefore, the interpretations of the 
results presented in this chapter are based more on estimation and description of the potential 
effects of maternal shifts in vitamins and nutrients that influence OCM, maternal shifts in 
metabolism of iAs, and shifts in population infant birthweights.  
Strengths of Chapter V 
Despite the limitations of Chapter V, there are several strengths of this work; many of 
these are outlined in the conclusions of Chapter IV; however, there are further strengths 
unique to this chapter.  
The first strength of Chapter V surrounds the choice of mediation methods applied to 
estimate both the direct and indirect effects of OCM indicators and maternal metabolism of 
iAs, on population shifts in infant birthweight z-scores. Specifically, by applying methods of 
causal mediation vs standard approaches (e.g. Baron and Kenny) to investigate mediation, we 
were able to model the relationships between the exposure, mediator, and outcome, allowing 
 183 
for exploration of non-linear models and potential important exposure-mediator 
interactions53. Furthermore, by examining the controlled direct effects, we were able to 
model how much birthweight would change on average when the mediator of maternal 
metabolism of iAs (%U-iAs, %U-MMAs, %U-DMAs) was set to a level of poorer 
metabolism. The findings from these models supported that there is potential interaction 
between the exposure of OCM and maternal metabolism of iAs. The finding of interaction 
serves to answer questions for whom these causes and effects occur. The results from this 
chapter of the interactive models indicate that the effects of B12 deficiency on infant 
birthweight occur when populations are folate deficient, but are further affected when 
populations also have poorer iAs metabolism. These biological interactions are imperative to 
understanding mechanisms associated with prenatal iAs exposure and population shifts in 
birthweights, and may be applied to investigate other iAs-associated health outcomes. 
The second strength of Chapter V is in the estimation of mediated effects of OCM 
and infant birthweight in the context of a modified relationship of B12 and infant birthweight 
by folate levels. The investigation of B12 and folate interaction is a huge strength of this 
study, as previous work has suggested that in populations supplemented with folic acid, there 
are interactions between imbalances of folate and B12. Such interactions are extremely 
relevant in multiple populations where the supplementation of folic acid is widespread and 
there are increases in B12 deficiencies.  
The last strength of Chapter V is the use of biomarkers in the context of mediation 
analysis. While it is a limitation that we cannot necessarily extrapolate our results to target a 
public health intervention (i.e. because of not knowing the levels of the nutritional intakes for 
the OCM indicators), the strengths of using biomarkers are that they may better inform 
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mechanistic studies; therefore, future studies should incorporate both nutritional data and 
biomarker data to inform interventions. Furthermore, by using metabolism of iAs, instead of 
exposure alone, we are able to see the effects on and of a biological mechanism that has been 
demonstrated to be more important than the levels of exposure to iAs alone, and in particular 
for shifts in birthweight. 
To my knowledge, only one other study has investigated the role of mediation in the 
context of environmental exposures during pregnancy54, thus this is a highly unexplored use 
of these methods in the vast fields of both environmental and reproductive/perinatal 
epidemiology. This method is incredibly useful for the target population of pregnant women, 
as it is as period of high susceptibility for the impacts of exposures of both nutritional and 
toxic substances. Furthermore, many study designs make establishing causality in these 
target populations extremely difficult because of ethical and practical limitations of studying 
pregnant women and in utero exposures, and due to the many complex biological changes 
unique to this period. Therefore, the application of causal mediation and interaction methods 
are imperative to future studies of environmentally associated diseases from prenatal 
exposures. 
Future directions related to Chapter V  
Future directions of this work include studies to address some of the potential 
limitations of the presented here in Chapter V, and of those from Chapter IV. These include, 
the application of a sensitivity analysis to investigate any residual or unmeasured 
confounding, investigating other potential mediation/modification analyses, and replication 
of these findings in another cohort(s).  
The first direction of future work related to Chapter V is to address the potential 
limitations of unmeasured confounding. One way to address potential unmeasured and/or 
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residual confounding is to employ sensitivity analyses. There are several methods to estimate 
such for the measured effects of mediation, as have been outlined by Vanderweele55. While a 
sensitivity analyses could be applied to all estimated effects, it will be particularly important 
to do such for the controlled direct effects, as these findings highlight potential interactions 
between the exposure of OCM indicators and iAs metabolism on infant birthweight. An 
example of a potential way to address this could be to use newly collected genetic data that 
may influence OCM and iAs metabolism, as proposed in the future studies section from the 
conclusions of Chapter IV. Specially, there is the potential that polymorphisms in genes that 
may influence both OCM and iAs metabolism may be unmeasured confounders or even 
mediators of the relationship between the exposure (OCM indicators) and the mediator (of 
iAs metabolism). Therefore, once key variants of polymorphisms are identified, we could 
conduct sensitivity analyses to measure a potentially biased estimate and compare it to the 
estimates presented in Chapter V. Furthermore, it may be that genotype for certain genes that 
may regulate OCM could actually be investigated as intermediates of the aim 1 from Chapter 
IV. We could test in a causal mediation approach whether genetic polymorphism may 
mediate or modify the relationship between OCM and iAs metabolism. These analyses may 
address a limitation of employing a cross-sectional analysis as genotype is fixed at birth and 
therefore would not be caused by the exposure of OCM. 
A second direction of future work related to Chapter V is to investigate the potential 
for mediation and/or interaction as investigated here in Chapter V, but with neonatal cord 
metabolites. This approach furthers the aims of this thesis, where the mediation analyses 
presented in this Chapter could be applied to the findings of Chapter IV of the relationship 
between maternal OMC indicators and the cord serum metabolites of iAs on infant 
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birthweights. This would be interesting as the findings from Chapter IV imply that maternal 
OCM indicators influence neonatal iAs metabolites. Furthermore, it is not yet known how the 
levels of fetal metabolites influence birth outcomes.  
A third potential area of future research related the work of Chapter V would build on 
one of the proposed future studies suggested in Chapter IV, where we could develop a model 
of a nutrient phenotype constructed from the data used in this study in combination with 
other existing data/and or future data. Furthermore, there is the potential to measure other 
factors in banked samples, to address issues in instability of the B12 serum markers- for 
example, Holotranscobalamin has been demonstrated to be a potential sensitive indicator of 
vitamin B12 status, and in pregnant populations where B12 levels decreased over the course 
of the pregnancy, holoTC levels remained constant in women with an adequate intake of 
vitamin B1256. 
A fourth direction of future work related to Chapter V would be to replicate these 
findings in other pregnancy cohorts.  Such replication will be carried out in another iAs 
exposed birth cohort from an existing collaboration with our lab within the prospective 
longitudinal cohort study, the New Hampshire Birth Cohort (NHBC) study. Benefits of 
replicating the mediation methods presented in this thesis in the NHBC cohort could 
potentially address many of the limitations presented here. Specifically, by investigating 
mediation analysis, the NHBC cohort would address the limitation of sample size of this 
thesis work presented here, as there are data on 1200 women and children exposed to low 
levels of iAs from drinking water. Furthermore, the limitation of temporality could be 
addressed, as nutritional data was collected before the iAs measurements and in the form of 
food frequency questionnaire data (with some repeated measures). There is also the potential 
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to use banked samples to measure OCM indicators from various tissue types in the NHBC 
cohort. Replication in this cohort could also potentially address unmeasured confounding, as 
the questionnaire data is vast. Depending on the distribution of the nutritional OCM 
indicators in the NHBC, there may also be the opportunity to target the differences by folate 
and B12 across the different categories (and exploration of other categories/cut points of 
folate levels). This would address a limitation of the mediation analysis presented in this 
chapter that did not capture the effects of higher B12 and higher folate, and it may be that iAs 
metabolism is different across these varying levels, as is suggested by the finding from 
Chapter IV that the %C-MMAs differed by tertiles of folate. Additionally, results from this 
chapter indicated that women in the higher B12 and higher folate levels had newborns with 
the lowest mean birthweight z-score. These results warrant further investigation. Using a US 
based cohort may also help with generalizability to the US population, as the findings relate 
to both the levels of iAs exposure in similar populations and country-wide nutritional 
supplementation. It will be interesting to compare results from two pregnancy cohorts and 
such findings could influence policy interventions. 
The methods applied in Chapter V are a unique feature of this study, and given the 
opportunity to replicate the findings in other cohorts presents exciting opportunities to further 
investigate the interactions between factors contributing to one carbon metabolism and 
metabolism of iAs during pregnancy and their impacts on adverse birth and other pregnancy 
related outcomes. This also presents great prospects for potential public health interventions 
to reduce the health impacts of iAs associated diseases. 
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Major findings of Chapter VI 
The work in Chapter VI builds on the work carried out in this thesis from chapters IV 
and V, where it was demonstrated that the levels of metabolites of iAs may be influenced by 
biomarkers of one carbon metabolism (see results Chapter IV) and that OCM indicators 
influence infant birthweight z-scores (see results Chapter V). The aims from Chapter VI 
focused on understanding how the overall hypothesis of this thesis was influenced by the 
levels of exposure to iAs, as measured in drinking water. This stemmed from the 
consideration that levels of exposure to iAs from drinking water may modify prenatal 
metabolism of iAs, and potential impacts between maternal metabolism of iAs and 
metabolism-associated changes in birthweight. The aim addressed in Chapter VI was Aim 3: 
Investigate the total and indirect effects of maternal levels of nutritional biomarkers 
involved in one carbon metabolism (B12, folate, homocysteine) on infant birthweight by 
different levels of drinking water iAs. This aim tested the hypothesis (Hyp 3): The levels of 
iAs in drinking water influence the effect of maternal nutritional biomarkers and the health of 
her newborn. Stratified mediation analysis were carried out to estimate the effects of all 
OCM indicators on infant birthweight z-scores and potential mediation by arsenic 
metabolism based on exposure to drinking water iAs below or at/above the EPA/ WHO 
guideline level of 10ppb. Knowing how OCM indicators influence birthweight across 
different levels of exposure could identify susceptible populations at risk. This information 
could be applied to risk assessments to better inform regulations for levels of iAs in drinking. 
This is important as regulations for levels of iAs allowed in drinking water vary by region, 
and are continually being reexamined. Additionally, in Mexico, iAs is currently regulated at 
25 ppb. Furthermore, there is evidence that health effects of iAs may occur even at the level 
below the WHO guideline level. 
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The first major finding of Chapter VI was that Dw-iAs was significantly correlated 
with U-tAs in the participants of the entire cohort 0.60 (<0.001) (as previously reported), 
suggesting that drinking water is the primary source of exposure to iAs in this population. 
This positive correlation remained strong for those whose iAs levels of drinking water were 
above the WHO level; however, this was not observed for those with exposure to Dw-iAs 
below the WHO guideline level. We did not find that the urinary proportions of metabolites 
were significantly associated with drinking water across the cohort. Although not statistically 
significant, (p=0.07) %U-MMAs were negatively correlated with drinking water levels in all 
women, and %U-iAs was marginally significantly (i.e. slightly greater than p of 0.05) 
negatively correlated (p=0.051) with drinking water levels in those exposed to levels above 
the WHO guideline level. These results suggest that there are correlations between the levels 
of iAs in drinking water, but not across all indicators of maternal metabolism, nor in 
categories below the WHO guideline level. 
The second major finding of Chapter VI is that homocysteine (Hcys) was 
significantly correlated with levels of iAs in drinking water. In the mediation analysis higher 
Hcys levels had a negative association with infant birthweight z-scores for those women with 
drinking water levels of iAs below the WHO guideline level of 10ppb, but not for those that 
who had drinking water levels of iAs higher then the WHO guideline level. Additionally, the 
effect estimate of higher Hcys levels (at or above the median of 6.4 μmol/L) compared to 
lower Hcy levels (below the median of 6.4 μmol/L) were negatively associated with infant 
birthweight. Additionally, the controlled direct effect of Hcys on infant birthweight when 
allowed to interact with %U-MMAs indicated that there was a negative relationship with 
infant birthweight. These data suggest the interaction of Hcys and maternal metabolism of 
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iAs may be particularly important at lower levels of exposure to iAs from drinking water. 
These complex biological interactions in the context of a dose response assessment have not 
been previously identified in iAs exposed pregnant populations.  
Limitations of Chapter VI 
There are limitations of the work carried out in Chapter VI that may influence the 
interpretations of the findings. Such limitations include those described more fully in Chapter 
V. However, there are additional limitations specific to Chapter VI.  
The first limitation of Chapter VI is in the context of the statistical estimation of the 
relationship between drinking water levels of iAs and the proportions of metabolites in 
maternal urine. Specifically, we did not find that all the proportions of arsenicals were 
associated with drinking water levels from correlation tests. This lack of correlation should 
be interpreted with caution, as there are many other factors that may confound this 
relationship. Mainly, these were modeled in a bivariate assessment without the inclusion of 
other key predictors. Future studies will need to model these relationships in a manner that 
would account for potential confounders of drinking water exposure and metabolism of iAs 
and examine the potential for linear and/or non-linear trends.  
The second limitation of the work from Chapter VI may lie in the choice for cutoffs 
of iAs drinking water levels that could influence the some of the null findings and imprecise 
estimates. Specifically, the differences in the relationships between OCM indicators 
deficiencies in the mediation analysis of the strata of those women with levels of drinking 
water iAs above the WHO guideline level should be interpreted with extreme caution, as the 
estimates are extremely imprecise.  
The last limitation of Chapter VI is that we are underpowered to detect multiple 
modifiers/mediators in this study. Specific to the findings of this thesis, because we found 
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that the association between B12 deficiency and infant birthweight z-scores are modified by 
folate levels, future work will need to consider such interactions as they relate to the levels of 
exposure. 
Strengths of Chapter VI 
Despite these limitations, there are many strengths of the work carried out in Chapter 
VI, which include the previously mentioned strengths from Chapter V. Specific to this work, 
there was strong correlation between exposure to iAs in drinking water and the maternal 
biomarker of urinary total arsenic, suggesting that there is little exposure misclassification.  
Future directions related to Chapter VI 
Future work of Chapter VI would build on the future work described for previous 
chapters of this thesis. Specific to Chapter VI, the focus on further research would aim to 
address some of the limitations discussed above, and to better explain the impact of the 
underlying exposure levels of iAs from drinking water on metabolism and iAs-associated 
disease. 
The direction for future work related to Chapter VI includes a more targeted analysis 
using multivariable regression models to include confounders not modeled in the bivariate 
assessment of this work to determine other factors that may explain the relationship between 
drinking water levels and iAs metabolism (gestational age, etc).   
The second direction for future work related to Chapter VI would address the 
limitation of sample size and the potential of multiple modifiers/mediators of the effects of 
OCM on infant birthweight. This work would examine the potential interaction of folate and 
B12 in the different drinking water strata in a larger population. Although we are limited in 
sample size to carry this out in the BEAR cohort, such considerations could be applied to 
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other data – such as the potential to replicate these findings in other cohorts (as mentioned in 
the future direction of Chapter V).  
 The last direction for future work related to Chapter VI is that within this data set, we 
would explore other cutoffs of drinking water levels of iAs that could be used to inform 
policies specific to Mexico, as their MCL is much higher (at 25 ppb) than the WHO.  
Overall conclusions Chapters IV, V, VI 
The overall public health significance of the work of this thesis is that we have 
identified key factors that may explain susceptibility for shifts of infant birthweight in an 
arsenic exposed population. This included interactions between both nutritional and 
environmental exposures. The importance of understanding the underlying mechanisms of 
iAs-associated disease was a recent focus of the national institute of environmental health 
workshop aimed at identifying emerging issues and research needs to address the multi-
faceted challenges related to arsenic and environmental health. The conclusions of this 
workshop were that there are still many research needs to address the underlying causes, and 
subsequent prevention, of iAs-associated diseases. This included the need to identify impacts 
of exposure in susceptible populations and of nutrition regulation in iAs metabolism for the 
potential of interventions. 
The methods applied here are a unique feature to address research gaps, and given the 
opportunity to replicate the findings in other cohorts presents exciting opportunities to further 
investigate the impacts and interactions between factors contributing to one carbon 
metabolism and metabolism of iAs during pregnancy and their impacts on adverse birth and 
other health outcomes. This is a highly unexplored use of these methods in the vast fields of 
environmental and reproductive/perinatal epidemiology. The conclusions of this thesis work 
provide a great framework for potential public health interventions to reduce the health 
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impacts of iAs associated diseases. Importantly, because some variation of metabolism of iAs 
may be explained by exposure to iAs from drinking water, and/or levels of OCM metabolism 
attempts to elucidate dose–response still remain imperative in iAs-associated health 
outcomes.  
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